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Despite recent advances in diagnosis and therapy, atherosclerosis-related 
cardiovascular disease remains a leading cause of morbidity and mortality 
worldwide. An important challenge is to detect silent atherosclerosis in 
asymptomatic people at risk, so that preventative strategies can be more effectively 
targeted. This thesis examines the pro-inflammatory/pro-atherogenic role of platelet 
hyperactivity and the consequent interaction of activated platelets with circulating 
monocytes to form monocyte-platelet aggregates (MPA), and investigates the 
potential usefulness of MPA measurement and/or monocyte phenotype 
characterization as surrogate markers of atherosclerotic disease. 
Using an experimental model of inflammation, namely that induced by influenza 
vaccine administration to healthy subjects, we found that MPA formation increases 
in the blood under pro-inflammatory conditions, and that this is accompanied by 
expansion of so-called CD14highCD16+ monocytes, which are distinct from 
“classical” CD14+CD16- cells and exhibit higher pro-inflammatory activity. In vitro 
experiments showed that MPA formation increases CD16 expression on 
CD14+CD16- monocytes.   
In an animal model of atherosclerosis (ApoE-/- mice), expansion of the murine 
counterpart of human CD16+ monocytes, namely Ly6Clow cells, occurred with age 
and their levels strongly related to the extent of atherosclerotic disease seen in the 
brachiocephalic artery. 
Finally, in a clinical study conducted in clinically healthy patients who had one or 




monocytes, but not of MPA, were found to increase in those patients who had 
carotid plaques compared to disease-free patients, and also showed a direct 
correlation with intima-media thickness (IMT) as evaluated by carotid 
ultrasonography. Unlike monocyte characterization, traditional cardiovascular risk 
stratification using the Framingham risk equation or the Joint British Societies 2 
charts showed no relationship to IMT or to the presence of frank plaque disease. 
 
In conclusion, our findings delineate a novel pro-atherogenic effect of platelet 
activation that is easily detectable in the peripheral blood through characterization of 
circulating monocytes. Measurement of CD14highCD16+ monocytes, but not MPA, 
offers a novel diagnostic approach to identify early atherosclerosis that gives 
information over and above cardiovascular risk estimation using traditional 
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1.1.1 Platelet structure and function 
“... In examining the content of such vessels (regardless of whether they are veins or 
capillaries) with an immersion objective, one will achieve the astonishing result that 
a third morphological element circulates along with red and white corpuscles. This 
is constituted of disc-shaped pale platelets with parallel surfaces, that rarely appear 
like lens-shaped, oval or round  structures; their diameter is a third or an half of red 
cells....They are generally isolated from each other, even if they can rarely adhere 
one to another to form clusters of variable dimensions. However, this is already a 
sign of their alteration...” (citation from Bizzozero 1883, p 661) [translation is 
mine]. 
It was as far back as December 1881 when the Italian pathologist Giulio Cesare 
Bizzozero (1816-1901) made his scientific report to the Royal Sciences Academy of 
Turin (Italy), providing the first evidence that the “third morphological element” of 
the blood, that many other authors (Hewson in 1780; Donne in 1842; Beale in 1850; 
Zimmermann in 1860 and Schultze in 1865) had described since the late 18th century 
as a blood component of dubious biological function, had an important role in 
thrombosis and coagulation (Gazzaniga & Ottini, 2001). Indeed, his great 
achievement was the demonstration that platelets have characteristics and functions 
different from those of erythrocytes and white cells, and that they “...constitute the 
major part of the thrombus and give rise to the accumulation of the abundant 
granular substance that is among leucocytes, and that was believed to derive from 
disrupted white cells...”(citation from Bizzozero 1883, p 701) . On the basis of  this 
observation, that was enabled by the development of intravital microscopy applied to 




mesenteric vessels of guinea pigs and rabbits, Bizzozero called these particles 
“piastrine” (Italian from the Latin emplastra, meaning embedding substance), that 
the English later termed “platelets” (little plates).  
More than a century of research in the field coupled with progress in laboratory 
techniques, have provided remarkable insight into the structural and functional 
complexity of platelets. These anucleate particles that circulate in the blood normally 
at 150-400 x 109 per litre, possess a composite network of membrane structures, 
including the plasmalemma, intracellular granules and canalicular systems, and 
originate from the segmentation of megakaryocytes. The different cellular 
compartments are regulated by an intricate cell signalling machinery that confers to 
platelets cellular plasticity, in terms of shape modifications in response to platelet 
agonists, and secretory ability in many different pathophysiological settings. For 
instance, specific receptors expressed on the platelet plasmalemma initiate an 
outside-in signalling pathway that leads to activation of protein phosphorylation 
cascades ultimately resulting in actin polymerization (Reed et al., 2000). This event, 
that culminates in a structural re-organization of the cytoskeleton, has been 
considered for many decades as the main determinant in organelle trafficking (the 
so-called “platelet release reaction”), due to the generation of a contractile force with 
consequent expulsion of intracellular granules (White et al.,1978; Painter et al.,1984; 
Loftus et al.,1989). More recent studies have revealed a process of fusion between 
the granule membrane and the plasmalemma, regulated by N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) family proteins, chaperon 
molecules that direct the function of the SNARE complex (such as GTPase Rab 
family) and the composition of the lipid membrane (reviewed by Reed et al., 2000 
and Flaumenhaft, 2003).  




The activity of this regulatory apparatus is disconnected from the biomolecular 
mechanisms that direct platelet shape changes, and seems to be modulated by 
agonist-specific effector molecules to ensure selectivity of granule content release as 
appropriate. Indeed, immunocytochemical and electron microscopic studies have 
identified three main types of storage organelles in platelets, known as dense, alpha 
and lysosomal granules. Their content can be classified into three main groups on the 
basis of their principal function (Ren et al., 2008):   
- platelet agonists (adenosine diphosphate (ADP), serotonin, epinephrine, 5-
hydroxytryptamine (5-HT) and calcium), contained in the dense-granules;  
- adhesion molecules (P-selectin, fibrinogen, von Willebrand factor (vWF), 
platelet factor 4 (PF4)), stored in alpha-granules; 
- lysosomal enzymes (cathepsin, hexosaminidase), within the lysosomes.  
However, these molecules only represent a minority of the entire array of functional 
mediators stored in circulating platelets, that comprise growth factors (such as 
vascular-endothelial growth factor, VEGF; platelet-derived growth factor, PDGF), 
pro-inflammatory molecules (including inteleukin-1β and CD40L) and a variety of 
chemokines (reviewed by Klinger & Jelkmann, 2002). 
The scenario is complicated by evidence that, despite lack of genomic DNA, 
platelets contain residual mRNA from megakaryocytes along with a complete 
translational apparatus, thus enabling the production of newly synthesised proteins 
(Harrison & Goodall, 2008). 
To date, the study of platelet structure and the understanding of their function are far 
from complete. However, the evidence to date indicates multiple roles for platelets, 




extending from their now well-established role in haemostasis and thrombosis to a 
more general pro-inflammatory action, as will be discussed later.  
 
1.1.2 Platelet activation 
The classical model of platelet activation describes a series of phenotypic and 
morphological changes in resting platelets such that they acquire adhesiveness to the  
vascular wall following exposure to pro-thrombotic  molecules (e.g. collagen, vWF) 
(Weiss et al.,1978; Tschopp et al.,1973; Savage et al.,1996), forming platelet-to-
platelet aggregates (homotypic aggregation) through interlinking by soluble adhesive 
proteins (especially fibrinogen) (Isenberg et al., 1987) and releasing a number of 
mediators that stabilize the initial aggregate and amplify thrombus formation 
(Siess,1989). The widespread view that vessel injury is the sole determinant of 
platelet activation has been largely abandoned in light of the evidence that  a variety 
of pathophysiological stimuli, including pro-inflammatory cytokines and infective 
agents (recently reviewed by Semple & Freedman, 2010) as well as shear stress 
(Kroll et al.,1996), can activate platelets with no detectable vessel damage. Evidence 
has also accumulated that, in these and other diverse pathophysiological settings, 
platelets exhibit differential biological responses due to activation of distinct 
biomolecular pathways. Importantly, pro-inflammatory activity mediated by 
interaction with circulating leucocytes (heterotypic aggregation) and release of  
inflammatory mediators constitutes an important aspect of platelet biology and 
provides strong pathophysiological links between inflammation and thrombosis 
(Semple & Freedman,2010; Kroll et al.,1996; Freedman & Loscalzo,2002). As a 
consequence, platelet activation is not limited to the occurrence of a local thrombotic 




event triggered by vascular damage and mainly sustained by homotypic aggregation. 
On the contrary, it is often part of a systemic inflammatory response that can develop 
independently of, or in addition to, local injury-related factors. Indeed, formation of 
heterotypic aggregates in the peripheral circulation has been observed not only 
during acute thrombotic events (Furman et al.,1998; Michelson et al.,2001; Furman 
et al.,2001; Sarma et al.,2002; Marquardt et al.,2009), but also in those clinical 
conditions associated with high blood thrombogenicity in  the absence of 
intravascular thrombosis, such as  auto-immune disorders (Joseph et al.,2001), 
haematological disease (Jensen et al.,2001; Wun et al.,2002), and in subjects with 
cardiovascular risk factors (Harding et al.,2004a; Harding et al.,2004b; Gkaliagkousi 
et al.,2009). Given this, as well as the ongoing discovery of ever more biomolecular 
mechanisms underlying the platelet response to different agonists, it is likely that the 
signalling pathways that regulate thrombus formation and platelet-leucocyte 
interaction may operate either together or independently under different 
circumstances. In keeping with this, some anti-platelet drugs that effectively reduce 
platelet-platelet aggregation, such as aspirin, may have very little or no effect on 










1.2 Homotypic aggregation 
Homotypic aggregation occurs at the site of a vascular lesion such as a ruptured 
atherosclerotic plaque or a traumatic injury, where exposed pro-thrombotic 
molecules provide an adhesive surface for recruitment of circulating platelets, 
followed by their activation and thrombotic plug formation (Tschopp et al.,1973; 
Weiss et al.,1978; Isenberg et al.,1987; Siess,1989; Savage et al.,1998). In vivo and 
in vitro observations suggest that this phenomenon is a complex and dynamic multi-
step process (Furie & Furie,2005; Kulkarni et al.,2000; Maxwell et al., 2007). The 
initial phase of adhesion of platelets to the vascular wall as well as to each other 
(primary reversible aggregation) is followed by a second phase of stabilization and 
growth of the initial platelet plug (secondary irreversible aggregation). Platelet 
activation has long been assumed to have a dual role in this process, as an initiating 
factor in platelet arrest and as an essential mediator of the transition from reversible 
to irreversible aggregation (Savage et al., 1996; Savage et al.,1998; Packam & 
Mustard, 1984). Technical advances in intravital microscopy and real-time perfusion 
studies have demonstrated that primary aggregation can also occur without the need 
for platelet activation under conditions of elevated shear stress (Maxwell et al., 2007; 
Ruggeri et al., 2006). However, when non-activated platelets adhere to the vessel 
wall they only form transient micro-aggregates that, in the absence of activation-
dependent release and generation of soluble agonists (principally adenosine 
diphosphate, ADP; thrombin and thromboxane A2, TxA2), disaggregate with 
translocation of platelets in the direction of flow (Maxwell et al., 2007). Central to 
homotypic aggregation is therefore the concept that platelets become activated in 
response to interaction with thrombogenic surfaces, and multiple ligand-receptor 
interactions are required to stabilize and amplify their adhesion and aggregation. 




1.2.1.Biomolecular mechanisms of platelet activation leading to homotypic 
aggregation 
Fibrinogen, vWF and collagen are able to initiate primary aggregation through the 
engagement of specific platelet integrins, namely glycoprotein (GP)IIb/IIIa (also 
designated α2bß3 integrin), GPIb and GPVI respectively (Savage et al.,1996; 
Nachman & Leung, 1982; Emsley et al.,2000). At low shear rate (<1000 s-1), the 
interaction between GPIIb/IIIa and fibrinogen has been demonstrated to constitute 
the predominant biomolecular event (Savage et al.,1996; Ruggeri et al.,1997; Savage 
et al.,1998). However, since GPIIb/IIIa is expressed in a low affinity state on the 
plasmalemma of quiescent platelets, initial stimulation of platelets by one or more 
soluble agonists in the vicinity of the lesion (e.g. ADP released from endothelial 
cells or thrombin locally produced) is required in order to activate downstream 
signalling pathways (inside-out signalling) that ultimately result in platelet shape 
change and activation of GPIIb/IIIa (Isenberg et al.,1987). When the shear rate rises 
within the range 1000 - 10000 s-1,   platelet activation is not required to induce 
primary aggregation, since the synergistic action of GPIIb/IIIa and GPIb suffice in 
promoting tethering and transient aggregation of discoid-shaped quiescent platelets 
to the vascular wall. Nevertheless, the ensuing activation of platelets induced by  
integrin engagement leads to release of soluble agonists, mainly ADP, which is 
essential in stabilizing the initial aggregate (Maxwell et al.,2007). At high shear rates 
(>10000 s-1  ), Ruggeri et al have shown both in vitro and in vivo that thrombus can 
form efficiently through a mechanism independent of platelet activation, that is 
solely mediated by interaction between vWF and GPIb giving rise to stable local 
adhesion of platelets to a thrombogenic surface and homotypic aggregation (Ruggeri 
et al.,2006). 




The in vivo role of these  ligand/receptor interactions has been evaluated in animal 
models selectively lacking one or more of the molecules involved in these pathways. 
In studies using vWF–/– mice, platelet accumulation and thrombus growth were 
markedly delayed but not absent in a model of ferric chloride-induced thrombosis 
(Ni et al.,2000), and the thrombogenic activity of platelets in laser-induced vessel 
wall injury was in fact comparable to that observed in wild-type mice (Dubois et 
al.,2007), suggesting that platelet thrombus formation can occur in the absence of 
vWF. Fibrinogen/vWF double knockout mice exhibit preserved platelet-to-platelet 
interaction (Ni et al.,2000), via a mechanism primarily triggered by thrombin and 
sustained by soluble agonist release (ADP) and different integrin signalling cascades 
(Dubois et al.,2007; Yang et al.,2006). Activation of the coagulation cascade at the 
site of vessel injury, with consequent generation of thrombin through the tissue 
factor (TF) pathway, has been proposed as a major contributor to the thrombogenic 
component of atherothrombotic disease (Corti et al.,2002; Libby, 2002). However, 
recent evaluation of the dynamics of thrombus formation on atherosclerotic plaques 
has shown that TF has a predominant role only in the amplification phase of platelet 
aggregation, whilst the first key event of platelet arrest and aggregation is crucially 
regulated by engagement of the collagen receptor GPVI (Reininger et al.,2010). 
Indeed GPVI blockade, but not plaque TF suppression, significantly inhibits 
thrombus development. In similar experiments performed by Penz et al (Penz et 
al.,2007), GPIb was found to be a crucial effector in plaque-induced thrombosis, a 
finding in agreement with the work of Ruggeri et al showing the importance of the 
vWF/GPIb axis in thrombus formation under conditions of high shear, and further 
confirmed in studies of interleukin 4-receptor/GPIb transgenic mice (Bergmeier et 
al.,2006), in which lack of activity of GPIb gives rise to a severe bleeding 




phenotype. However, compared to the relatively mild effect on thrombogenic 
response to vascular injury observed in vWF-knockout mice, these results are 
strongly suggestive of an additional thrombogenic mechanism sustained by GPIb 
that may interact with ligands other than vWF.  
Taken together, these findings  imply that, independent of the initial thrombogenic 
stimulus and blood flow conditions, platelet-to-platelet interaction only results in 
irreversible aggregation once stable adhesion to the vascular wall, mediated by 
multiple receptor-ligand binding events, is established.  Figure 1.1 summarises the 











Figure 1.1 Ligand-receptor interactions sustaining platelet homotypic aggregation. 
Fibrinogen, vWF and collagen anchor platelets to the vascular wall by engaging specific 
platelet receptors (GPIIb/IIIa, GPIb and GPVI respectively). The ensuing activation of 
platelets induced by integrin engagement, along with the action of soluble agonists (i.e. ADP 
and thrombin), leads to platelet release of soluble thrombogenic molecules (ADP and TxA2) 
that stabilise the initial aggregate, by inducing the recruitment of other circulating platelets 
and the conformational change of GPIIb/IIIa from a low- to a high-affinity state for 
fibrinogen that acts as a bridge between platelets (circled). P2Y1 and P2Y12: ADP- receptors;  
PAR-1 and PAR-4 : thrombin-receptors; TP: TxA2 receptor. 




1.3 Heterotypic aggregation 
By contrast with homotypic aggregation, which is confined to the vascular wall, 
heterotypic complex formation occurs in circulating blood. The association of 
platelets with leucocytes was first reported in the late 1970s and described as 
“platelet satellitism”. It referred to the in vitro phenomenon of platelets rosetting 
around leucocytes observed in ethylenediaminetetra-acetic acid (EDTA)-
anticoagulated blood of patients with a wide variety of clinical conditions, 
particularly immunological disorders (Kjeldsberg & Swanson, 1974; Mant et 
al.,1975; White et al.,1978; Djaldetti et al.,1978; Peters et al.,1998). From these 
clinical observations, scientific interest rapidly moved to the study of platelet-
leucocyte interaction, in order to characterize the underlying mechanisms and 
elucidate the potential pathophysiological implications. Due to the inflammatory 
nature of atherosclerosis, heterotypic aggregation in this condition has been a major 
area of research. In subjects with coronary atherosclerosis, leucocyte-platelet 
aggregation was initially identified within the coronary circulation, in close 
proximity to atherosclerotic lesions (Mickelson et al.,1996). The same study reported 
a higher level of heterotypic complexes in the vicinity of plaques with thrombotic 
complications as compared to uncomplicated ones. In further clinical studies, 
heterotypic complexes were observed in the systemic circulation of patients with 
coronary atherosclerosis (Ott et al.,1996; Furman et al.,1998; Michelson et al.,2001; 
Furman et al.,2001, Sarma et al.,2002), their levels being increased during acute 
thrombotic events. These findings suggest that circulating heterotypic aggregates 
form in parallel with thrombi, as a consequence of local platelet activation sustained 
by vascular damage. However, the presence of atherosclerotic lesions may not be 
mandatory for heterotypic aggregation, as raised levels of such aggregates have been 




described also in clinically healthy subjects with cardiovascular risk factors (Harding 
et al.,2004a, Harding et al.,2004b, Gkaliagkousi et al.,2009) – although such 
subjects may well have subclinical atherosclerosis – as well as in patients with other 
inflammatory conditions (reviewed by von Hundelshausen & Weber, 2007). 
Adhesion between platelets and leucocytes is stable, does not require adhesion to 
pro-thrombotic surfaces, and is a systemic phenomenon whose extent depends on the 
degree of platelet activation (Table 1.1). Early in vitro experiments performed on 
whole blood showed that platelet activation by a variety of agonists results initially 
in homotypic aggregation mediated by fibrinogen-GPIIb/IIIa interaction, which is 
followed – in the absence of an adhesive vascular surface – by platelet 
disaggregation and subsequent platelet adhesion to leucocytes, with monocytes 
having a competitive advantage over other white cells in binding activated platelets 
(Rinder et al.,1991a). Inhibition of fibrinogen binding to GPIIb/IIIa is even able to 
enhance the interaction of activated platelets with leucocytes, and the heterotypic 
complexes so formed, that are mainly composed of monocyte-platelet aggregates 
(MPA), display a strong pro-inflammatory action mediated by newly expressed 
molecules such as CD40L and P-selectin on their surface, along with  pro-thrombotic 











 Table 1.1 Comparison between homotypic and heterotypic aggregation [From 















































1.3.1 Biomolecular mechanisms of platelet activation leading to heterotypic 
aggregation 
The pioneering work of Jungi et al (Jungi et al.,1986) demonstrated that platelets 
acquire adhesiveness to leucocytes when stimulated with thrombin in a 
concentration-dependent manner, whilst non-activated platelets show little tendency 
to associate with white cells, any such association being explained by low-grade 
spontaneous activation of platelets undergoing handling in vitro. A number of other 
researchers confirmed these results (Hamburger et al.,1990; Rinder et al.,1991a; 
Rinder et al.,1991b), and it is now well established that platelet activation, 




independent of the initial stimulus, is required to trigger platelet-leucocyte 
interaction. As part of the underlying molecular mechanism, expression of the 
adhesion molecule P-selectin on the plasmalemma of activated platelets appears to 
be crucially involved (Larsent et al.,1989; Hamburger et al.,1990). P-selectin, also 
designated CD62P and previously referred to as GMP-14O or PADGEM protein, is a 
transmembrane molecule stored in the alpha-granules of platelets. Upon stimulation, 
the granules fuse with the plasma membrane and P-selectin thus translocates from 
the cytosolic compartment to the extracellular surface, where it acts as a receptor for 
circulating white cells (Larsent et al.,1989). Alpha-granule release reaction with 
consequent P-selectin expression on the platelet surface is induced by a number of 
different stimuli, including thrombogenic molecules (collagen, vWF, fibrinogen) and 
strong platelet agonists (thrombin, thromboxane). However, it can also follow 
stimulation with weak platelet agonists or inflammatory molecules, such as 
epinephrine, prostaglandin E2 (PGE2) and chemokines, that in the absence of other 
agonists do not sustain platelet homotypic aggregation (Offermanns, 2006), but 
rather sensitise platelets to the actions of other agonists (Hjemdahl et al., 1994). 
Hence, exposure of P-selectin on platelets can occur during effective thrombus 
formation, but also when sub-clinical platelet activation (i.e in the absence of a 
thrombotic event) is sustained by different pathogenetic stimuli. From reviewing all 
the existing literature, it appears likely that this phenomenon can be largely 
attributed to the selective and differential modulation of the platelet release reaction 
by different agonists (reviewed by Passacquale & Ferro, 2011a). Indeed, strong 
platelet agonists are able to sustain thrombus formation and concomitant platelet 
heterotypic aggregation by inducing full platelet degranulation, with consequent 
release of platelet-derived pro-thrombotic agents stored in dense-granules and 




adhesive/pro-inflammatory molecules contained in the alpha-granules (Figure 1.2). 
For instance, thrombin and thromboxane activate G-protein coupled receptors 
(GPCR) that feed-back on the Gq- and G12/13-signalling cascade whose main effector 
is phospholipase C (PLC) which then activates protein kinase C (PKC). On the other 
hand, weak platelet agonists, including ADP and epinephrine, are characterized by a 
common ability to bind GPCR that activate Gi-dependent transduction pathways, 
thus resulting in reduction of the activity of protein kinase A (PKA) via suppression 
of intracellular cyclic AMP (cAMP).  
 
Figure 1. 2. Model of agonist-selective modulation of alpha and dense granule release in 
human platelets. Different platelet agonists (ADP, thrombin and TxA2) activate distinct 
transduction pathways. Thrombin- and TxA2-dependent Gq- and G12/13-signalling cascades 
result in phospholipase C (PLC) activation, mainly the PLC-β isoform, that via hydrolysis of 
membrane phospholipids and generation of two second messengers, IP3 and DAG, leads to 
the activation of protein kinase C (PKC) enzymes. PKC comprises different isoforms: the 
classical subgroup (α, β) whose activation is calcium-dependent and mediated by the 




synergistic action of IP3 ad DAG; and the calcium-insensitive isoforms (δ,θ) regulated by 
DAG. In human platelets activation of conventional Ca-dependent PKC isoforms 
(α, β) stimulates effects on dense granule release and platelet aggregation, while the Ca-
insensitive isoforms of PKC (δ,θ) inhibit these (Gilio et al., 2010). ADP, either produced at 
the site of a vascular lesion by endothelial cells or released by platelets as a consequence of 
dense-granule exocytosis, interacts with P2Y1 receptors that, via Gq-proteins, trigger the 
same molecular pathways regulated by thrombin and TxA2. In this way, ADP regulates 
dense granule exocytosis. Moreover, ADP interaction with P2Y12 receptors induces a  Gi-
dependent transduction pathway that inhibits PKA via negative modulation of adenylyl 
cyclase (AC) and intracellular cAMP.  The inhibition of AC, and the consequent reduction 
in cAMP levels, removes the self-limiting mechanism of platelet activation sustained by 
PKA activity, thus producing an amplification of the activator pathways through release of 
alpha-granule content. Reduction in cAMP levels also decreases the enzymatic activity of 
platelet nitric-oxide synthase (NOS). NOS inhibition down-regulates PKG and, in turn, PKA 
activity. [From Passacquale & Ferro, 2011a]. 
 
Hence, distinct phosphorylation cascades that act on different cellular targets appear 
to selectively regulate dense- and alpha-granule release reaction. The intracellular 
content of cAMP appears to be the main regulator of P-selectin expression and 
consequent heterotypic aggregation. Table 1.2 summarises the effects of several 











Table 1.2. Effect of platelet agonists/inhibitors on intraplatelet cAMP and consequent 





Effect on heterotypic 
aggregation
ADP Stimulatory, requires 




Adenosine Inhibitory Inhibitory 
Epinephrine Very little Stimulatory
Prostaglandin E2 via EP3 
receptor
None alone Stimulatory
Prostaglandin E2 via EP4 
receptor
Inhibitory Inhibitory 
Prostaglandin E1 via EP3 
receptor
None alone Stimulatory
Prostaglandin E1 via IP 
receptor
Inhibitory Inhibitory 
Chemokines None alone Likely stimulatory
β-adrenoceptors Inhibitory Inhibitory 











The ligand for P-selectin, namely P-selectin glycoprotein ligand (PSGL)-1, is 
constitutively expressed on the plasmalemma of leucocytes (Yang et al.,1999). 
Within the leucocyte population, the expression of PSGL-1 on the cellular surface of 
monocytes is highest (Kappelmayer et al., 2001), and this could in part explain their 
preferential affinity to platelets over other white cells.   




The preferential binding of platelets to monocytes may also be ascribed to an 
additional role played by other ligands specifically present on the plasmalemma of 
monocytes, which may play a role following on from P-selectin/PSGL-1 interaction.  
Indeed, PSGL-1 is not only an adhesion but also a signalling molecule, as further 
described in the following paragraphs.  
 
1.3.2 Kinetics of heterotypic complex formation 
The kinetics of interaction between platelets and leucocytes have been extensively 
explored through both in vitro experiments and in vivo investigations (Table 1.3), 
and demonstrate that the adhesion of platelets to circulating leucocytes is a rapid and 
transient event following platelet activation.  In 1991 Rinder et al (Rinder et 
al.,1991b) developed a flow cytometric assay allowing the quantification of platelet-
leucocyte adhesion in terms of percentage of white cells binding platelets and 
number of platelets per leucocyte. They co-incubated the different subpopulations of 
white cells purified from peripheral blood with autologous platelets previously 
stimulated with different agonists. A time course was performed to follow 
heterotypic aggregation within each white cell subtype. They showed that platelet-
leucocyte complexes form within a few minutes of platelet activation (2-10 min, 
dependent on the white cell subtype), and that the number of platelets per leucocyte 
increases in a time-dependent manner.  
These results appear to reproduce the in vivo dynamics of heterotypic aggregation. 
Indeed, a recent study performed in apoE-/- mice (Huo et al.,2003) showed that 
intravenous injection of activated platelets led to sequestration of circulating white 
cells within a few minutes of infusion (5 min) and persisting for up to 80 min for 




neutrophils (PMN) and 180 min for monocytes. No such effect was reported for 
lymphocytes, confirming once more the differential binding ability of activated 
platelets to different leucocyte sub-populations. The same experiment repeated in 
baboons showed similar findings (Michelson et al.,2001). After injection of activated 
platelets, formation of circulating aggregates with monocytes and PMN occurred 
within 1 min. The in vivo half-lives of circulating monocyte-platelet and PMN-
platelet complexes were 30 min and 5 min respectively. No heterotypic aggregates 
were detectable after 2 hours.   
 
Table 1.3. Kinetics of heterotypic aggregation. Data are from both in vitro experiments 
and in vivo investigations in different animal models. Level of heterotypic aggregates 
obtained in vitro refers to the percentage of each type of cell binding platelets after 
stimulation with ADP or thrombin, while in animal models it was evaluated in the peripheral 
blood after intravenous injection of activated platelets. 
In vitro exp
(Humans)
In vivo exp Cell type Start of 
effect
(min)

























































However, the in vivo circulation time and the clearance of heterotypic complexes in 
humans remain to be clarified. In subjects who have suffered cerebrovascular events, 




including stroke and transient ischemic attack (TIA), the circulating level of 
leucocyte-platelet aggregates increases dramatically during the acute phase, and 
returns to values comparable to those observed in healthy controls only after 3 
months (Htun et al.,2006). High concentrations of heterotypic aggregates have also 
been reported during the first 4 hours following acute myocardial infarction (Furman 
et al.,2001). The number of leucocyte-platelet complexes is increased with respect to 
the general population also in subjects with hypertension (Gkaliagkousi et al.,2009), 
diabetes (Harding et al.,2004b), and in smokers (Harding et al.,2004a). This suggests 
that a certain degree of persistent and chronic heterotypic aggregation occurs in these 
clinical conditions, even in the absence of an acute thrombotic event. 
 
1.4 Monocyte-platelet aggregates: linking thrombosis to 
inflammation 
Monocyte-platelet aggregation is not a simple epiphenomenon that accompanies 
platelet activation but carries important pathophysiological implications. The 
interaction between activated platelets and monocytes, as occurs in the context of 
thrombus formation, contributes to thrombus stabilization by amplifying platelet 
activation and favouring homotypic aggregation at sites of vascular injury (Furie & 
Furie,2005). On the other hand, heterotypic aggregation following activation of 
platelets in response to infectious or inflammatory agents results in modulation of 
the immunological response. Of note, platelets are known to mediate phagocytic-like 
functions, internalizing bacteria and viruses (Zucker-Franklin et al.,1990; Youssefian 
et al.,2002), and to express Toll-like receptors (TLR) that are critical for regulating 
innate immune mechanisms (Medzitov & Janeway, 2000). In keeping with this, a 




number of in vitro and in vivo pre-clinical studies, as well as clinical observations, 
have provided evidence of anti-inflammatory actions of anti-platelet drugs, such as 
aspirin and clopidogrel (reviewed by Muhlestein, 2010). 
Apart from being a robust index of platelet activation, monocyte-platelet aggregation 
is therefore of functional importance with both pro-thrombotic and pro-inflammatory 
effects.  
 
1.4.1 Monocyte-platelet aggregates:  a reliable method for assessment of degree 
of in vivo platelet activation 
A number of laboratory tests are available to study blood thrombogenicity. They 
include:  
- morphological analysis of platelets (including volume and mass), as shape 
changes are suggestive of platelet activation;  
- concentration of metabolites produced by activated platelets (urinary 11-
dehydrothromboxane B2, serum TXB2; plasma β-thromboglobulin; PF4);  
- platelet aggregometry, which measures in vitro the clumping of platelets 
either spontaneously or in response to platelet agonists;  
- flow cytometry analysis of molecules expressed on the platelet plasmalemma 
following activation, such as GPIIb/IIIa in its high-affinity form or granular 
products (P-selectin).    
Amongst all these techniques, platelet aggregometry is regarded as the gold standard 
in the research setting. However, flow cytometry, through the use of monoclonal 
antibodies that specifically bind platelet receptors, offers the highest sensitivity and 




indeed it has been applied in an aggregometry context to measure micro-aggregates 
in samples of platelet-rich plasma and whole blood (Abrams et al.,1990). Indeed, the 
development of whole blood flow cytometry in 1987 (Shattil et al.,1987) represented  
a major technical advance in the functional testing of platelets as it minimises sample 
manipulation and the unavoidable platelet activation that occurs in vitro during 
platelet-rich plasma preparation. The possibility to study platelets in their 
physiological environment (whole blood) and the ability to simultaneously analyse 
multiple activation-dependent surface markers, in only a small sample of blood (200 
µl), has favoured widespread application of this technique in many clinical trials. 
However, its usefulness in clinical practice remains unclear, mainly due to the lack 
of an accepted gold standard assay available for widespread clinical use for 
comparison.  
Flow cytometry also allows the quantification of circulating MPA, based on double 
immunostaining of the blood for the monocytic marker CD14 and the constitutive 
antigen CD42b expressed on platelets. Double-positive cells are considered to 
represent the population of circulating monocytes binding activated platelets. 
Compared to P-selectin expression on platelets, the measurement of MPA in the 
peripheral blood offers a number of advantages, and is now regarded as the most 
sensitive and robust index of platelet activation (Michelson et al.,2001). Indeed, 
following degranulation, activated platelets rapidly lose their surface P-selectin while 
continuing to circulate and function in the peripheral blood (Michelson et al.,1996). 
Therefore, the level of P-selectin expression on platelets may underestimate the true 
degree of platelet activation. Consistent with this, in two separate clinical studies in 
patients with acute coronary syndrome, circulating P-selectin positive platelets were 
not increased compared to healthy controls whereas, by contrast, the level of 




circulating MPA was higher in patients with respect to normal subjects, with the 
degree of MPA increase being more pronounced in the presence of myocardial 
infarction (Furman et al.,1998; Michelson et al.,2001). These results can be in part 
explained by a difference in the half-life of P-selectin and MPA in the blood 
(Michelson et al.,2001). In light of this and other evidence, circulating MPA are 
believed to be a better indicator of platelet activation than the level of CD62P-
expressing platelets. 
 
1.4.2 Effect of platelet interaction on monocyte function 
Accumulating evidence indicates that contact of monocytes with platelets regulates 
their function and enhances their pro-inflammatory activity (Figure 1.3). Intercellular 
signalling via adhesion molecule ligation stimulates monocytic production of various 
cytokines, including tumour necrosis factor (TNF)-α  (Weyrich et al.,1995; Weyrich 
et al.,1996) and TF (Celi et al.,1994; Lindmark et al.,2000). The expression of 
chemokines, induced by thrombin-activated platelets, has been also reported (Gawaz 
et al.,1998). P-Selectin/PSGL-1 interaction sustains these events through the 
activation of both tyrosine-kinase-dependent signalling and transcription factor NF-
κB. However, PSGL-1 engagement is not exclusively responsible for these 
processes.  Indeed, TF expression by monocytes is reduced not only by a P-selectin-
blocking antibody but also by IL-10 (Celi et al.,1994). Moreover, ligation of TREM-
1 also induces NF-κB activity and subsequently secretion of monocyte chemotactic 
protein (MCP)-1, TNF-α, and IL-8 (Weyrich et al.,1995; Weyrich et al.,1996; 
Bouchon et al.,2000).  




Platelet-dependent activation of NF-kB in monocytes also regulates gene 
transcription of the cyclooxygenase enzyme type 2 (COX-2) (Dixon et al.,2006).  
Following prolonged platelet interaction, a series of MAPK signalling events are 
activated in monocytes, leading to stabilization of the COX-2 transcript and 
increased COX-2 protein expression. COX-2 is an inducible enzyme involved in 
arachidonic acid metabolism and biosynthesis of prostanoids. COX-2 and its 
terminal products are cell- and tissue-specific. The enzymatic activity of COX-2 in 
monocytes principally leads to the production and release of PGE2 (Cipollone et 
al.,2008), which not only exerts potent pro-inflammatory effects, including 
enhancement of monocytic migration (Panzer et al., 2004), but is also able to 
stimulate platelet activation per se (Fitzgerald, 1991; Reilly & Fitzgerald, 1993). 
Cross-talk between monocytes and platelets induces pro-thrombogenic activity. 
Expression of P-selectin, tissue factor and CD40L is higher on the surface of micro-
aggregates compared to the levels expressed on activated platelets only (Zhao et 
al.,2003). At the site of thrombus formation, accumulation of TF leads to 
coagulation, the generation of more thrombin, and the propagation of a fibrin clot 
(Furie & Furie, 2005). Moreover, MPA formation is believed to have a pro-
atherogenic effect due to facilitation of monocyte infiltration into the vascular wall, 
as further discussed in the following paragraphs.  
 















• Increased adhesiveness to 
platelets and endothelium
• Secretion of pro-inflammatory 
cytokines (TNF-α, IL-8)








Figure 1.3 Interaction with platelets stimulates pro-inflammatory activity in 
monocytes. Schematic representation of the general molecular pathways activated in 
monocytes upon interaction with platelets and the consequent effect on their pro-
inflammatory activity. Engagement of monocytic PSGL-1, TREM-1 and CD40 by platelet 
P-selectin, TREM-1 ligand and CD40L stabilizes cell adhesion and activates intracellular 
signalling leading to NFκB (nuclear factor κ B), MAPK, and  COX-2 (cyclo-oxygenase 2) 
activation. Their activity leads to production of pro-inflammatory cytokines (TNF-α and IL-
8) and synthesis of prostanoids (PGE2 is the main prostanoid deriving from COX-2 activity 
in monocytes). Over-expression of integrins, particularly the β2 integrin CD11b/CD18 
(Mac-1), further stabilizes the interaction between monocytes and platelets and favours 











1.5 Monocyte-platelet aggregates in atherosclerosis 
1.5.1 Evidence from in vitro experiments and in vivo animal models 
Activated platelets have a dual role in atherosclerosis, since they are responsible for 
the thrombotic complications of “vulnerable plaques” but also contribute to lesion 
initiation and progression (Davi’ & Patrono, 2007). The pro-inflammatory nature of 
platelets underlies their pro-atherogenic effect, and the ability to interact with 
monocytes to form MPA constitutes a central pathophysiological mechanism. 
Upon activation, platelets adhere to the vascular endothelium where they act as a 
bridge between the vascular wall and circulating white cells, through the release of 
inflammatory mediators that exert a chemotactic action on circulating monocytes 
(i.e. soluble CD40L), and/or through direct engagement of PSGL-1 constitutively 
expressed on monocytes (reviewed by McEver, 2001). Therefore, adherent platelets 
facilitate monocyte recruitment into the vascular wall. In keeping with this, 
interference in platelet binding to the endothelium, by blocking the platelet adhesion 
molecule for vWF, namely GPIb, prevents progression of atherosclerosis (Massberg 
et al., 2002).  
On the other hand, monocytic PSGL-1 engagement by platelet P-selectin induces 
production of superoxide anion radicals from monocytes (Tsuji et al.,1994), and 
tyrosine phosphorylation of various cytoplasmic proteins, including pp125 focal 
adhesion kinase, ERK, Syk, Src kinase, and paxillin (Hidari et al.,1997; Haller et 
al.,1997; Urzainqui et al.,2002; Wang et al., 2007). These biomolecular pathways 
lead to integrin activation on monocytes, resulting in further stabilization of cellular 
adhesion (monocyte-platelet and monocyte-endothelium interactions) and synthesis 
and release of monocytic pro-inflammatory chemokines. Further interactions are 




through CD40L/CD40, TREM-1 ligand/TREM-1 (which may also promote integrin 
expression), and CD36/CD36 via thrombospondin (van Gils et al., 2009). The 
multiple receptor-ligand interactions (Figure 1.4), the humoral factors released at the 
site of vascular injury and monocytic infiltration into the sub-endothelium amplify 
the pro-inflammatory milieu within the vascular wall, and this further contributes to 
and sustains atherosclerotic plaque development.     
Direct in vivo evidence supporting the role of MPA in atherogenesis has been 
reported by Huo et al (Huo et al.,2003). They demonstrated that activated platelets 
injected into apoE-/- mice aggregate with circulating monocytes, thereby promoting 
the onset and progression of atherosclerotic lesions by favouring monocytic 
infiltration into the vessels.  
 
1.5.2 Clinical observations 
Increased formation of MPA in the peripheral circulation of patients with 
atherosclerotic disease is now well described. High levels of MPA have been 
reported in subjects with acute cardiovascular events as well as in asymptomatic 
patients with underlying vascular disease. Apart from being an index of increased 
blood thrombogenicity, it is believed that MPA may exert a pro-atherogenic effect in 
humans, but this hypothesis remains to be proved. The abovementioned experiments 
in apoE-/- mice (Huo et al.,2003) suggest that interaction between platelets and 
monocytes is not only a localized phenomenon occurring at sites of  vascular 
damage, but occurs in the peripheral circulation with resultant MPA formation which  
then induces a damaging effect on blood vessels. In this context, it is noteworthy that 
the level of MPA observed in patients presenting with acute coronary syndrome has 




been demonstrated not only to be an indicator of platelet activation, but also to have 
predictive value for future cardiovascular events and hospitalizations for 
cardiovascular disease (Ashman et al.,2009).     
 
1.6 Polymorphonuclear neutrophil (PMN)-platelet interaction 
As previously discussed, activated platelets also adhere to PMN to form heterotypic 
aggregates although with a lesser binding affinity than that displayed for monocytes, 
thus resulting in a lower amount and a shorter in vivo half-life of PMN-platelet 
complexes in the peripheral blood compared to MPA (Table 1.3). This has important 
implications as regards the sensitivity of the distinct types of heterotypic aggregate to 
reflect in vivo platelet activation (Michelson et al., 2001). Nevertheless, as with 
MPA formation, PMN-platelet interaction modulates the biological function of 
PMN, and this results in a distinct but important effect of these heterotypic 
complexes on atherosclerosis-related inflammation.  
 
1.6.1 Biomolecular mechanisms underlying PMN-platelet aggregation 
 The reasons why activated platelets preferentially adhere to monocytes remain to be 
elucidated. Increased expression of PSGL-1 on the surface of monocytes compared 
to the levels foound on granulocytes has been proposed as a potential explanation 
(Kappelmayer et al., 2001, Bournazos et al., 2008a). Moreover, adhesive cellular 
interactions other than PSGL-1/P-selectin binding have been demonstrated to be 
important in the stabilization of the initial aggregate between platelets and 
monocytes (as discussed above).  




However, the formation of PMN-platelet complexes gives rise to unique 
biomolecular characteristics that are not shared by monocyte-platelet aggregation. 
Unlike monocytes, in which additional adhesive events seem to be secondary to, 
and/or sustained by, PSGL-1-dependent cellular activation, the pre-activation status 
of granulocytes seems to have a more decisive role in the initial interaction with 
platelets. Indeed, activated PMN have been observed to undergo a re-distribution of 
PSGL-1 on their extracellular surface, from a diffuse to a more concentrated spatial 
localization in uropods, and this event has been proposed to favour receptor/ligand 
interaction with platelets (Bournazos et al., 2008a). Moreover, PMN activation as 
sustained by the pro-inflammatory peptide n-formyl-methyl-leucyl-phenylalanine 
(fMLP), induces the extracellular β2 integrin CD11b-CD18 (Mac-1) to undergo 
conformational changes which lead to an increase in the binding affinity of PMN to 
platelets, even in the absence of platelet activation (Evangelista et al., 1996, 
Bournazos et al., 2008a). Indeed, Mac-1 can either establish a bridging complex with 
platelet receptors through fibrinogen (Spangenberg et al., 1993) or directly  interact 
with molecules expressed on the platelet plasmalemma such as GPIb or ICAM 
(Cerletti et al, 1999). Following Mac-1 dependent PMN-platelet interaction, further 
stabilization of the complex requires platelet activation and the consequent 
engagement of leucocyte PSGL-1 by platelet P-selectin (Evangelista et al., 1996). 
Therefore, PMN-platelet interaction requires a dual adhesive mechanism involving a 
co-adjuvant action of PSGL-1 and Mac-1 ligation. By contrast with monocytes, 
blockade of Mac-1, that does not exert any modulatory effect on MPA formation 
(Steiner et al., 2003), is able to prevent PMN-platelet aggregation with similar 
efficacy to anti-PSGL-1 or anti-P-selectin blocking antibodies (Evangelista et al., 
1999; Haselmayer et al., 2007). Suggestions in to the differences in the biomolecular 




mechanisms involved in the differential binding of platelets to monocytes and to 
neutrophils also come from the observed divergence in effect of the anti-coagulant 
sodium citrate on the levels of heterotypic complexes measured in human samples: 
blood collected into sodium citrate contains less MPA than that measured when 
blood is anti-coagulated with  heparin or hirudin, due to the calcium chelating 
activity that distinguishes the former which reduces the calcium-dependent contact 
between PSGL-1/P-selectin occurring ex vivo (Bournazos et al., 2008b). No such 
difference is observed on the level of PMN-platelet aggregates when these different 
anti-coagulants are used, thus suggesting a minor dependency of PMN-platelet 
interaction on the calcium-dependent PSGL-1/P-selectin binding.  Figure 1.4 and 1.5 
illustrate the mechanisms involved in heterotypic aggregation between platelets and 
both PMN and monocytes. 
 
 




































Figure 1.4 Adhesive mechanisms involved in heterotypic aggregation. Molecules in red 
rectangles are those necessary for heterotypic aggregate formation, while molecules 
indicated in green rectangles are those that participate in stabilization of the complexes.  
For PMN-platelet interaction, engagement of both PSGL-1 and Mac-1 by P-selectin and 
GPIb/ICAM respectively is required, and blockade of each of these interactions abolishes 
heterotypic complex formation. Their binding affinity for platelet ligands is influenced by 
PMN pre-activation status, independent of platelet stimulation. For MPA formation, PSGL-1 
ligation is considered the main effector, whilst Mac-1 participates in further stabilization of 
the initial aggregate. However, Mac-1 blockade does not exert any modulating activity on 
MPA formation, which is strongly inhibited by PSGL-1 or P-selectin blocking agents only.  
Monocyte activation status does not influence MPA formation. The molecules illustrated in 
this scheme activate signalling pathways as shown in Figure 1.5. The consequent release of 
pro-inflammatory cytokines and reactive oxygen species (ROS) positively feed-to cause 
both platelet and white cell activation, thus amplifying the pro-inflammatory activity of the 








1.6.2 Effect of platelet interaction on PMN function 
As is the case with monocytes, contact with activated platelets modulates the pro-
inflammatory activity of PMN through mutual cross-talk involving adhesion 
molecules and humoral factors released by activated cells. Reactive oxygen species 
production by PMN is induced by PSGL-1 ligation, this effect being amplified by 
the presence of fibrinogen (Ruf et al., 1992). Since fibrinogen binds to 
CD11b/CD18, it can be hypothesised that the participation of Mac-1 in adhesion also 
has functional consequences by sustaining platelet-dependent activation of PMN. On 
the other hand, PSGL-1 binding enhances the adhesion of PMN to fibrinogen 
through the activation of β2 integrins (Xu et al., 2007) that can be further sustained 
by the secretion of IL-8 from platelet-activated PMN (Hidari et al., 1997). PSGL-1, 
along with Mac-1 activation, also stimulates PMN degranulation (Hidari et al., 1997) 
and enhances their phagocytic ability (Maugeri et al., 2009). Additionally, given the 
role of Mac-1 in mediating leukocyte interaction with endothelial ICAM-1 and 
VCAM-1, activation of CD11b on PMN secondary to platelet interaction carries 
important implications in promoting PMN adherence to the vascular endothelium 
and their trans-migration into inflamed tissues (Xu et al., 2007). In this setting, the 
previously demonstrated ability of the intracellular domain of PSGL-1 to interact 
with, and induce a re-organization of, the cytoskeleton (Ba et al., 2005) is likely to 
contribute to PMN adhesion, rolling and consequent migration through the vascular 
endothelium (Tauxe et al., 2008). The interaction between CD40 and CD40L, 
described above as an importnat adjunctive cellular adhesive mechanism involved in 
the stabilization of MPA, is also a significant player in PMN-platelet interaction 
since lack of its expression, either on platelets or leucocytes, has been found to 
reduce, but not abolish, the formation of PMN-platelet heterotypic complexes 




(Lievens et al., 2010). Moreover, TREM-1-mediated interaction between PMN and 
platelets has been described as a crucial effector in  the activation of PMN and 
consequent IL-8 release in response to platelet co-incubation (Haselmayer et al., 
2007). Figure 1.5 summarises the functional effects exerted by activated platelets on 
PMN and monocytes as a consequence of heterotypic aggregation. The enhancement 
of pro-inflammatory activity induced by platelets on both cell types suggests a co-
ordinated and concerted action of both MPA and PMN-platelet aggregates in the 
























Figure 1.5. Biomolecular pathways activated in monocytes and PMN following platelet 
interaction and engagement of adhesion molecules. Blue arrows indicate in-cell signalling 
induced by leucocyte-platelet aggregation, while red arrows illustrate the effect of the main 
mediators that, following release/production by platelet-activated cells, exert positive 
feedback on the initial molecular mechanisms and consequently cell activation status. 
Briefly,  PSGL-1 ligation induces ROS-dependent activation of NFkB that translocates into 
the nucleus to induce pro-inflammatory gene transcription. Cell release of pro-inflammatory 
cytokines amplify the reaction through MCP-1–dependent recruitment of other leukocytes 
and autocrine TNF-α/IL-8-induced cell activation. The concomitant activation of MAPK by 
PSGl-1 stabilizes the transcript of COX-2 (induced by NFkB) and promotes its protein 
expression, with consequent production of prostanoids deriving from its enzymatic activity. 
These further activate the cell and sustain cell migration. Migration is also influenced by 
PSGL-1 through both direct and indirect effects (this latter sustained by protein kinase 
activation) on the actin cytoskeleton. The resulting structural re-organization of the 
cytoskeleton facilitates leucocyte adhesion and rolling on the vascular endothelium and 
subsequent tissue transmigration. PSGL-1 dependent activation of kinases activates β2 
integrins such as Mac-1. The concerted action of multiple adhesion molecules, including 
CD40, TREM-1 and Mac-1, further amplifies the biomolecular mechanisms underlying 
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1.6.3 Role of PMN-platelet interaction in atherosclerosis 
The role of PMN in the pathophysiology of atherosclerosis has received very little 
consideration compared to that given to monocytes. This is due to a relative lack of 
evidence concerning the recruitment of  PMN into human atherosclerotic lesions, by 
contrast with that regarding monocyte/macrophage colonization within plaques 
which is observable throughout the course of the disease, in both early and advanced 
vascular lesions. Initial observations that PMN are detectable in atherosclerotic 
arteries of primates (Trillo, 1982), and the more recent descriptions of  granulocytes 
infiltrating plaques in murine models of atherosclerosis (Zernecke et al., 2008; van 
Leeuwen et al., 2008; Rotziu et al., 2010), have never been supported by similar 
histological findings in human specimens. Some workers (Weber & Noels, 2011; 
Drechsler et al., 2011) have proposed that the fact that human plaques stain positive 
for myeloperoxidase (MPO) indicates the presence of PMN, based on the fact that 
PMN are particularly rich in MPO. However, this only provides indirect evidence of 
potential PMN infiltration in human atherosclerosis, and does not exclude the 
possibility that MPO could derive from monocyte-macrophage cells that also contain 
this enzyme, albeit in lower quantities (Daugherty et al., 1994). Failure to detect 
PMN within plaques might be attributable to poor sensitivity of the current 
methodologies or to fast turnover of PMN within tissues, as recently indicated by 
Drechsler (Drechsler et al., 2011), or even to a differentiation programme of PMN in 
the post-migration phase that might alter their phenotype. Regardless of this 
considerations, even if PMN trafficking is truly low in vascular lesions, their 
pathophysiological involvement in atherosclerosis may occur through mechanisms 
other than direct recruitment into the arterial wall. Evidence has emerged that PMN 
favour monocyte trans-migration through the release of intracellular granules 




containing chemotactic substances such as azurocidin (Soehnlein et al., 2005) and 
cathepsin G (Chertov et al., 1997), that attract monocytes locally and increase their 
adhesiveness to endothelial cells by inducing integrin activation.  In accordance with 
this, depletion of neutrophils in animal models of atherosclerosis reduces monocyte 
infiltration into vascular lesions in the early stage of disease (Drechsler et al., 2010). 
In this context, it is reasonable to hypothesise that platelet-dependent activation of 
PMN that follows heterotypic aggregation may amplify the pro-inflammatory/pro-
atherogenic activity of PMN. However, the poor stability of PMN-platelet complexes 
makes it problematic to detect variations in the level of these aggregates in the 
peripheral blood in the context of acute and sub-acute thrombotic events, making 
difficult the evaluation of the relationship between their dynamics of formation and 
the occurrence of cardiovascular events in humans. In the peripheral blood of 
patients with acute ischaemic stroke, MPA level increases with no change in the 
concentration of PMN-platelet complexes, either during the acute or convalescent  
phases compared to controls (McCabe et al., 2004; Tsai et al., 2009; Cao et al., 
2009). Controversial results have been reported by Marquardt (Marquardt et al., 
2009) who observed that PMN-platelets are more consistently elevated than MPA 
over the 90 days following acute stroke, although a completely different 
methodology was used to that in the previously mentioned studies, and this could 
have affected the results. In the context of coronary disease, increased formation of 
PMN-platelet complexes has been detected only during acute myocardial infarction 
(Linden et al., 2007) and in unstable angina (Ott et al., 1996), whilst patients with 
stable angina were found to have levels of PMN-platelet aggregates comparable to 
control subjects (Ott et al., 1996; Furman et al., 1998b; Linden et al., 2007). On the 
contrary, MPA formation increases in both stable and unstable coronary disease 




compared to healthy controls. Moreover, in patients with underlying cardiovascular 
risk factors but asymptomatic for cardiovascular disease, in whom increased MPA 
levels have been reported  even in the absence of acute thrombotic events, the 
formation of PMN-platelet complexes is not affected and their levels are similar to 
those measured in healthy subjects (Tuttle et al., 2003; Kaplar et al., 2001).  
Taken together, the evidence suggests a primary role of PMN-platelet aggregation in 
the setting of acute thrombotic events. In accordance with this, a modulatory action 
of PMN-platelet complexes on the pro-thrombotic/pro-coagulant activity of 
monocytes has been described by Halvorsen (Halvorsen et al., 1993) who 
demonstrated enhancement in TF expression on monocytes through PMN-derived 
cathepsin G. However, the poor stability of PMN-platelet complexes may 
underestimate their level of formation during the sub-acute and chronic phases of 
atherosclerosis and, as a consequence, their contribution to the progression of 
disease. With regards to their contribution to disease progression, this can be largely 
ascribed to the action of PMN-platelet complexes on promoting and amplifying 
monocyte pro-atherogenic activity.  
 
1.7 Monocytes 
Monocytes constitute 5-10% of peripheral blood leucocytes in humans. They 
originate in the bone marrow from a myeloid precursor, enter the peripheral 
circulation and, after a short half-life in the blood (approximately 3 days), migrate 
into the tissues to give rise to resident macrophages as well as dendritic cells. The 
morphology of circulating monocytes in the peripheral blood is heterogeneous as 
they vary in size, granule content and nuclear morphology. Differential expression of 




surface molecules has also been reported and has allowed their phenotypic 
classification into different subsets which display distinct inflammatory properties 
(Auffray et al.,2009). However, due to the complexity of their morphological and 
functional heterogeneity, monocyte characterization in humans still remains an 
active area of research and the precise pathophysiological relevance of each subset in 
different inflammatory conditions remains unclear. In the context of cardiovascular 
disease, one of the major challenges is to understand the pro-atherogenic role of 
distinct subpopulations, and to determine whether their pattern of distribution in the 
peripheral blood might be indicative of stage of disease. 
 
1.7.1 Monocyte heterogeneity and characterization 
Monocytes were initially identified by their expression of the differentiation antigen 
CD14 on the extracellular membrane. CD14 is a 55-kDa glycoprotein anchored to 
the membrane through glycophosphatidylinositol (Simmons et al.,1989). It functions 
as a receptor for bacterial lipopolysaccharide (LPS) and acts by transferring LPS 
from the circulating protein:lipopolysaccharide complex  to the  Toll-like receptor 
4/MD-2  on monocytes. Engagement of this complex results in intracellular 
activation of the nuclear transcription factor NFκB and MAPK signalling, with 
consequent up-regulation of inflammatory genes (Wright et al., 1990; Bochkov et 
al., 2002). CD14 is then crucially involved in the adaptive immune response by 
promoting innate host defence mechanisms, such as release of inflammatory 
cytokines, and in up-regulation of co-stimulatory molecules. CD14 also recognizes 
apoptotic cells and favours, in this way, the phagocytosis of such cells (Devitt et al., 
1998).   




The ability of monocytes to infiltrate various tissues and terminally differentiate into 
distinct cellular lines with tissue-specific functions (macrophages, dendritic and 
Langherans cells and also osteoclasts) raises the question of whether different 
subsets of monocytes in the peripheral blood commit to specific maturation 
programmes and/or target organs. In 1989, the identification of a novel 
subpopulation of monocytes was reported and characterized by double positivity for 
the classical marker CD14 and a different surface molecule known as CD16 
(Passlick et al., 1989). This latter is a low-affinity immunoglobulin G (IgG) Fc 
receptor initially described on the extracellular membrane of natural killer (NK) cells 
and neutrophils (Fleit et al., 1982; Chang et al., 1983).  Flow cytometry analysis of 
the peripheral blood revealed that two subsets of monocytes are distinguishable on 
the basis of these two differentiation antigens, and include the “classical” monocytes 
highly expressing CD14 but not CD16, and those double positive for these molecules 
(although the level of CD14 expression is lower in this compared to the classical 
population). These subpopulations were then named CD14++CD16- and 
CD14+CD16+. The distinction was recently refined in 2003 (Ancuta et al., 2003) 
when, within the group of CD16 positive monocytes, the presence of two different 
cellular subsets was described, characterized by differential fluorescence intensity 
for the CD14 signal: CD14highCD16+ and CD14lowCD16+, to be distinguished from 
the classical CD14highCD16- cells.  
It has been demonstrated that these different subpopulations exhibit distinct 
functions in inflammation, in terms of phagocytic ability, cytokine production and 
infiltrative ability (Table 1.4). This can be in part ascribed to the distinct 
combinations of chemokine receptors and adhesion molecules present on their 




cellular surface (Gordon & Taylor, 2005; Ziegler-Heitbrock, 2007; Ingersoll et al., 
2010). 
 
Table 1.4. Different functions in inflammation displayed by human monocyte subsets in 
relation to distinct phenotypes.  
FUNCTIONAL CHARACTERIZATION PHENOTYPIC CHARACTERIZATION
FUNCTION CD14+CD16- CD14+CD16+ IMPLICATED 
MOLECULES
EXPRESSION ON  
CD14+CD16-









No data No data
Antigen 
presentation































Cytokine production reported is that obtained in response to LPS stimulation of monocytes. 
 
1.7.2 Monocytes in atherosclerosis: recruitment into the vascular wall 
An initiating event in atherosclerosis is the accumulation of macrophages within the 
vascular wall and their modification into lipid-laden foam cells (Shashkin et al., 
2005) through a process regulated by the balance between uptake of modified low-
density lipoprotein (LDL) cholesterol and efflux of cholesterol and other lipids. 
Monocytes infiltrating tissues give rise to macrophages, and therefore it is largely 
accepted that monocytic colonisation of the sub-endothelial space is responsible for 
the formation of the lipid core central to atherosclerotic plaques. However, monocyte 
recruitment into the human vascular wall has never been observed directly. Evidence 




comes from morphological analyses that show monocytes adherent to the luminal 
endothelium (Gerrity, 1981), or ex vivo perfusion studies that demonstrate monocyte 
adhesiveness to atherosclerotic arteries but not healthy ones (Ramos et al., 1999; 
Huo et al., 2000). Moreover, in vivo animal experiments have demonstrated that 
silencing of different genes coding for adhesion molecules involved in monocyte-
endothelium interaction results in beneficial effects on disease progression, and in 
particular reduces accumulation of monocyte-macrophage cells in the plaque (Wu et 
al., 2009). However, the difficulty in phenotypic characterization of monocytes in 
mouse blood (as will be illustrated in Chapter 3) and in identification of homologues 
in the different species limit the direct translation of evidence obtained in animal 
models to human disease and, more importantly, confuse our understanding of what 
monocytic subset predominates in the pathogenesis of human atherosclerosis. 
It is only recently that the homology between murine and human monocytes has 
been clarified (Table 1.5). Based on a microarray approach (Ingersoll et al.,2010) 
Ingersoll et al have identified the counterpart of human CD14highCD16+ cells as so-
called Ly6ChighCD115+ murine monocytes, to be distinguished from the 
Ly6ClowCD115+ subset that shows a similar gene expression pattern to human 
CD14lowCD16+ monocytes. Ingersoll’s work refined the previous functional 
characterization of murine monocytic subsets based on their differential ability to 
migrate into the tissues, and particularly the vascular wall. Geissmann et al 
(Geissmann et al.,2003) demonstrated that Gri- cells (corresponding to the 
Ly6ClowCD115+ subset) have a “patrolling” role in the vascular wall as compared to 
Gri+ monocytes, these findings being in agreement with Potteaux et al who showed 
that atherosclerotic plaques in ApoE-/- mice (an established model of atherosclerosis 
that develops as a consequence of increased LDL-cholesterol level in these animals) 




are mainly infiltrated by Ly6Clow monocytes (Potteaux et al.,2011). Controversial 
data were obtained by Swirski et al (Swirski et al., 2007) who found that Ly6Chigh 
dominate in ApoE-/- mice and infiltrate the plaques in greater number than do 
Ly6Clow. The different methodological strategies used in the phenotypic 
characterization of monocytes in these studies, coupled with different ages of the 
animals as well as the anatomical sites studied, might account for the variability in 
results. Indeed, stage of disease and differences in shear stress and/or tissue 
microenvironment are likely to favour preferential recruitment of one monocytic 
type over another through selective modulation of specific endothelial surface 
integrin expression, monocyte chemoattractant protein (MCP) production and 
chemokine ligand accumulation (i.e. RANTES). For instance, early atherosclerotic 
lesions are rich in endothelium-derived MCP-1 (Cybulsky et al., 1991; Shyy et al., 
1994), while in advanced stages of disease the high level of activated platelets at 
plaque sites is responsible for local release of RANTES (von Hundelshausen et al., 
2001). Moreover, trans-endothelial migration assays performed with human 
monocytes have shown that CD14+CD16+ and CD14+CD16- cells respond differently 
to agents such as macrophage inflammatory protein (MIP)-1α, MIP-1β, and MCP-1 
(Weber et al.,2000). Similarly, the expression pattern of adhesion molecules 
including CD11b and CD11c, that bind ICAM-1, VCAM-1 and E-selectin on the 
endothelium, as well as of chemokine receptors, differs between the two 
subpopulations of human monocytes (Gordon & Taylor, 2005). The recent 
comparison between human and murine monocytes performed by Ingersoll et al 
(Ingersoll et al.,2010) has confirmed these observations, implying a functional 
distinction of monocytic subsets in both species, and a distinct responsiveness and 
ability to infiltrate the inflamed vascular wall depending on the micro-environment 




(reviewed by Wollard & Giessmann, 2010; Ley et al., 2011 and Weber & Noels, 
2011).   
 
Table 1.5 Comparison between human and murine monocyte subsets, based on 










CD14 +++ ++ ++ +
CD16 - + + ++
Ly6C ND ++ ND +
CD115 +++ +++ +++ +++
F4-80 ND + ND +
CD11b ++ + ++ +
CD11c ++ + +++ +++
CX3CR1 + + ++ ++
CCR2 + + - -
CCR5 + + - +
FUNCTION
Vascular adhesion in 
small blood vessel
In response to 
CCL2




Mainly mediated by 
CX3CL1










NA Predominate in 
atherosclerotic
aorta





The listed molecules are those mainly implicated in the pro-atherogenic activity of 
monocytes. ”Classical” human monocytes are CD14+CD16- cells and their murine 
counterpart is the Ly6Chigh population. Non-classical human monoocytes are 
CD14+CD16+ cells and their murine counterpart is the Ly6Clow subset.  CD11b and 
CD11c are integrins that participate in monocyte-vascular infiltration via interaction 
with adhesion molecules ICAM-1 and VCAM-1. CX3CR1, CCR2 and CCR5 are 
chemokine receptors that determine responsiveness of monocytes to different 
chemotactic/migratory stimuli and regulate monocyte infiltration in atherosclerotic 
arteries (Tacke et al., 2007; Combadiere et al., 2008). CXCR1 interacts with CXCL1 
(otherwise known as fractalkine); CCR2 and CCR5 recognize CCL2/MCP-1 and 




RANTES respectively. CD14 and CD16 expression enable distinction of human 
monocytes, whilst the murine subsets which are identified as CD115+F4-80low cells, 
are distinguished based on Ly6C differential expression. ND=not detected; NA=no 
data available. 
 
1.7.3 Monocyte heterogeneity and atherosclerosis: clinical observations 
The characterization of human monocytes in the setting of cardiovascular disease is a 
recent area of investigation, and to date very few data on this have been published. 
One of the first studies was performed in a cohort of 247 patients with coronary 
artery disease (CAD), in whom a higher number of circulating CD14+CD16+ 
monocytes was found compared to controls (Schlitt et al.,2004). Moreover, the level 
of cells double positive for CD14 and CD16 showed a significant and independent 
association with degree of coronary atherosclerosis and serum concentration of the 
pro-inflammatory cytokine TNF-α. The largest population study is known as the “I 
LIKE HOMe study” (Rogacev et al., 2010), and was designed to assess the 
correlation between the pattern of distribution of the different monocytic subsets in 
the peripheral blood and the presence of obesity (a recognized cardiovascular risk 
factor) and of subclinical atherosclerosis, as defined by carotid intima-media 
thickness (IMT). The study involved 622 healthy volunteers and showed a strong 
association between level of CD16+ monocytes and body mass index (BMI) as well 
as IMT. These data are strongly suggestive of a potential pro-inflammatory and pro-
atherogenic effect of CD14+CD16+ cells in humans.  In line with this evidence, the 
percentage of circulating CD14highCD16+ cells appears to predict future 
cardiovascular events, at least in dialysis patients (Heine et al., 2008) and in non-
dialysis chronic kidney disease (CKD) (Rogacev et al., 2011). Moreover, a reduction 




in the baseline level of circulating CD14+CD16+ monocytes has been described in 
healthy subjects undergoing regular exercise training (Timmerman et al.,2008), 
which would be expected to protect against atherosclerosis and cardiovascular 
disease. Similarly, weight loss in obese subjects was found to significantly reduce 
the level of CD14+CD16+ cells in parallel with a reduction of IMT (Poitou et al., 
2011). A study in subjects with type 2 diabetes mellitus reported no difference in the 
different monocyte populations compared to normal people; however, increased 
fluorescence intensity of CD14 antigen on the whole monocytic population was 
observed in diabetics, and this correlated with the level of C reactive protein and the 
presence of arterial disease (Patino et al.,2000).  
It is clear that the pattern of distribution of monocytic subsets in the peripheral blood 
is dynamic, and changes in these subsets may reflect the inflammatory status which 
in turn relates to atherosclerosis. However, the biological significance of the changes 
observed under these pathophysiological circumstances remains unclear. A recent 
study was conducted to investigate the phenotype of monocytes and their 
relationship with the clinical course and outcome of 46 patients after stroke.  Soon 
after the acute event, patients showed a transient increase in the percentage of 
circulating CD14highCD16+ cells which peaked at 48h, while the subset of 
CD14lowCD16+ decreased and the “classical” monocytes did not change. 
Interestingly, the level of CD14highCD16+ cells was predictive of  better prognosis in 
terms of mortality, while increase of CD14highCD16- cells was associated with poor 
outcome and increased size of cerebral infarction (Urra et al.,2009). These results 
seem to suggest a potential beneficial action of the double positive subset of 
monocytes, despite the fact that a number of previous investigations, performed in 
vitro and in animal models together with the clinical observations abovementioned, 




support the hypothesis that they likely have a pro-atherogenic effect. Moreover, the 
pattern of distribution of the monocyte subtypes in the peripheral blood of the study 
population prior to the acute event was unknown. The authors of this study cite the 
high migratory and phagocytic activity as well as the pro-angiogenic activity of 
CD14highCD16+ cells as possible mechanisms favouring the resolution of brain 
damage in the area of infarction. However, the same functional features might exert 
detrimental effects within an atherosclerotic lesion, leading to progressive increase 
of plaque size and destabilization. Table 1.5 summarises the changes in circulating 
monocytes seen in different clinical studies, together with the association of these 
changes with clinical parameters.  
 









The table shows differences observed in the study population when compared to healthy 
controls. Nomenclature of the monocyte populations used in the table, as well as in the text, 
is as reported by the authors in each study. CKD: chronic kidney disease; NIDDM: type 2 
diabetes mellitus; MFI: mean fluorescence intensity; CRP: C reactive protein; CV 
cardiovascular; BMI: body mass index; IMT: intima-media thickness. 






(Rogacev et al., 2011)
119 CD14+CD16+ Future CV events
Coronary artery disease 
(Schlitt et al.,2010)




622 CD14+CD16+ BMI, IMT
Dialysis
(Heine et al.,2008)
94 CD14+ CD16+ Future CV events
NIDDM
(Patino et al.,2000)










1.8 Anti-thrombotic and anti-inflammatory properties of anti-
platelet drugs 
Platelet inhibition is a well established therapeutic intervention  in the clinical 
management of atherosclerosis-related cardiovascular disorders. In  patients with 
prior cardiovascular events, including myocardial infarction and stroke, and in those 
with symptomatic peripheral or stable coronary vascular disease, the use of anti-
platelet drugs provides significant benefit in the prevention of further thrombotic 
events. More debated, and still the subject of much controversy, is whether anti-
platelet therapy has any place in primary prevention in subjects presenting with 
cardiovascular risk factors, but who are otherwise healthy and asymptomatic for 
atherosclerotic disease. In such cases, any net clinical benefit of anti-platelet therapy 
depends on the balance between prevention of arterial thrombosis on the one hand 
versus bleeding complications on the other. As a general rule, anti-platelet therapy is 
recommended in cases where the risk of  future cardiovascular events outweights the 
hazard of bleeding complications, as is generally the case in secondary prevention. 
Therefore, in primary prevention, the prescription of anti-platelet therapy requires a 
careful clinical evaluation on a case-by-case basis, of the risks cersus benefits of 
such therapy (reviewed by Passacquale & Ferro, 2011b).  
Unfortunately, currently available diagnostic approaches for cardiovascular risk 
stratification, although useful on a population basis, carry important limitations in 
terms of accuracy in predicting future cardiovascular events in a given individual.  
This will be discussed further in Chapters 4 and 5 of this thesis. In the following 
sections, an overview of the current indications that guide the use of anti-platelet 




drugs in clinical practice, and the effect of different anti-platelet agents on both pro-
thrombotic and pro-inflammatory activity of platelets, will be given.  
 
1.8.1. Indications for the use of anti-platelet therapy in clinical practice 
Aspirin, dipyridamole and the thienopyridine derivatives clopidogrel and prasugrel, 
are the most widely used anti-platelet drugs in clinical practice.  
Aspirin is a non-steroidal anti-inflammatory drug that acts on the enzymatic activity 
of   cyclooxygenase (COX)-1. It acetylates a serine hydroxyl group at position 529 in 
COX-1, and the consequent steric modification of the enzyme inhibits the 
metabolism of arachidonic acid, thus inducing a  defect in the synthesis of TxA2 
which is the main prostanoid deriving from  platelet COX-1 activity (Patrignani et 
al., 1982; FitzGerald et al., 1983, Patrono et al., 2005) .   
Dipyridamole reduces platelet activation through several biochemical processes, 
namely an increase in intracellular cyclic AMP (cAMP), alteration in the 
biosynthesis of prostanoids, and potentiation of the inhibitory effect of adenosine on 
platelets by blocking its degradation and uptake by erythrocytes and other vascular 
cells (Harker & Kadatz, 1983).  
Thienopyridines are pro-drugs that require oxidation by hepatic cytochrome P-450 to 
be converted into their active metabolites. The active compounds selectively and 
irreversibly bind the (ADP) purinergic receptor P2Y12 on platelets, thus preventing 
ADP-dependent platelet activation (Williams et al., 2008). A similar mechanism of 
action is shared by the most recently developed P2Y12  antagonist ticagrelor, that 
belongs to the cyclopentyl-triazolo-pyrimidine chemical class of drugs. Ticagrelor 




induces reversible blockade of the P2Y12 receptor, and has shown superiority to 
clopidogrel in reducing cardiovascular events in subjects with acute coronary 
syndrome (PLATO trial, 2011; Wallentin et al., 2009), as well as having a potential 
advantage of shorter time of offset, which may be useful for example if surgery is 
contemplated: its action wears off in 24-72 hours compared to thienopyridines which 
take at least 5 days to wear off  (reviewed by Cattaneo & Podda, 2010).  
The differential mechanisms of action of currently available anti-platelet drugs are 

















Table 1.7. Comparison of indications for different anti-platelet agents in 
cardiovascular prophylaxis. [Modified from Passacquale & Ferro, 2011b]  
DRUG / MECHANISM ACUTE CORONARY SYNDROME / PCI STABLE ANGINA AND OTHER 
CARDIOVASCULAR DISEASE 
PRIMARY PREVENTION FOR 
THOSE AT HIGH 
CARDIOVASCULAR RISK 
Aspirin
Reduces production of 
platelet agonist 




with clopidogrel or prasugrel (see below)
Long-term therapy:  
75mg daily 
First line option for:
1. prior myocardial infarction 
2. stable angina
3. transient ischaemic attack (in 
combination with dipyridamole: 
see below) 
75 mg daily long-term 
ONLY when calculated 10-year 
cardiovascular risk >20% and




Metabolites inhibit platelet 
activation by preventing 
ADP from binding to its 
platelet receptor  P2Y12
Acute therapy: 
Loading dose 600mg / Maintenance Dose 
75mg daily
IN COMBINATION WITH aspirin  75mg daily 
(UNLESS aspirin is contraindicated or not 
tolerated) for 12 months.
Long-term therapy: 
After 12 months discontinue (but 
continuing aspirin 75mg daily) or review 
First line option for:
1. prior stroke
2. peripheral vascular disease
3. multivessel disease
4. prior myocardial infarction (ONLY
when aspirin is contraindicated or 
not tolerated )
75 mg daily long-term
As for aspirin, but ONLY when 
aspirin is contraindicated or not 
tolerated
75 mg daily long-term
Prasugrel
Metabolites inhibit platelet 
activation by preventing 
ADP from binding to its 
platelet receptor  P2Y12
Acute therapy:
ONLY if required urgently, or in patients 
with type 2 diabetes, or if stent thrombosis 
occurs while taking clopidogrel, or if 
clopidogrel is contraindicated.
Loading Dose 60mg /  Maintenance Dose 
10mg daily 
IN COMBINATION WITH aspirin 75mg daily 
(UNLESS aspirin is contraindicated or not 
tolerated) for 12 months
Long-term therapy: 
After 12 months discontinue (but 
continuing aspirin 75mg daily) or review
No data available No data available 
Ticagrelor
Inhibits platelet activation 
by preventing ADP from 
binding to its platelet 
receptor  P2Y12
Acute therapy: 
Loading dose 180mg / Maintenance Dose 
90mg twice daily
IN COMBINATION WITH aspirin  75mg daily 
(UNLESS aspirin is contraindicated or not 
tolerated) for 12 months.
Long-term therapy: 
After 12 months discontinue (but 
continuing aspirin 75mg daily) or review 
No data available No data available 
Modified-release 
Dipyridamole
1. Potentiates inhibitory 
effect of adenosine on 
platelets by reducing its 
degradation and uptake
2. Increases intracellular 
cAMP
3. Modulates biosynthesis 
of prostanoids
Not indicated First line option for:
1. transient ischemic attack IN 
COMBINATION WITH aspirin 75mg 
daily (or alone if aspirin is 
contraindicated or not tolerated) 
2. prior stroke ONLY when 
clopidogrel is contraindicated, IN 
COMBINATION WITH aspirin 75mg 
daily (or alone if aspirin is 
contraindicated or not tolerated) 








1.8.1.1 Secondary prevention 
According to the most recent guidelines for secondary cardiovascular prophylaxis, 
aspirin remains the first line option for long-term treatment (more than 12 months) of 
patients with acute coronary syndrome (encompassing STEMI, NSTEMI and 
unstable angina) and stable angina (CG48 NICE guidelines, 2007; CG94 NICE 
guidelines, 2010). On the other hand, clopidogrel is recommended in subjects with 
prior stroke or peripheral vascular disease (CG90 NICE guidelines, 2010). The 
recommended choices of one anti-platelet agent over another are based on review of 
the literature to identify the most effective treatment in specific clinical settings, 
coupled with an economic analysis of cost/benefit ratio. Direct comparison of the 
efficacy of aspirin and clopidogrel in long-term cardiovascular prophylaxis has 
shown no important differences between the two drugs (CAPRIE trial, 1996). 
Therefore, taking into consideration cost-effectiveness analyses, aspirin is 
recommended as first-line and, when contraindicated or not tolerated, clopidogrel is 
used as an alternative (CG48 NICE guidelines, 2007). Superiority of clopidogrel in 
preventing cardiovascular events in patients with peripheral vascular disease 
(subgroup analysis of CAPRIE trial, 1996) as well as recurrent stroke (PROFESS 
trial) support its preference over aspirin in these particular clinical settings (Table 
1.7).  
The different mechanisms of actions of anti-platelet agents might explain their 
differing effectiveness in distinct clinical conditions. Moreover, with their separate 
molecular targets, co-administration of these drugs provides for a concerted 
modulation of multiple signalling pathways involved in platelet activation, that 
results in superior anti-thrombotic efficacy compared to that obtained with 




monotherapy. Dual anti-platelet intervention is restricted  to the  treatment of 
patients immediately after a thrombotic event, and is recommended for the first 12 
months following ACS and PCI (Task Force for Diagnosis and Treatment of Non-
ST-Segment Elevation Acute Coronary Syndrome of European Society of 
Cardiology et al., 2007; Van de Werf F et al., 2008; CG182 NICE guidelines 2009; 
CG90 NICE guidelines 2010; CG 236 NICE guidelines, 2011), a period when more 
aggressive platelet inhibition consistently reduces the risk of a secondary event to a 
level which greatly outweighs potential heamorragic complications (CREDO trial, 
2002; CURE trial, 2003; CLARITY trial 2005; COMMITT trial, 2005). Aspirin plus 
clopidogrel is generally recommended in cases of acute coronary syndrome, whilst 
prasugrel is preferred over clopidogrel in diabetic patients, in whom the greater anti-
platelet effect of prasugrel has shown clinical advantages over clopidogrel 
(TRITON-TIMI 38 trial, 2007). A greater anti-platelet effect of ticagrelor over 
clopidogrel has been demonstrated in the PLATO trial (Wallentin et al., 2009), and 
ticagrelor is now considered a valid therapeutic alternative to thienopyridines for the 
treatment of acute coronary syndrome (NC 236 NICE guidelines, 2011). However, 
the anti-platelet superiority of both prasugrel and ticagrelor over clopidogrel has 
been demonstrated only in one clinical trial for each drug (TRITON-TIMI38 for 
prasugrel and PLATO for clopidogrel) and, because of this, further trials are required 
to address the real benefit of these novel anti-platelet drugs in clinical practice. For 
the long-term management of patients with acute coronary syndrome, aspirin alone  
is preferred over dual anti-platelet therapy, since the use of dual therapy in the long 
term gives rise to a risk of bleeding that outweighs the anti-thrombotic benefit 
(CHARISMA trial, 2006; MATCH trial, 2004).  




For the treatment of transient ischaemic attack, current guidelines indicate the use of 
aspirin plus dipyridamole (CG90 NICE guidelines, 2010), whilst for stroke 
clopidogrel alone is recommended, since it provides similar efficacy to 
aspirin+dipyridamole with a reduced risk of haemorrhagic complications (PROFESS 






















Table 1.8. Efficacy and safety profile of different anti-platelet drugs and regimes. 
[Modified from Passacquale & Ferro, 2011b]. 
TRIAL STUDY 
POPULATION
TREATMENT FOLLOW-UP END-POINT NNT NNH
ACUTE CORONARY SYNDROME 
UNSTABLE ANGINA, NSTEMI, STEMI:
CREDO 2116 pts scheduled 
for elective PCI
Clopidogrel vs placebo
Aspirin in all pts
(81-325 mg)
12 months CV death, MI, or
stroke
33 48
CURE 12 562 pts with ACS 
with NSTEMI 
Clopidogrel + aspirin 
vs Placebo + aspirin 
(Aspirin dose 75-325 mg) 








CLARITY 3491 pts with STEMI Clopidogrel + aspirin 
vs Placebo + aspirin 
(Aspirin dose 150-325 mg) 
30 days Death, recurrent 
MI 
16 500 
COMMIT 45 852 pts with MI 
93% STEMI/7% NSTEMI
Clopidogrel + aspirin 
vs Placebo + aspirin 





PLATO 18,624 patients with
ACS (STEMI/NSTEMI)
Ticagrelor + aspirin









PCI-CURE 2658 pts with ACS 
undergoing PCI








PCI-CLARITY 1863 pts with STEMI 
undergoing PCI 
Clopidogrel + aspirin 
vs Placebo + aspirin 
(Aspirin dose 150-325 mg) 
30 days Death, recurrent 
MI, or stroke
22 100 
CURRENT 25086 pts with ACS 
undergoing early PCI
Clopidogrel double dose 
vs Clopidogrel standard 
dose
30 days CV death, MI, or 
stroke
30 20.53
TRITON-TIMI 38 13,608 pts with ACS 
scheduled for PCI
Prasugrel vs clopidogrel
Aspirin in all pts
(75-162 mg)
15 months CV death, MI, or
stroke
45 45
STABLE ANGINA AND OTHER CARDIOVASCULAR DISEASE
MATCH 7599 high-risk pts Aspirin vs placebo 
Clopidogrel in all pts 
(75mg)





CHARISMA 15 603 pts with 
multiple risk factors 
or evident CV disease
Clopidogrel vs placebo 
Aspirin in all pts 
(75-162 mg)
28 months CV death, MI or 
stroke
200 250
CAPRIE 19 185 pts with 








PROFESS 20 333 pts with 




2.5 years Recurrent stroke 500 200
 




Table 1.8 [continued] 
Efficacy is expressed as number needed to treat (NNT), according with to formula 
NNT=1/ARR, where ARR (absolute risk reduction) = CER (control event rate) – EER 
(experimental event rate); CER refers to aspirin and EER to the other anti-platelet drug(s) as 
specified for each trial. Safety is expressed as number needed to harm (NNH), calculated 
with the same formula as NNT but on the basis of bleeding disorders reported in each trial. 
Clinical trials are divided according to study population: 
- acute coronary syndrome (ACS) encompassing unstable angina, ST-elevation myocardial 
infarction  (STEMI) and non-ST-elevation myocardial infarction (NSTEMI); 
 - ACS undergoing percutaneous coronary intervention (PCI);  
- stable atherosclerotic disease including stable angina, peripheral vascular disease and those 

















 1.8.1.2 Primary prevention 
As mentioned above, by contrast to the situation with secondary prevention, the 
place of anti-platelet therapy in patients asymptomatic for atherosclerotic disease is 
much debated. The JBS-2 guidelines recommend the use of aspirin in patients with a 
calculated cardiovascular risk of greater than 20% over 10 years (Joint British 
Societies’ guidelines 2005); however, even here, its use for this indication should be 
judged on an individual basis (Barnett et al., 2010),  and only following correction of 
high blood pressure, due to the risk of major bleeding complications in patients with 
uncontrolled hypertension treated with any anti-platelet medication. On the other 
hand, the recent Antithrombotic Trialists’ Collaboration meta-analysis 
(Antithrombotic Trialists' (ATT) Collaboration 2009), which reviewed the efficacy 
of aspirin in preventing serious vascular events in six primary prevention trials, 
showed equivocal net benefit of aspirin in subjects without prior disease, since the 
reduced rate of vascular events in the aspirin arm was counterbalanced by a higher 
risk of major gastrointestinal and extracranial bleeds compared to placebo. 
Therefore, the use of anti-platelet drugs in primary prevention requires a full 
comprehensive evaluation of the risk of experiencing future cardiovascular events 
versus the risk related to bleeding complications.  
However, parameters other than simply the rate of bleeding events could be 
implicated in the lack of clinical benefit deriving from anti-platelet intervention in 
primary prevention trials. An importnat aspect that should be taken into account in 
the analysis of results is the heterogeneity of the study populations studied.  
Asymptomatic patients can be at a different stages of the atherosclerotic disease 
process, some having silent vascular lesions that might benefit greatly from anti-




platelet intervention much more than those who are at the earliest stages of 
atherosclerosis development. Lack of a diagnostic tool able to effectively 
characterize and distinguish such sub-groups of patients in relation to stage of 
disease makes it difficult to ascertain, in such studies, which patients do and which 
do not benefit from anti-platelet therapy. 
Moreover, in all the clinical trials, including those designed for primary prevention, 
the main outcomes have been reduction of fatal and non-fatal cardiovascular events, 
the emphasis being on the pharmacological modulation of acute thrombus formation. 
It is reasonable to hypothesise that, in the early stages of atherosclerosis, when 
vascular lesions are developing, targeting the pro-inflammatory action of platelets, 
for example through therapeutic modulation of heterotypic aggregation, may produce 
greater benefit than a pharmacological approach mainly affecting platelet homotypic 
interaction, which associates with acute thrombotic complications in the later stages 
of disease. In the future, drugs which are designed to specifically inhibit heterotypic 
aggregation may prove to be more useful in primary prevention than those which 
inhibit homotypic aggregation.  
 
1.8.2 Anti-inflammatory effect of anti-platelet drugs  
Different anti-platelet drugs display significant divergence in the pharmacological 
modulation of heterotypic aggregate formation, despite similar inhibitory effects on 
platelet-platelet aggregation (and consequent thrombus formation) (Passacquale & 
Ferro 2011a). As described above, homotypic and heterotypic aggregation are 
sustained by distinct molecular pathways that selectively regulate the alpha and 
dense granule release reactions. Homotypic aggregation appears to be mainly related 




to dense granule release, with alpha granule content acting as a amplifier of platelet 
activation and thrombus growth. Heterotypic aggregation is directed by alpha 
granule exocytosis and consequent P-selectin expression, an event that is not related 
necessarily to dense granule release and can occur also in the context of sub-clinical 
platelet activation. The distinct abilities of different anti-platelet agents to interfere in 
the biomolecular pathways that regulate alpha and dense -granule release confer on 
them differential anti-inflammatory and anti-thrombotic properties (Figure 1.6).  





























Figure 1.6. Pharmacological modulation of dense and alpha-granule release reaction. 
Aspirin irreversibly blocks the enzymatic activity of COX-1 which is a key enzyme in the 
metabolism of arachidonic acid to produce prostanoids. COX-1 converts arachidonic acid to 
the unstable intermediate prostaglandin G2 (PGG2). Further metabolism of PGG2 by 
hydroperoxidases (HOX) leads to prostaglandin H2 synthesis that is finally converted into 
prostanoids by tissue-specific isomerases (platelets mainly contain TxA2 synthase resulting 
in production and release of TxA2). By acting on COX-1, aspirin reduces TxA2-dependent 
platelet activation, with the main effect being on dense granule release and consequent 
homotypic aggregation. However, aspirin does not affect the pathway regulated by ADP that 
acts on alpha-granule release. Indeed, although negatively modulated by aspirin, the minimal 
release of ADP stored in dense granules is able to stimulate platelets through P2Y12 and 




P2Y1 receptors.  Activation of the P2Y12-dependent pathway leads to alpha granule 
exocytosis that sustains heterotypic aggregation via P-selectin translocation to the platelet 
plasmalemma. Thienopyridines are able to modulate this biomolecular pathway through 
preventing ADP from binding its specific receptor P2Y12. The resulting preservation of 
PKA inhibitory action on both alpha and dense granule release negatively modulates 
heterotypic and homotypic aggregation [Modified from Passacquale & Ferro, 2011a].  
 
For instance, aspirin-mediated platelet inhibition is regulated by  COX-1-dependent 
modulation of dense granule release. Indeed, an early study reported that alpha 
granule exocytosis, as detected by P-selectin expression, vWF and beta-
thromboglobulin secretion, was not at all influenced by COX-1 blockade, in platelets 
stimulated with either ADP or thrombin (Rinder et al., 1993).  These data imply that 
TxA2 signalling is primarily involved in dense granule but not alpha granule 
secretion. In accordance with this, Li et al. reported no effect in healthy subjects of 
aspirin either on platelet P-selectin expression or on platelet-leucocyte aggregation, 
after stimulation with ADP, thrombin or platelet activating factor (Li et al., 2003). 
Similarly, Klinkhardt et al. found that aspirin did not affect the formation of 
leucocyte-platelet complexes in the circulation (Klinkhardt et al., 2003), and 
Moshfegh et al. demonstrated a reduced effect of aspirin when compared to other 
anti-platelet drugs in reducing platelet P-selectin expression (Moshfegh et al., 2000). 
Since heterotypic aggregates are believed to promote atherosclerosis progression 
through sustaining a pro-inflammatory state, this relative lack of effect of aspirin on 
heterotypic aggregation may explain at least in part the lack of any clear effect on 
atherosclerosis progression as well as the poorer results on clinical outcome, 
particularly in the setting of primary prevention. 




 As regards the thienopyridines, antagonism of P2Y12 has been demonstrated  to 
directly affect homotypic aggregation, as well as  effectively reduce CD40L and P-
selectin expression and consequent platelet-leucocyte aggregate formation (Storey et 
al., 2002). In accordance with these findings, thienopyridines, but not aspirin, have 
been shown to reduce platelet P-selectin expression, which can be explained by their 
ability to inhibit ADP-induced alpha-granule release (Klinkhardt et al., 2003; Storey 
et al., 2002).  Prasugrel has shown greater efficacy than clopidogrel in modulating 
heterotypic aggregation  and P-selectin expression, in ADP-stimulated platelets 
obtained from subjects with atherosclerosis treated with the two different 
thienopyridines (Braun et al., 2008).  
Thus, P2Y12 blockade may modulate vascular inflammation in addition to platelet 
thrombosis (Antonino et al., 2009), and this peculiar action on the pro-inflammatory 
activity of platelets might conceivably result in more effective cardiovascular 
prophylaxis than aspirin in the early stages of disease. Clinical trials are needed to 
invesigate this hypothesis. So far, very little evidence exists to show a beneficial 
action of anti-platelet therapy on disease progression. In an early clinical study, 
Ranke (Ranke et al., 1993) described  reduction of carotid atherosclerosis 
progression in aspirin-treated patients following one year administration of 900 mg 
aspirin daily, which is certainly above the dose clinically used normally for 
cardiovascular prophylaxis; a few years later, Kodama (Kodama et al., 1999) showed 
delayed progression of carotid intima-media thickness (IMT) in type 2 diabetics 
either on aspirin 81mg/day or ticlopidine 200 mg/day compared to untreated patients 
over a 3-year follow-up period. However, no additional evidence supporting a 
beneficial action of anti-platelet drugs on atherosclerosis progression has been 
reported in the following decade or more of research in the field. On the contrary, as 




described above, doubt has been on any role for aspirin in preventing cardiovascular 
events. Further studies are required to establish whether and for what group of 
patients, aspirin and/or thienopyridines or other anti-platelet drugs can provide anti-
atherosclerotic activity. However, before such studies can be done, development of 
innovative modalities enabling more selective and accurate cardiovascular risk 
stratification of individual patients is required, so that these studies can be carried out  


















1.9 Aims of the work 
The work presented in this thesis aimed to develop novel biomarkers of silent 
atherosclerosis, with a view to improving cardiovascular risk stratification of 
asymptomatic patients at risk of future events and hence more effectively targeting 
cardiovascular preventative strategies. Given the relevance of platelet activation in 
the pathophysiology of atherosclerosis, the hypothesis was that differential levels of 
MPA, widely recognised as the most robust available index of blood 
thrombogenicity, are detectable in the peripheral blood of patients with 
cardiovascular risk factors according to degree of disease progression, thus enabling 
the distinction between those with  plaques from disease-free patients. Moreover, 
due to the functional role of activated platelets in modulating monocyte biological 
activity, I felt that further investigation of MPA formation and its downstream 
effects could shed further important light on the underlying atherosclerosis.  
 Therefore, in the first part of my project, the importance of monocyte-platelet 
interaction in human inflammatory pathophysiology was explored, in order to test 
the hypothesis that formation of MPA has pro-inflammatory actions by inducing 
phenotypic changes in circulating monocytes (Chapter 2). 
In the second part, the relevance of platelet-dependent modulation of monocyte 
phenotype to the pathophysiology of atherosclerosis was investigated. For this 
purpose, we conducted a study in an animal model of atherosclerosis (ApoE knock-
out mice), in which the pattern of distribution of the different circulating monocyte 
subsets was analysed at different stages of disease, either in the presence or absence 
of anti-platelet therapy (Chapter 3). 




In the third part, we investigated whether circulating MPA level and/or monocyte 
phenotype are altered in clinically healthy subjects with underlying cardiovascular 









induces a pro-inflammatory 










As discussed in Chapter 1, platelet activation plays a major role in the pathogenesis 
of atherosclerosis and its complications through a combination of pro-thrombotic 
and pro-inflammatory actions that not only promotes the occurrence of acute 
thrombotic events but also contributes to vascular lesion initiation (Davi’ & Patrono, 
2007). Activated platelets can bind to the vascular endothelium through a number of 
receptor-ligand interactions that mediate their local accumulation at the site of a 
vascular lesion (Zimmerman, 2001; van Gils et al., 2009). The arrest of activated 
platelets on the arterial wall is an event that can precede plaque formation  and acts 
as a promoting factor for monocyte recruitment and subsequent infiltration of the 
sub-endothelial space (Massberg et al., 2002). The participation of activated platelets 
in this early stage of disease is attributable to a number of different mechanisms. 
Adherent platelets induce endothelial cells to expose adhesion molecules on the 
luminal surface and synthesise chemotactic factors that recruit circulating  
monocytes (Massberg et al., 2002). On the other hand, adherent platelets constitute 
an adhesive surface per se for circulating monocytes, through platelet P-selectin-
mediated monocytic PSGL-1 ligation (Zimmerman, 2001), and the release of 
platelet-derived inflammatory mediators into the local microenvironment exerts a 
further chemotactic action on circulating monocytes (i.e. soluble CD40L). 
Additionally, their contact with platelets causes enhanced cytokine and prostanoid 
production by monocytes (Weyrich et al., 1995; Weyrich et al., 1996; Dixon et al., 
2006) as well as increased adhesiveness to the vascular endothelium (da Costa et al., 
2006) by inducing integrin over-expression and activation; this not only increases 
monocyte adhesiveness to the vascular endothelium but also enhances trans-
endothelial migration, thus resulting in amplification of the inflammatory response 
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within the vascular wall. It is largely recognized therefore that local heterotypic 
aggregation between monocytes and platelets at the site of a vascular lesion has 
important pro-atherogenic effects (Zimmerman, 2001; Massberg et al., 2002; Huo et 
al., 2003; Huo & Ley, 2004). However, given that MPA are detectable in peripheral 
blood, it is likely that the interaction between monocytes and platelets is not a 
phenomenon strictly confined to the vascular wall, but also found in the systemic 
circulation which may potentially exert a damaging effect on the arteries. 
 
Since circulating monocytes comprise different sub-populations with distinct 
infiltrative and migratory properties into the tissues, that can be identified by their 
differential expression for CD14 and CD16 (Weber et al., 2000; Belge et al., 2002), 
we hypothesised that contact with platelets induces  a pro-inflammatory change in 
monocyte phenotype towards a type more predisposed to contribute to the 
atherosclerotic process.  
 
2.2.Aims 
The overall aim of this chaper was to investigate the effect of platelet activation and 
consequent formation of MPA on the phenotype of monocytes.  
In the first part, we analysed levels of MPA and the normal pattern of distribution of 
the different monocyte subtypes in the circulation of healthy subjects in vivo, as well 
as the relationship between MPA level in the peripheral blood and circulating 
monocyte phenotype in response to a mild acute inflammatory stimulus, namely that 
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in response to influenza immunisation (Posthouwer et al., 2004). Vaccine 
administration has been demonstrated to represent a reliable “human model” of mild 
inflammation and has been used by other investigators to examine cardiovascular 
(patho)-physiology under pro-inflammatory conditions (Clapp et al., 2004; Donald et 
al., 2006; Wallace et al., 2010).  
In the second part, we determined in vitro the underlying mechanism by which 
monocyte-platelet interaction modulates monocyte phenotype and adhesiveness to 
the vascular endothelium. 
 
2.3 Methods 
2.3.1 Effect of influenza immunization on circulating MPA and monocyte 
phenotype 
MPA levels and monocyte phenotype were analyzed in a cohort of  twelve healthy (9 
male, 3 female; age 25-30 years) employees of Guy’s and St Thomas’ NHS 
Foundation Trust, who were attending the Trust’s Occupational Health service to 
receive influenza immunization. Participants were studied immediately before and 2 
days post-immunisation. At the first visit, blood (32 ml) was taken for full blood 
count and biochemistry screening, as well as for high sensitivity C-reactive protein  
(hs-CRP) assay, measurement of CD62P+ platelets (reflecting degree of platelet 
activation), determination of MPA level and characterization of monocytes. At the 
second visit, blood (4 ml) was once again taken, for repeat determination of hs-CRP, 
CD62P+ platelets and MPA, as well as monocyte characterization. 
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Percentage of CD62P+ platelets was analyzed by flow cytometry (FACSCalibur, 
Becton Dickinson (BD), Oxford, UK) on whole blood immunostained with 
fluorescein isothiocyanate (FITC)-conjugated anti-human CD42b and 
allophycocyanin (APC)-conjugated anti-human CD62P (BD Bioscience, UK). 
10,000 events in total were acquired within the platelet gate, as identified on forward 
and side light scatter plot. MPA determination and monocyte characterization were 
performed by whole blood flow cytometry, as described below. 
The study was approved by St Mary’s Hospital Research Ethics Committee, London, 
UK. All participants gave written informed consent. 
 
2.3.2 Monocyte characterization and MPA measurement in peripheral blood  
More detailed monocyte and MPA characterization was performed by whole blood 
flow cytometry analysis in a additional cohort of 15 healthy subjects (10 male, 5 
female; age 25-35 years).  Samples were processed immediately after venepuncture 
according to the following protocol. 100 µl whole blood, collected in sodium citrate 
(0.3% final concentration), was transferred into polystyrene tubes (BD Bioscience, 
UK) and incubated with saturating concentrations of the following antibodies: 
peridinin chlorophyll protein complex (PerCP)-conjugated anti-human CD14, FITC-
conjugated anti-human CD16, APC-conjugated anti-human CD42b or CD62P, 
phycoerythrin (PE)-conjugated anti-human CD11b or CD11c (all from BD 
Bioscience), APC-conjugated anti-human Toll-like receptor (TLR)-2 or 4, and APC-
conjugated anti-human CD162 (PSGL-1) (eBioscience, UK). Isotype control 
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antibodies were used as negative control. These were added in different 
combinations to whole blood immediately after collection, and the incubation 
continued for 20 min at 4°C.  Erythrocytes were then lysed with 1ml FACS lysing 
solution (BD Bioscience, UK), for 10 min at room temperature, followed by two 
washes with phosphate buffered saline (PBS) supplemented with 0.2% bovine serum 
albumin and 0.1% sodium azide. Samples were fixed in 1% paraformaldehyde and 
kept at 4°C until analysed by flow cytometry (FACSCalibur, Becton Dickinson, 
Oxford, UK) within a maximum of 48 h from sample preparation.  
Forward- and side-light scatter parameters were used to access the monocyte 
population, and a total of 20,000 events was acquired. The negative and positive 
delineators were determined from the isotype control fluorescence.  
Monocyte subsets were identified by double immunostaining for CD14 and CD16. 
The percentage of CD14+ cells also expressing CD42b (all platelets) or CD62P 
(activated platelets) was also calculated and taken as representative of total MPA 
(Figure 2.1 and 2.2). By gating for each monocyte subtype, we also calculated the 
percentage of MPA formed by the different subsets of monocytes,  and we analyzed 
their positivity and mean fluorescence intensity (MFI) for PSGL-1, in order to 
identify potential differences in the ability of distinct monocyte subpopulations to 
bind platelets. The percentage of cells positive for CD11b/c or TLR-2/4 as well as 
the MFI for CD11b/c or TLR-2/4 was also analyzed within the different monocyte 
gates. Post-acquisition analysis was performed using FlowJo software (Tree Star, 
Ashland, OR). A schematic representation of the method used for flow cytometry 
analysis is illustrated in Figure 2.2. 
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Figure 2.1 Monocyte-platelet aggregates.  Detection of monocyte-platelet aggregates in 
whole blood by immunofluorescence confocal microscopy. Whole blood was stained with 
PE-conjugated anti-human CD14 (red) and FITC-conjugated anti-human CD42b (green). 
The overlay  shows a double-stained aggregate.  
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STEP 1: acquisition 
of total events in 
whole blood







Figure 2.2 Schematic representation of flow cytometry analysis of whole blood. Samples were 
stained with PerCP-CD14, FITC-CD16 and APC-CD42b. The forward scatter light plot allowed the 
identification of the different leucocyte types. Acquisition was then gated for the monocyte population 
which was distinguished into three subsets on the basis of CD14 and CD16 expression: R1, 
CD14highCD16-; R2, CD14highCD16+; R3, CD14lowCD16+. Post-acquisition analysis was performed to 
study the percentage of MPA formed by each subtype. Q2 (quadrant in the right corner) indicates the 
percentage of monocytes binding platelets (as defined by double positivity for CD14 and CD42b). 
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2.3. 3 Monocyte-platelet co-culture experiments 
2.3.3.1 Cell isolation, MPA measurement and monocyte  characterization 
Whole blood (30 ml) collected in EDTA was subjected to Lymphoprep gradient 
centrifugation. The plasma obtained was centrifuged (1400×g, 4 °C, 6 min) to obtain 
platelets and platelet-conditioned medium (PCM). Platelets were resuspended, under 
sterile conditions, in PBS containing 5 mmol/l EDTA, centrifuged  (500×g, room 
temperature, 5 min) and resuspended (25 × 109 platelets/ml) in serum-free RPMI-
1640. PCM was obtained by stirring isolated platelets in serum-free RPMI-1640 
(1200 rpm, 10 min, 4 °C), followed by removal of platelets by centrifugation 
(10,000×g, 3 min, room temperature) and collection of supernatant.  
Mononuclear cells obtained after Lymphoprep gradient centrifugation of whole 
blood underwent immunomagnetic negative selection for CD14+CD16- monocytes 
(kit from Invitrogen) according to the manufacturer’s instructions. Purity of 
isolation, as determined by antigen expression (CD14+, CD16-, CD3-, CD4-, CD8-, 
CD20-) using flow cytometry, was 78-82% in all experiments. Isolated cells were 
resuspended in serum-free RPMI-1640 (106cells/ml), and transferred to polystyrene 
tubes.  
Aliquots of purified autologous platelets or equal volumes of PCM were added to 
monocyte suspensions (1 ml final volume, monocyte:platelet ratio 1:100 in 
experiments where platelets were added) and incubated at 37°C, 4% CO2 for 48 h. 
Although these experiments were performed in the absence of pharmacological 
platelet agonists, the platelet isolation and culture procedure prior to addition to 
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monocytes induced platelet activation, with P-selectin expression measured at 
87±3%.  
Viability of monocytes, as assessed by Trypan Blue dye exclusion, was >95% 
immediately after their isolation and after 48h culture, either in the presence or 
absence of platelets/PCM. CD16 expression and MPA formation were assessed by 
flow cytometry at different time points. The supernatants were also collected and 
soluble P-selectin measured according to the manufacturer’s instructions (R&D 
System, UK).  
 
2.3.3.2 Investigation of the role of platelet P-selectin binding to monocyte 
PSGL-1 in modulating MPA and monocyte phenotype 
The above experiments were repeated by co-incubating monocytes with platelets or 
PCM in the presence of monoclonal anti-human PSGL-1 blocking antibody 
(10µg/ml; Chemicon), and the effect compared to that obtained with isotype control 
(mouse anti-human IgG, 10µg/ml; Chemicon). 
Additionally, monocytes were treated for 48h with increasing concentrations of 
soluble human recombinant P-selectin (0-240 ng/ml, R&D System), and monocyte 
CD16 expression as well as MPA formation in vitro were measured at the end of the 









2.3.3.3 Monocyte adhesion to endothelial cells 
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical 
cords obtained from uncomplicated deliveries following healthy pregnancies; these 
were obtained from the labour ward at St Thomas’ Hospital, with written informed 
consent from the mothers. HUVEC isolation was performed using previously 
described methods (Jaffe et al., 1973). When the endothelial cells were confluent at 
passage three, HUVEC were seeded onto coverslips in 12-well plates. The following 
day, HUVEC were stimulated with TNF-α (10 ng/ml, Invitrogen) for 3h at 37°C, 
and then washed with PBS. A cell suspension containing monocytes pre-cultured 
either in medium alone or with platelets for 48h was added to the coverslip cultures. 
After a further 2h incubation at 37°C, non-attached cells were removed by vigorous 
pipetting. Immunostaining using PE-conjugated anti-CD14 and FITC-conjugated 
anti-CD16 was then performed at 4°C for 20 min. After washing in PBS twice, 
HOECHST solution was added for nuclear staining and removed after 2 min 
incubation, following which cells were fixed in 1% paraformaldeyde. The coverslips 
were mounted on slides with mounting medium and analyzed by fluorescence 
microscopy. Cells positive for monocytic markers were counted in ten fields (20x 
magnification). 
 
2.3.4 COX-2 expression in monocytes 
We investigated COX-2 induction in monocytes co-incubated for 18h with either 
platelets or medium alone. Following such incubation, cells were permeabilized with 
Triton X100 0.01%, and immunostained for 20 min at 4°C in PBS/0.2% BSA 
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containing PE-conjugated mouse anti-human COX-2 antibody (Calbiochem,UK; 
1µg/ml). After washing in PBS and fixation in 1% paraformaldeyde, cells were 
resuspended in 10µl PBS, seeded on a microscope slide and examined under 
fluorescence microscopy (40x magnification, Zeiss LSM, 510 META). 
 
2.3.5 Thromboxane and PGE2 receptor expression on monocytes 
Expression at the mRNA level of the thromboxane receptor (TP) (α isoform) and the 
different PGE2 receptors (EP1, EP2, EP3 and EP4) was studied by semi-quantitative 
reverse transcriptase polymerase chain reaction (RT-PCR), in freshly isolated 
monocytes and those cultured for 48h either in medium alone or with platelets. Total 
RNA was extracted by phenol-chloroform extraction (TRIZOL, Invitrogen) and 
resuspended in RNase- and DNase-free water. RNA concentration was analyzed by 
NanoDrop and 500 ng total RNA used for cDNA synthesis. Equal aliquots of cDNA 
were then PCR-amplified by Taq Polymerase (Invitrogen, UK) in a 40µl reaction 
containing 1x Buffer, 250 µM dNTPs, 4 mM MgCl2, 1.25 µM of each primer, 2U 
Taq. The conditions of amplification were as follows: an initial 5min at 95°C for 
denaturation; 36 cycles of 95°C for 1min, 60°C for 1min and 72°C for 1min 30s; and 
a final extension step of 72°C for 10min. The sense and antisense primers used, and 









Table 2.1 Sequence of primers used for RT-PCR. 
 
 
2.3.6 Investigation of the role of COX-2 and PGE2 in modulating MPA and 
monocyte phenotype 
CD16 expression and MPA formation were analyzed following monocyte co-
incubation with platelets for 48h, either in the presence or absence of different COX 
inhibitors: NS-398 (10µM, a COX-2-selective inhibitor) (Kato et al., 2001), SC-560 
(30nM, a COX-1-selective inhibitor) (Kato et al., 2001) and aspirin (0.5mM, a non-
selective COX inhibitor). The effect of PGE2 receptor blockade on CD16 expression 
and MPA level was also examined using the EP1/EP2-selective antagonist AH-6809 
(10µM; Cayman) and the EP4-selective antagonist AH-23848 (10µM; Cayman) 
(Meya et al., 1993), either alone or in combination. In other experiments, monocytes 
were stimulated with PGE2 (1µM) for 48h. NS-398, aspirin and EP antagonists were 
resuspended in DMSO/PBS solution (1:3), whilst SC-560 was resuspended in 
ethanol. PGE2 was resuspended in PBS. In all experiments, the effects of each 
agonist/antagonist were compared to those obtained using the respective vehicle. 
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2.3.7 Statistical analysis 
All data are presented as mean ± SD. Statistical analysis was performed using 
GraphPad Prism 4 software. Differences in level of hs-CRP, CD62P+ platelets, MPA 
and monocyte phenotype before and after influenza vaccine were evaluated by 
paired Student’s t test, and the associations between these different parameters were 
analyzed by least squares and multiple regression analyses. All other statistical 
comparisons were by ANOVA, with or without repeated measures as appropriate. In 


















2.4.1 Influenza immunisation causes an increase in circulating MPA and a shift 
in circulating monocytes towards CD16 positivity 
Administration of the influenza vaccine induced a mild inflammatory response in all 
participants, as demonstrated by an increase in hs-CRP 2 days post-immunisation (0.57±0.26 
mg/L at baseline vs 2.94±1.44 mg/L two days post-immunization, p=0.002). The systemic 
inflammatory response was paralleled by an increase in degree of platelet activation, as 
reflected by CD62P+ platelet positivity and level of MPA (Figure 2.3A). We also observed a 
change in distribution pattern of monocyte subsets, with an expansion of the pool of 
CD14+CD16+ monocytes (Figure 2.3B). Within this double positive pool, the subset of 
CD14highCD16+ monocytes showed the greatest increase in percentage (from 4.7±3.61% to 
10.44±4.79%, p=0.003), whilst the CD14lowCD16+ subset did not change significantly (Figure 
2.3B).  
 
In examining the relationship between the percentage of CD14highCD16+ monocytes and other 
variables examined (hs-CRP, CD62P+platelets and MPA levels), a linear correlation was 
found between the CD14highCD16+ subpopulation and both hs-CRP and percentage of 
CD62P+ platelets. However, levels of CD14highCD16+correlated more closely to percentage of 










 Figure 2.3 Effect of influenza immunisation on platelet activation and monocyte 
phenotype. Percentage of CD62P+platelets and MPA (A), and monocyte characterization 
(B), measured at baseline (PRE) and 2 days after influenza immunization (POST). Figures 
show representative dot plots obtained from flow cytometry, as well as accumulated data 
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from n=12 experiments. Monocytic subsets are designated R1 (CD14+CD16-), R2 
(CD14highCD16+) and R3 (CD14lowCD16+). (C), Regression analyses for CD14highCD16+ 
monocytes (R2) vs CD62P+platelets and vs hs-CRP.  
 
2.4.2 Detailed characterization of circulating monocytic subsets and MPA  
As shown above, on the basis of CD14 and CD16 expression, circulating monocytes were 
distinguished into three subsets: CD14+CD16-, which constituted the majority (82.74±5.99% 
of total monocytes), with smaller contributions from CD14+CD16+ cells, comprising 
CD14highCD16+ (4.98±1.76%) and CD14lowCD16+ subtypes (4.99±2.03%) (Figure 2.4A). All 
of these monocytic subsets expressed the adhesion molecules CD11b and CD11c on their 
extracellular surface. However, the level of expression of CD11b was higher on CD14+CD16- 
cells than on CD14lowCD16+ monocytes, whereas these latter cells expressed an increased level 
of CD11c compared to the CD14+CD16- subpopulation; the CD14highCD16+ cells 
demonstrated an intermediate phenotype, expressing both CD11b and CD11c at high level 
(Figure 2.4B). CD14highCD16+ cells also represented the monocytic subtype with the highest 
expression level for both TLR-2 and TLR-4. Specifically, all the different subsets of 
monocytes were positive for TLR-2, but the MFI value was higher in CD14highCD16+ cells 
than in the other monocyte subtypes.  TLR-4 was found to be expressed by 76.35±12.3% of 
CD14+CD16- monocytes, 91.7±5.8% of CD14highCD16+ (p=0.02 vs CD14+CD16-) and 
82.03±7.26% of CD14lowCD16+ cells (p>0.05 vs CD14+CD16-). Moreover, CD14highCD16+ 
cells exhibited higher MFI for TLR-4 compared to the other monocytic subtypes (Figure 
2.4C). 
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Figure 2.4  Circulating monocyte characterization. (A) Percentage of the different 
circulating monocyte subpopulations, with a representative whole blood flow cytometry dot 
plot showing CD14 and CD16 expression, as well as accumulated data from n=10 
experiments presented graphically. (B) Representative flow cytometry dot plots for CD14 
and CD11b (left) or CD11c (right) in the different monocyte subsets. Graph displays MFI 
values for CD11b (filled bars) and CD11c (open bars) in each subset (n=10). (C), 
Representative flow cytometry dot plots for CD14 and TLR-2 (left) or TLR-4 (right) in the 
different monocyte subsets. Graph displays MFI values for TLR-2 (filled bars) and TLR-4 
(open bars) in each subset (n=10). *,**, *** p<0.05, <0.01 and <0.001 respectively vs R3. †, 
‡








Circulating MPA, as defined by double positivity for CD14 and CD42b, accounted for 
15.2±6.7% of the monocytic population. No significant difference was observed in the ability 
of the different monocyte subpopulations to interact with platelets (Figure 2.5A). In 
accordance with this, a similar expression of PSGL-1 was observed in all the distinct 
monocyte subpopulations (Figure 2.5B).  However, as expected, the number of 
CD14+CD62P+ events was less than the number of CD14+CD42b+ events, most likely 
attributable to P-selectin shedding from the plasmalemma of activated platelets, as has been 































Figure 2.5 Circulating MPA characterization.  (A) Representative flow cytometry dot plots for 
CD14 and CD42b (left panel) or CD62P (right panel). Graph shows data accumulated from n=10 
experiments illustrating the %  MPA formed by the different monocytic subsets, as determined from 
CD14+CD42b+ (filled bars) or CD14+CD62P+ (open bars) events (n=10). (B) Representative flow 
cytometry dot plots for CD14 and CD162 (PSGL-1) in the different monocyte subsets. Graph displays 
MFI values for CD162 in each subset (n=10). In black, red and blue are CD14+CD16- (R1), 
CD14highCD16+ (R2) and CD14lowCD16+ (R3). 
 
Chapter Two 




2.4.3 Monocyte-platelet interaction leads to a phenotypic change of CD14+CD16- 
monocytes towards CD14+CD16+ 
An initial experiment was performed to study the kinetics of CD16 expression and MPA 
formation, when monocytes in culture were co-incubated with either autologous platelets or 
medium alone, for up to 48h.  Monocytes in medium alone showed a progressive time-
dependent increase of CD16 cell surface expression. Co-incubation with platelets up-regulated 
CD16 expression to a greater degree from 18h onwards (Figure 2.6A). MPA formation 
increased in a time-dependent manner, even when monocytes were incubated with medium 
alone; this reflects an unavoidable degree of platelet contamination of the monocyte sample, 
with resultant MPA formation. Nevertheless, the addition of exogenous platelets to the culture 
medium substantially augmented MPA formation, at all time points examined from 18h 
onwards (Figure 2.6B).  
On the basis of these results, in subsequent experiments the effect of platelets (or 
corresponding medium) on CD16 expression in isolated monocytes was investigated at 24h 
and 48h of co-culture, whilst the effect on MPA formation was measured at 48h.  These 
experiments confirmed that co-incubation with platelets for 48h caused significant up-
regulation of CD16 on monocytes as compared with medium alone (Figure 2.6C), and an 
increase in MPA formation (Figure 2.6D). Regression analysis showed a direct relationship 
between level of MPA formation and percentage of monocytes expressing CD16 at 48h 
(Figure 2.6E).  
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Figure 2.6 Effect of platelets on monocyte phenotype. Percentage of CD14+CD16+ 
monocytes (A) and MPA (B), following incubation of monocytes with platelets (M+P, solid 
line) or medium alone (M, dotted line) for different times (n=1). Dot plots show flow 
cytometry analysis after 48h culture. Accumulated results from n=10 experiments showing 
percentage of CD14+CD16+ monocytes (C) and MPA (D) after co-incubation of monocytes 
with platelets (M+P) or medium alone (M). (E), Regression analysis of MPA level vs 
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percentage of CD14+CD16+ cells at 48h. (F), Percentage of CD14+CD16+ cells (upper panel) 
and MPA (lower panel) after co-incubation of monocytes with platelets for different times, 
either in the presence of isotype antibody (solid line) or anti-PSGL-1 blocking antibody 
(dotted line) (n=4). **, *** p<0.01 and <0.001 respectively vs anti-PSGL-1. 
 
Although CD16 induction was also seen in monocytes incubated with PCM for 48h, the 
percentage of CD16+ cells was considerably lower than that achieved by incubation with 
platelets (Figure 2.7A). As expected, MPA levels following monocyte culture in PCM was 
unchanged compared to monocytes in medium alone (Figure 2.7B), as were levels of soluble 
P-selectin in the medium (Figure 2.7C). However, soluble P-selectin levels were much greater 
following monocyte co-culture with platelets (Figure 2.7C). 
In order to ascertain whether P-selectin binding to monocytic PSGL-1 is in itself sufficient to 
induce the phenotypic changes observed in monocytes, we examined the effect of co-
incubation with anti-human PSGL-1 blocking antibody or isotype control. Blockade of PSGL-
1 abrogated MPA formation from monocytes in the presence of platelets, and also markedly 
reduced the degree of induction of CD16 expression (Figure 2.6F). Similarly, anti-PSGL-1 
blocking antibody abolished the PCM-induced up-regulation of CD16 on monocytes (Figure 
2.7A). However, soluble P-selectin alone, when added to the culture medium of CD14+CD16- 
monocytes, exerted no demonstrable effect on CD16 expression in monocytes, even at 










Figure 2.7 Effect of platelet-free conditioned medium on monocyte phenotype. 
Percentage of CD14+CD16+ monocytes (A) and MPA (B), following 48h incubation of 
monocytes in medium alone (M), platelet-free conditioned medium either in the absence 
(M+PCM) or presence (M+PCM+anti-PSGL-1) of anti-PSGL-1 blocking antibody, or 
platelets (M+P) (n=3 for each). (C), Soluble P-selectin measured in the supernatant of 
monocytes cultured for 48h under different experimental conditions as shown. (D), 
Percentage of CD14+CD16+ monocytes after 48h exposure to different concentrations of 
soluble P-selectin. *** p<0.001 vs M. 
Chapter Two 




2.4.3 CD14+CD16+ monocytes exhibit increased adhesiveness to activated endothelium  
In  monocytes co-incubated with platelets as well as in those maintained in medium alone, 
cells adhering to TNF-α-pre-activated HUVEC were almost exclusively CD14+CD16+; only 
occasional monocytes  expressing CD14 but not CD16 were observable (Figure 2.8A). 
CD14+CD16+ cells showed a higher expression of both CD11b and CD11c compared with the 
CD14+CD16- subtype (Figure 2.8C).  Pre-treatment of monocytes with platelets increased the 
number of CD14+CD16+ monocytes attaching to HUVEC (Figure 2.8A and 2.8B).  
 
Figure 2.8 Effect of platelets on monocyte adhesiveness to endothelial cells and 
expression of adhesion molecules. (A), Photomicrographs showing CD14-PE (red) and 
CD16-FITC (green) staining of monocytes adhering to  TNF-α-pre-activated HUVEC 
(stained with HOECHST, blue), following 48h culture in medium alone (M) or in the 
presence of platelets (M+P). (B), Number of monocytes/field following 48h pre-culture in 
medium alone (M), in the presence of platelets (M+P) either with or without NS-398 (n=3). 
** p<0.01 vs M. (C), Expression of CD11b (filled bars) and CD11c (open bars) in the same 
cellular suspension tested in the HUVEC adhesion assay, in monocyte subpopulations 
classified according to CD14 and CD16 positivity. *p<0.05 vs CD14+CD16-. 
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2.4.4 COX-2 induction and consequent PGE2 generation underlies the phenotypic 
changes observed in monocytes in response to interaction with platelets 
As previously reported (Dixon et al., 2006), co-incubation with platelets for 18h induced 
COX-2 expression in monocytes (Figure 2.9A). Since this effect temporally preceded the 
phenotypic and functional changes described above in response to monocyte-platelet co-
culture (Figure 2.6), we wished to determine whether COX-2 induction was responsible for 
inducing these changes, by examining the effect of COX-2 inhibition on monocyte phenotype 
and function. Platelet-dependent up-regulation of CD16 on monocytes was markedly reduced 
by the COX-2 selective inhibitor NS-398, while no effect was observed in response to the 
COX-1 selective inhibitor SC-560; aspirin also reduced platelet-dependent up-regulation of 
monocytic CD16, to a degree comparable to NS-398 (Figure 2.9B). MPA formation was not 
affected by SC-560, NS-398 or aspirin (Figure 2.9C). Treatment with NS-398 also led to a 
marked reduction in the number of monocytes adhering to TNF-α-pre-activated HUVEC 
(Figure 2.8B)  As before, we found that CD14+CD16+  cells exhibited an advantage in binding 
to HUVEC over the CD14+CD16- subset.   
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Figure 2.9 Platelet-dependent COX-2 up-regulation in monocytes and effect of COX inhibitors on 
monocytic CD16 expression and MPA formation. (A), Immunofluorescence staining for COX-2 
(red) in monocytes cultured in medium alone (M) or with platelets (M+P) for 18h. Photomicrographs 
are representative of n=3 experiments. Change in CD16 expression (B) and MPA (C) in monocytes co-
cultured with platelets, expressed as % change in CD14+CD16+ and CD14+CD42b+ cells respectively, 
as compared to monocytes cultured in medium alone, after 48h.  Also shown are the effects of NS-398, 
SC-560 and aspirin addition to monocyte-platelet co-culture (n=3-4). *, ** p<0.05 and <0.01 
respectively vs M. 
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In order to clarify whether the effects on CD16 expression obtained with NS-398 and aspirin, 
but not with SC-560, were attributable to differential responsiveness of monocytes to the 
COX-1- and COX-2-derived prostanoids thromboxane A2 and PGE2 respectively (Rothe et 
al., 1996), the mRNA expression of  TP and EP receptors was studied (Figure 2.10A). TP 
expression was found in CD14+CD16- monocytes immediately after isolation, whilst after 48h 
incubation, either in medium alone or with platelets, it became undetectable. Freshly isolated 
CD14+CD16- cells expressed PGE2 receptors, mainly EP2 and EP4 isoforms, with only small 
amounts of EP1 and no EP3 mRNA detectable. After 48h incubation in medium alone, 
mRNA for EP2 and EP4 were still detectable, albeit at lower levels than in freshly isolated 
cells; moreover, EP1 mRNA also became undetectable. Notably, when monocytes were co-
incubated with platelets for 48h, the decrease in mRNA for EP1, EP2 and EP4 was less than 
that observed in monocytes cultured in medium. 
 
We next examined the effect of different PGE2 receptor antagonists on platelet-dependent 
CD16 up-regulation in monocytes (Figure 2.10B) as well as on MPA formation (Figure 
2.10C). The EP1/EP2-selective antagonist AH6809 markedly reduced monocytic CD16 up-
regulation. Although the EP4-selective antagonist AH23848 appeared also to decrease CD16 
up-regulation, this did not reach significance, and there was no additive effect of AH23848 and 
AH6809, suggesting that EP1 and/or EP2 are predominantly involved in modulating 
monocytic CD16 up-regulation in response to platelet interaction. Moreover, the effect of 
AH6809 on the CD16 increase was similar to that seen in response to NS-398, aspirin or anti-
PSGL-1 blocking antibody (Figure 2.7B). The two EP antagonists also reduced formation of 
MPA in vitro, with this effect being significant when they were used in combination rather 
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than singly; and their combined effect was comparable to that in response to anti-PSGL-1 
blocking antibody (Figure 2.8C).  
 
Figure 2.10 Role of COX-2 up-regulation and of PGE2 on platelet-dependent monocytic 
CD16 expression and MPA formation. (A) mRNA level of EP and TP receptors in freshly 
isolated monocytes (lane 1), and after 48h culture either with medium alone (lane 2) or 
platelets (lane 3). 18S ribosomal RNA expression is shown as housekeeping RNA. 
Experiment is representative of n=3.  
Effects of AH6809 and AH3848, alone or in combination (COMB), NS-398, aspirin or anti-
PSGL-1 blocking antibody on CD16 expression (B) and MPA (C) in monocytes co-cultured 
with platelets for 48h, expressed as % change in CD14+CD16+ and CD14+CD42b+ as 
compared to monocytes co-cultured with platelets alone. * p<0.05 vs M+P. 
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The role of PGE2 in determining  platelet-dependent CD16 over-expression in monocytes was 
further explored by studying the effect of PGE2 alone (1µM) on monocyte phenotype. No 
detectable modulation of level of CD16 expression was exerted by PGE2 alone compared with 




























Figure 2.11 Lack of effect of PGE2 alone on monocyte CD16 expression. Monocytes were incubated  
in medium alone (M), in the presence of PGE2 (1µM) (M+PGE2) and with autologous platelets (M+P) 
for 48h. The graph shows the expression of CD16 measured by flow cytometry on cultured cells and 
expressed as % of variation in M+PGE2 and M+P as compared to untreated cells (M) (n=3). 
Representative flow cytometry dot plots shows the percentage of CD16+ monocytes (upper right 










The present data demonstrate that MPA formation gives rise to a phenotypic change 
of circulating monocytes toward CD16+ cells, which display increased endothelial 
adhesiveness. We have shown that this change is mediated by platelet-dependent 
COX-2 up-regulation and consequent PGE2 synthesis in monocytes, and that this 
process can be prevented by selective blockade of either COX-2 enzymatic activity 
or EP receptors.  
 
2.5.1 MPA formation drives the acquisition of a CD16+ phenotype by “classical” 
human monocytes 
Our interest in the study of CD16 expression on human monocytes stems from the 
finding that CD14+CD16+ cells identify a subgroup of circulating cells with higher 
pro-inflammatory activity than the “classical” CD14+CD16- subpopulation (Belge et 
al., 2002). To date, no direct evidence exists in the literature that double positive 
cells originate from “classical” monocytes. This study is the first to show that the 
presence of activated platelets, with consequent MPA formation, induces CD16 up-
regulation on CD14+CD16- monocytes. Although other groups have reported that 
platelets can alter monocytic CD16 expression (Ammon et al.,1998), this has been 
interpreted as an effect on terminal monocytic maturation toward macrophages; 
however, our in vitro results together with our in vivo data point to a change in 
circulating monocyte phenotype rather than a terminal differentiation event. 
Importantly, due to the isolation techniques used in previous studies (elutriation of 
peripheral blood mononuclear cells), circulating double positive monocytes were 
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included in the cells under investigation; and since CD16 antigen was measured in 
the cell supernatant, the prior presence of CD14+CD16+ monocytes is likely to have 
affected the results obtained in such studies. Our in vitro experiments were 
performed specifically with isolated CD14+CD16- monocytes, using flow cytometry 
which allowed the direct detection of CD16 on their cellular surface, enabling us to 
measure the percentage of cells developing positivity for the CD16 marker over 
time. Moreover, we have quantified the degree of interaction between monocytes 
and platelets by measuring monocyte-platelet complexes formed in vitro. Interaction 
with platelets up-regulated CD16 antigen on isolated monocytes, with this effect 
being directly related to the level of MPA. Although simple co-incubation of 
CD14+CD16- monocytes with human recombinant P-selectin did not induce CD16 
expression, anti-PSGL-1 blocking antibody, which we have found to abrogate MPA 
formation (Gkaliagkousi et al., 2009), abolished platelet-induced over-expression of 
CD16 on monocytes, demonstrating that physical contact of monocytes with 
platelets is critical in this process, most likely by P-selectin / PSGL-1 binding 
sustaining multiple receptor-ligand interactions between these cells which trigger the 
final phenotypic changes.  
On the other hand, our experiments suggest that soluble mediators released during 
the process of platelet activation also exert an important modulatory effect on 
monocyte phenotype, since CD16 up-regulation was induced by PCM, albeit to a 
much lower extent than platelets. Nevertheless, PSGL-1 blockade completely 
abolished both platelet-dependent and PCM-dependent CD16 up-regulation, 
suggesting that engagement of monocytic PSGL-1 by either soluble or platelet-
associated P-selectin is a crucial factor in itself to induce platelet-dependent change 
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in monocyte phenotype. However, the lack of observed effect of soluble P-selectin 
alone on monocytic CD16 expression demonstrates that the cross-talk between 
monocytes and platelets is a complex process in which multiple 
mediators/interactions are likely to be required. In this scenario, the PSGL-1/P-
selectin axis is necessary but not sufficient in itself to drive the acquisition of the 
CD16 phenotype by human monocytes. 
 
2.5.2 Biomolecular mechanisms underlying platelet-dependent CD16 expression 
in monocytes: relevance  of COX-2 activity 
This  study has only explored a specific aspect of the mechanism by which MPA 
formation modulates monocyte phenotype and function. The main focus was on the 
relevance of COX enzymatic activity, in particular that of COX-2 inducible isoform, 
based on the evidence that dysregulation in the synthesis of eicosanoids  is a key 
factor in sustaining chronic inflammatory conditions, including atherosclerosis 
(Smith & Langebach, 2001; Cipollone et al., 2008). Moreover, monocytic COX-2 
expression has been suggested to exert pro-atherogenic effects (Cipollone et al., 
2008), and COX-2 up-regulation with consequent PGE2 overproduction in 
circulating monocytes has been even proposed as a marker of asymptomatic 
atherosclerosis (Beloqui et al., 2005). Nevertheless, there is not therapeutic benefit 
of COX-2 inhibition in cardiovascular disease, and in fact the overall effect is 
detrimental as will be discussed in more details in Chapter 5 of this thesis.  
In accordance with the findings of Dixon (Dixon et al., 2006), we have found that 
interaction with platelets induces COX-2 expression in monocytes, and that 
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monocytic COX-2 enzymatic activity, that leads mainly to PGE2 synthesis 
(Cipollone et al., 2008), is a crucial mediator of platelet-dependent change of 
monocytic phenotype. Indeed, the selective COX-2 inhibitor NS-398 prevented the 
increased CD16 expression on monocytes co-incubated with platelets. In parallel 
with these findings, selective blockade of PGE2 receptors mirrored the effects 
observed with COX-2 inhibition. Of note, we found that aspirin counteracted 
platelet-dependent up-regulation of CD16 on monocytes co-incubated with platelets 
to a similar extent as NS-398. Others have demonstrated that aspirin, used at 
concentrations similar to that used in our experiments, modulates PGE2 synthesis in 
monocytes and gives rise to similar effects as those caused by COX-2 specific 
inhibition (Penglis et al., 2000); additionally, the COX-1 selective inhibitor SC-560 
has been found to be less effective than the COX-2 selective inhibitor NS-398 in 
reducing PGE2 production by bone marrow-derived dendritic cells (Harizi et al., 
2002). It is likely that, in our in vitro experiments, aspirin blocked monocytic PGE2 
production by COX-2 inhibition, since the same effect on CD16 up-regulation was 
seen with NS-398 but not with SC-560.  
Our results, therefore, point at a major role exerted by COX-2-derived PGE2 in 
regulating the phenotype of human monocytes in response to platelet interaction. 
However, PGE2 stimulation alone did not modulate monocytic CD16 expression, 
most likely because of the absence of concomitant stimuli and factors, including 
those related to PSGL-1 ligation by platelet P-selectin which we have found to be  
necessary but not sufficient in itself to induce platelet-dependent change in monocyte 
phenotype. Based on our findings, it can be hypothesized that concomitant activation 
of the PSGL-1/ P-selectin axis and PGE2 receptor stimulation play a causal role in 
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mediating monocytic CD16 expression following MPA formation (Figure 2.10, each 
necessary but not sufficient in themselves to mediate this effect).  Consistent with 
this hypothesis, blockade either of heterotypic aggregation (using anti-PSGL-1 
blocking antibody) or of COX-2 activity / PGE2 receptors reduced platelet-dependent 
CD16 expression with similar efficacy. The potential relevance of these findings in 
the therapeutic modulation of the pro-inflammatory effects mediated by MPA will be 
discussed in Chapter 5.  
 
2.5.3 Potential implications in atherosclerosis    
The phenotypic changes induced by MPA formation were found to modulate 
adhesiveness of monocytes to endothelium. Our data suggest that CD14+CD16+  
monocytes have greater potential to adhere to activated endothelium than 
CD14+CD16-  monocytes. In our adhesion assay, monocyte interaction with 
endothelial cells occurred through a mechanism independent of bridging via 
activated platelets. Indeed, the presence of the COX-2 inhibitor in our co-culture 
experiments reduced monocytic adhesion to endothelial cells, despite the fact that the 
same level of MPA was present in the cell suspension added. The reduction in 
CD14+CD16+ monocytes in response to COX-2 inhibition resulted in reduced 
binding of isolated monocytes to activated endothelium. The different adhesive 
properties of the various monocytic subsets may be attributed to differential 
expression of adhesion molecules on their cellular surface. CD11b and CD11c have 
been recognized as crucial mediators of monocyte-endothelium interaction (Kubo et 
al., 2000; Wu et al., 2009). We observed that CD16+ cells, both those developed in 
vitro and those found in the peripheral blood of healthy subjects, display higher 
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levels of these integrins on their surface compared to monocytes positive for CD14 
only.  
We also observed that other molecules involved in the activation of monocytes and 
their pro-inflammatory activity (Zhang & Ghosh, 2001; Barton & Medzhitov, 2002), 
namely TLR-2 and TLR-4, are expressed on CD14+CD16+ monocytes to a higher 
degree than on other subsets. On the other hand, levels of PSGL-1 expression was 
found to be similar among the different monocyte subsets, and CD14+CD16+ cells 
did not differ from the other monocyte subpopulations in their ability to bind 
activated platelets and form MPA, at least in healthy subjects. Consistent with this, 
in our influenza immunization study, similar levels of MPA formed by each subset 
of monocytes were observed both at baseline and post-immunization. Therefore, the 
increased levels of MPA seen in the context of an acute inflammatory state, such as 
that induced by influenza immunization, are essentially attributable to increased 
platelet activation. In our experimental model of inflammation, we found that the 
increase in hs-CRP, activation of platelets and consequent MPA formation are 
accompanied by an increase in the percentage of CD16+ monocytes in the 
circulation, mainly driven by expansion of the CD14highCD16+ subpopulation. It 
cannot be excluded that the vaccine per se drives the phenotypic changes observed 
on circulating monocytes. However, the level of CD14highCD16+ cells was found to 
be strongly and directly related to the percentage of CD62P+ platelets, suggesting 
that the degree of platelet activation influences the phenotype of monocytes in the 
peripheral blood by shifting them towards positivity for CD16.  
The fact that this phenomenon is observable in response to a non-specific pro-
inflammatory stimulus is indicative of poor specificity for CD62P+ platelet and MPA 
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measurement in the diagnosis of atherosclerosis-related inflammation. Nevertheless, 
these data provide evidence that a host of modifications occur in the phenotype of 
circulating monocytes in response to a pro-inflammatory stimulus, rendering them 
more pro-inflammatory and with increased endothelial adhesiveness, and that these 
are strongly related to – and are likely to be driven by –  the extent of platelet 
activation. In the setting of atherosclerosis, the exposure to a chronic inflammatory 
stimulus, such as that which occurs in the presence of cardiovascular risk factors, 
may lead to a similar response. In keeping with this, a characteristic pattern of 
distribution of the different monocytic subtypes has been reported in the blood of 
subjects with dyslipidemia (Rothe et al., 1996), obesity (Rogacev et al., 2010), 
coronary artery disease (Schlitt et al., 2004) and kidney failure (Rogacev et al., 
2011), with the population of CD14+CD16+ cells being expanded in those cohorts 
when compared to healthy controls. In similar clinical conditions, higher values of 
circulating MPA have been described (Furman et al., 1998; Sarma et al., 2002; 
Ashman et al., 2003; Gkaliagkousi et al., 2009), suggesting that the formation of 
heterotypic aggregates between platelets and monocytes may sustain a potential pro-
atherogenic action by increasing the number of pro-inflammatory CD14+CD16+ cells 
in the circulating blood, and not just at the level of the atherosclerotic plaque. Figure 
















































Figure 2.12 Pro-atherogenic effect of MPA formation. The diagram depicts the cellular 
interactions between platelets and endothelium, and between platelets and monocytes. 
Activated platelets interact with a dysfunctional endothelium through multiple receptor-
ligand interactions. These involve adhesion molecules including vWF, PSGL-1 and ICAM-1 
on endothelial cells that interact with platelet GPIb, P-selectin and GPIIb/IIIa (this latter 
through fibrinogen), as previously and extensively reviewed by van Gils (van Gils et al., 
2009). Adherent platelets act as a bridge between circulating monocytes and the arterial 
wall, platelet P-selectin on activated adherent platelets engaging PSGL-1 on circulating 
monocytes. The local formation of MPA promotes monocyte-endothelium interaction by 
inducing over-expression of adhesion molecules on both endothelial cells (Massberg et al., 
2002) and monocytes (da Costa et al., 2006).  
MPA formation in the peripheral circulation may also promote atherosclerosis through the 
induction of a CD16+ phenotype on circulating monocytes. This is mediated through the P-
selectin/PSGL-1 axis and consequent activation of COX-2 in monocytes, with synthesis of 
pro-inflammatory prostanoids such as PGE2.  CD16+ cells are characterized by higher 
expression of adhesion molecules such as CD11b and CD11c compared with classical 
CD14+CD16- monocytes, that facilitate and enhance monocyte adhesiveness to the vascular 
endothelium (Passacquale et al., 2011c). In this way, activated platelets can stimulate 
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monocytic vascular infiltration through a mechanism independent of their bridging action at 
the site of a vascular lesion.   
 
2.5.4 Conclusion 
In conclusion, our findings shed new light on the relevance of platelet-monocyte 
interactions in the pathophysiology of inflammation. Of particular note, MPA 
formation induces a change in the phenotype/endothelial adhesiveness of monocytes 
that is easily detectable in the peripheral blood by measuring CD16 expression in 
circulating monocytes. Whether variation in degree of platelet activation and number 
of CD16+ monocytes occurs in the context of atherosclerosis and are strictly related, 
and whether this phenomenon has pro-atherogenic implications remain to be 
clarified, and these aspects will be explored in Chapters 3 and 4.  
The second noteworthy finding deriving from this study is that the series of 
biomolecular events that follow MPA formation, which result in a change in the 
biological function of monocytes, can be pharmacologically modulated. This carries  
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3.1.1 ApoE-/- mice as an experimental model of atherosclerosis 
Apolipoprotein E deficient (ApoE-/-) mice were developed by two different 
laboratories (Piedrahita et al., 1992; Plump et al., 1992) as an experimental model of 
atherosclerosis. ApoE is a structural component of both very-low-density 
lipoproteins (VLDL) (Shore & Shore, 1973) and high-density lipoproteins (HDL) 
(Mahley, 1985), as well as a protein constituent of intestine-derived chylomicrons 
(Driscoll & Getz, 1986). It acts as a ligand for low-density lipoprotein (LDL) 
receptors expressed on cells, thus favouring the internalisation of lipoproteins and 
their removal from the peripheral circulation (Hui et al., 1981). The scavenging 
action of ApoE for lipoproteins is therefore a crucial regulator of cholesterol 
metabolism, and lack of its expression in ApoE-/- mice gives rise to severe 
hypercholesterolemia and predisposes the animals, otherwise resistant to 
atherosclerotic disease (Paigen et al., 1987), to fatty streak accumulation throughout 
the vascular tree (Piedrahita et al., 1992).  
An early study performed in ApoE-/- mice to evaluate atherosclerosis progression 
showed that foam cell lesions develop in the aortic sinus at 10 weeks of age in 
animals on rodent chow diet, to become fibrous plaques in mice aged 20 weeks. 
High fat diet accelerates the process (Reddick et al., 1994), although this associates 
with extreme variability of lesion area (Meir & Leitersdorf, 2004). However, murine 
plaques generally fail to develop a perfectly formed fibrous cap and yet occurrence 
of thrombo-embolic events is unusual (Caligiuri et al., 1999). Indeed, the 
histological appearance of a lesion, even in a more advanced stage of disease, is 
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typical of a xanthoma, constituted of fat-filled macrophages situated in the arterial 
intima (Seo et al., 1997) that can reach such dimensions that it can cause vascular 
occlusion (although this is a rare event) (Caligiuri et al., 1999). On the other hand in 
humans, the early  atheroma generally consist of a well-defined fibrous cap 
overlying a necrotic core, and lesions often progress with evidence of erosion and 
healing of the fibrous cap, complicated by local thrombus formation with consequent 
distal embolisation, these events being responsible for much of the  symptomatology 
and even death (Virmani et al., 2000). However, it is worth mentioning that the 
majority of the histological findings described in ApoE-/- mice derive from studies of 
the aorta and aortic sinus.  An extensive analysis of plaque distribution in ApoE-/- 
mice has revealed that different anatomic sites display distinct histological features 
(Seo et al., 1997), and lesions seen within the brachiocephalic artery more closely 
resemble those seen in human atherosclerosis, due to the presence of an acellular 
necrotic core, erosion of the necrotic mass and intraplaque haemorrhage, features 
that are not observable in aortic lesions (Seo et al., 1997; Rosenfeld et al., 2000). 
Taken together, these considerations suggest that ApoE-/- mice offer a good, although 
not perfect, experimental model for the study of early human atherosclerosis, and 
provide mechanistic information mainly focused on the events that surround 
monocyte infiltration and lipid core formation within the vessels. 
 
3.1.2 Monocyte characterization in ApoE-/- mice  
Since their generation in 1992, a number of researchers have conducted studies in 
ApoE-/- mice to investigate the mechanisms involved in monocyte chemotaxis, 
recruitment and transmigration into the sub-endothelial space. In recent years, 
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following the discovery of monocyte heterogeneity, particular interest has been 
aroused in the identification of the distinct roles played by different monocytic 
subpopulations in the pathogenesis of plaque development. This area of research, 
however, has posed major difficulties of interpretation and comparison of data 
between different laboratories, mainly due to methodological issues related to the 
characterization of murine monocytes. Unlike humans, mice do not express a 
monocyte-specific marker, and the identification of this cell population is generally 
performed by using multiple “gating strategies” on flow cytometry based on a 
combination of antibodies that allow exclusion/inclusion of white cell populations 
according to their phenotype. For instance, the initial criteria to identify monocytes 
were by firstly their mononuclearity and secondly their myeloid nature. Indeed, 
monocytes have a low side-scatter plot profile in the flow cytometer (SSClow), easily 
distinguishable from the high side scatter characteristic of neutrophils, and higher 
level of expression of CD11b (CD11bhigh) (de Bruijn et al., 1994; Lagasse & 
Weissman, 1996; Biermann et al., 1999) compared to other mononuclear cells 
belonging to the lymphocyte class (CD11blow cells). Lagasse and Weissman also 
showed that absent or low expression of the epitope Gr-1,  a myeloid differentiation 
antigen (Hestdal et al., 1991), in  SSClowCD11bhigh cells is a discriminating criterion 
to distinguish monocytes from other white cell types (Lagasse & Weissman, 1996). 
Based on the finding that monocyte recruitment into lymphatic tissue is mediated by 
selective activation of receptors for chemokines (Palframan et al., 2001), Geissmann 
first demonstrated the heterogeneity of circulating monocytes in mice (Geissmann et 
al., 2003), by providing evidence that molecules involved in monocyte adhesion to 
endothelium (such as the fractalkine receptor CX3CR1) and chemokine receptors are 
differentially expressed on monocytes (as previously discussed in Chapter 1 and 
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summarized in Table 1.5). In accordance with Geissmann’s results, Sunderkötter 
(Sunderkötter et al., 2004) showed that murine monocytes can be differentiated into 
distinct populations based on differential expression of Ly-6C (ER-MP20, a 
monocyte/macrophage differentiation antigen). Moreover, he demonstrated that 
SSClowCD11bhigh are uniformly positive for the macrophage-colony stimulating 
growth factor (M-CSF) CD115, which has been proposed as a universal marker for 
mononuclear phagocytes (Hume et al., 2002). 
Recently, in an attempt to explore the extent of similarity between murine and 
human monocytes, Ingersoll (Ingersoll et al., 2010) described a “gating strategy” for 
the characterization of murine monocytes in peripheral blood by flow cytometry, that 
defines the monocytic population as CD115+F4/80low cells (both of which are 
markers of monocytes-macrophages), and within this group distinguishes two 
cellular subsets based on differential expression of Ly6C. He reports that Ly6Chigh 
are the counterpart of “classical” CD14+CD16- human cells, and Ly6Clow cells 
correspond to human pro-inflammatory CD14+CD16+ monocytes. 
 
3.2 Aims 
The aims of the current work were twofold: we firstly wished to determine whether a 
change in the distribution pattern of circulating monocytes, similar to the expansion 
of pro-inflammatory CD14+CD16+ cells observed in the clinical study of mild 
inflammation described in Chapter 2, is present in the context of atherosclerotic 
disease; and secondly, we wished to address in vivo the potential contribution of 
platelet activation in modulating the phenotype and, in turn, the pro-atherogenic 
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activity of  circulating monocytes. ApoE-/- mice were used as an experimental model 
of atherosclerosis, and studied at different time points according to disease 
progression, either in the presence or absence of conventional anti-platelet treatments 
(aspirin and clopidogrel).  
 
3.3 Methods 
3.3.1 Mice and study design 
Homozygous male ApoE-/- mice (B6.129P2–apoEtm1Unc/J) and wild-type 
C57BL/6J mice were purchased from Charles River Laboratories (Edinburgh, UK). 
In the first part of the study, aiming at establishing the relationship between blood 
monocyte phenotype and atherosclerosis progression, eight week-old ApoE-/- mice 
were switched to a Western high-fat diet (HFD) that contained 21% fat from lard and 
0.15% (wt/wt) cholesterol (Special Diets Services, Witham, UK). ApoE-/- mice were 
sacrificed before (baseline) or at 4 or 8 weeks post-commencement of HFD. ApoE+/+ 
mice (C57BL/6J) underwent the same procedures and were used as controls.  
For the second part of the study, an additional group of ApoE-/- mice were kept on 
HFD for 8 weeks either in the absence (HFD alone) or in the presence of 
concomitant anti-platelet therapy: aspirin (high-dose, 300 mg/ kg/ day; or low-dose, 
5 mg/ kg/day) or clopidogrel (25 mg/kg/day). The choice of drug concentrations 
administered in the current study is based on previously published work, in which 
these drug concentrations have been tested in mice, and provided evidence of 
consistent inhibitory effect on platelet activation when administrated at the above 
indicated concentrations (Cyrus et al., 2002; Hoving et al., 2010). Drugs were given 
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in drinking water. Due to the instability of aspirin in solution, water with aspirin 
added was replaced every other day (Cyrus et al., 2002), whereas clopidogrel has 
demonstrated to be stable in solution up to 60 days (Skillman et al., 2010), and 
therefore water containing clopidogrel was changed weekly. 
The following parameters were examined: phenotype of circulating monocytes by 
flow cytometry; plaque burden and macrophage-dependent lipid content by Oil Red 
O staining of the brachiochephalic artery; phenotype of monocytes infiltrating the 
brachiochephalic artery by flow cytometry. The techniques are described in details in 
the following sections. All studies were performed in accordance with the guidelines 
of the United Kingdom Home Office (PPL 70/6646; PIL 70/20776). 
 
3.3.2 Monocyte characterization in peripheral blood  
Monocyte characterization was performed by whole blood flow cytometry as 
described by Ingersoll (Ingersoll et al., 2010). Peripheral blood was drawn via 
cardiac puncture using syringes containing heparin as anticoagulant, from mice 
anaesthetized with isoflurane. Immediately after collection, 100 µl blood was 
incubated for 20 min at 4°C with the following antibodies: fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse CD115, allophycocyanin (APC)-conjugated anti-
mouse F4/80, phycoerythrin (PE)-conjugated anti-mouse Ly6C, peridinin 
chlorophyll protein complex (PerCP)-conjugated anti-mouse B220 (this latter was 
from BD Biosciences, UK, whereas all other antibodies were from eBiosciences, 
UK). Isotype control antibodies were used as negative control. Red blood cells were 
lysed at the end of the incubation time with FACS lysing solution (BD Bioscience), 
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and the resulting cell suspension was washed twice in PBS supplemented with 0.2% 
BSA and 0.1% sodium azide. Cells were finally resuspended in PBS containing 1% 
paraformaldehyde, and kept at 4°C until analyzed within a maximum of 48h from 
sample preparation. 
At the flow cytometer (FACSCalibur, Becton Dickinson (BD), Oxford, UK) 50 000 
events in total were acquired. Monocyte characterization was performed on a  post-
acquisition analysis conducted using FlowJo software (Tree Star, Ashland, OR). In 
accordance with Ingersoll’s analysis strategy, the following steps were performed:  
• gating of the SSClow cells (with consequent exclusion of SSChigh neutrophils);  
• exclusion of B220+ cells, representative of B lymphocytes 
• identification of CD115+F4/80low cells as the monocyte population 
• analysis of Ly6C expression within this population to distinguish the 
different monocytic subsets 
Monocytes were therefore defined as SSClow B220- CD115+ F4/80low cells. The 
number of cells expressing such a phenotype over the total 50 000 events acquired 
was taken as an estimation of monocyte count in the peripheral blood. Percentage 
and number of events with differential expression of Ly6C within this population 
identified the monocyte distribution pattern. A schematic representation of the 
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Figure 3.1 Monocyte characterization in murine blood: gating strategy A total of  50 
000 events were acquired (plot 1), including mononuclear (monocytes and lymphocytes) and 
polymorphonuclear (neutrophils) cells. On a post-acquisition analysis, mononuclear cells 
were gated and the expression of B220 evaluated within this cell subgroup (plot 2). B220+ 
cells (in blue) were then excluded, and further analysis was performed on the population of 
B220- cells (in black). Within  the population of SSClow B220- cells the expression of CD115 
and F4/80 was studied to identify CD115+F4/80low events (plot 3) representative of the total 
monocytic population (in red). Final analysis of level of expression of Ly6C within the 
SSClow B220- CD115+ F4/80low cells (red) was carried out (plot 4) to calculate percentage and 
number of Ly6Chigh and Ly6Clow monocytes (upper and lower  right quadrant respectively). 
In grey is the isotype control for each combination of antibodies. 
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3.3.3 Measurement of in vivo platelet activation  
Due to the requirement of four-color staining for monocyte characterization, and the 
availability of a four-colour flow cytometer (FACSCalibur, Becton & Dickinson, 
UK) for data acquisition, addition of a fifth antibody against a platelet marker (i.e 
CD42d), to identify MPA (CD42d-expressing monocytes) was not possible. In initial 
experiments, the specificity in detecting monocytes by different combinations of 
antibodies based on a 3-colour staining was tested in female ApoE-/- mice aged 8 
weeks, and compared to the classical 4-colour strategy described by Ingersoll 
(Ingersoll et al., 2010) and detailed above. We found that simultaneous detection of 
all 4 markers abovementioned (B220, F4/80, CD115 and Ly6C) is required for 
consistent interpretation. In particular, anti-mouse Ly6C was needed to distinguish 
the monocyte subpopulations. Exclusion of anti-mouse B220 from the antibody 
cocktail (which was then composed of anti-mouse F4/80, CD115 and Ly6C) gave 
rise to inclusion into the CD115+ F4/80+ gate of  ~5% of  B220+cells (Figure 3.2). 
Therefore, we concluded that lack of detection of this cell type in the flow 
cytometric analysis could compromise the specificity for monocyte analysis, 
particularly taking into consideration that expansion of so-called plasmacytoid cells, 
which are B220+ Ly6Chigh cells, has been described in the peripheral blood of ApoE-/- 
mice on HFD (Swirski et al., 2007). In accordance with this, in our preliminary 
experiments to standardize the whole blood staining technique, the presence of this 
cell subtype was observable in samples collected from ApoE-/- (Figure 3.2) but not 
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Figure 3.2 Standardization of murine whole blood flow cytometry for monocyte 
analysis. A preliminary experiment was conducted in female ApoE-/- mice to compare the 
specificity of two different antibody cocktails in identifying monocytes by flow cytometry. 
The 4-colour staining method described by Ingersoll (Ingersoll et al., 2010) using anti-
mouse B220, F4/80, CD115 and Ly6C (panel 2) was compared to 3-colour staining based on 
F4/80, CD115 and Ly6C detection only (panel 1). Acquisition was gated for mononuclear 
cells (gate on 1A and 2A). Presence of anti-mouse B220 in the antibody cocktail enabled the 
identification of a population of cells (2B) that included two different subtypes (in blue and 
orange in the lower plots of pnel 2). The blue cell subset was B220+ F4/80- CD115- (2F); the 
orange cells were B220+ F4/80low and ~5% of them were positive for CD115 (2F). The lower 
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plots of panel 2 show the overlay of these two B220+ cells over the population of B220- cells 
(black). This latter contain the monocytic population defined by double positivity for F4/80 
and CD115 (2C and 2G). Absence of anti-mouse anti-B220 in the antibody cocktail (panel 
1) led to inclusion of B220+F4/80lowCD115+ cells in the monocyte count, resulting in 
overestimation of Ly6Chigh number compared to the value measured in the presence of anti-
mouse B220 (48.24% in 1D versus 44.07% in 2D). 
  
In evaluating the need for the two myeloid markers F4/80 and CD115, we observed 
that F4/80 staining alone, in combination with anti-mouse B220 and Ly6C only, 
made it difficult to distinguish positive from negative cells due to the low level of 
expression of this marker on circulating monocytes. Addition of anti-mouse CD115 
antibody was the optimal combination to distinguish monocytes from the non-
monocytic population by plotting F4/80 against CD115 (Figure 3.3), and enabled the 
identification of a few events that were F4/80+ but CD115-, most likely representing 






Figure 3.3. Standardization of murine whole blood flow cytometry for monocyte 
analysis. Addition of anti-mouse CD115 to the antibody cocktail containing anti-mouse 
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CD115- (arrow). In the blood of ApoE-/-mice, where plasmacytoid (orange dots) and 
monocytic cells (within the black population) expand (Swirki et al., 2007) and are in close 
proximity to each other (A),  contamination from plasmacytoid cells is likely to affect the 
purity of the B220- gate. The shift of F4/80+ cells along the CD115 axis (B and C) according 
to cell positivity for this marker facilitates the identification of monocytes (defined as B220- 
F4/80low CD115+) in murine blood (upper right quadrant of C). 
  
As regards the staining for CD115 in the absence of anti-F4/80 and in the presence 
of anti-mouse B220 and Ly6C, this gave good correspondence in the identification 
of monocytes compared to complete 4-colour staining. However, since it has been 
demonstrated that stability of CD115 staining is affected by any time delay in blood 
processing (Breslin et al., 2011) and, more importantly, that CD115 can undergo 
cleavage from the extracellular membrane during inflammatory processes (Ziegler-
Heitbrock et al., 2010), we decided not to rely on CD115 staining alone, in the 
absence of an additional myeloid marker, due to the  need to compare animals at 
different stages of atherosclerotic disease, and consequent potential differences in the 
level of expression of CD115. Additionally, given the phenotypic correspondence 
between human and murine monocytes based on Ingersoll’s gating strategy, we 
considered that translatability of our results to the human setting would be greatest 
from our animal study by using his methodological approach.  
Therefore, in the present experiments, the degree of in vivo platelet activation was 
defined as the percentage of P-selectin expressing platelets in the peripheral blood 
only. For this purpose, heparinised blood was stained with FITC-conjugated anti-
mouse CD42d (a constitutive platelet marker) and PE- conjugated anti-mouse 
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CD62P (P-selectin), for 20 min at 4°C. After red cell lysis with FACS lysing 
solution (BD Bioscience) and washing in PBS supplemented with 0.2% BSA and 
0.1% sodium azide, cells were resuspended in PBS containing 1% 
paraformaldehyde, and kept at 4°C until analyzed within a maximum of 48h from 
sample preparation. At the flow cytometer a total of 50 000 events was acquired on  
logarithmic forward- and side-scatter scales and post-acquisition analysis of  P-
selectin expression within the CD42d-positive gate (% of CD42d+CD62P+ events) 
was performed using FlowJo software (Tree Star, Ashland, OR). 
 
3.3.4 Tissue harvesting 
For histological analyses and phenotypic characterization of monocytes infiltrating 
atherosclerotic tissue, immediately after blood collection for the flow cytometry 
studies as described above, mice were perfused through the left ventricle with 
physiological saline containing heparin 10U/L for 10 min, following which they 
were culled with a ketamine/xylazine overdose. The brachiocephalic artery together 
with the right subclavian artery, aortic arch and left carotid artery was removed en 
bloc and immediately transferred into 4%  formaldehyde before undergoing Oil Red 
O staining. For monocyte characterization, the brachiocephalic artery only was 
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3.3.5 Oil Red O staining 
Red Oil powder (Sigma, UK) was resuspended in pure methanol at a concentration 
of 5%.  The working solution for staining was prepared in water at a final 
concentration of  0.5%. Vessels collected as described above were opened to expose 
the intraluminal part and were incubated in the Oil Red O (ORO) staining solution 
for 10min. After subsequent washing firstly in pure methanol and secondly in water, 
they were analysed by dissection microscopy. Pictures were captured at 2.5x and 
3.5x magnification and analysed using ImageJ software for total and (ORO)-positive 
plaque area measurement.    
 
3.3.6 Characterization of monocytes infiltrating the brachiocephalic artery 
Immediately after collection, the brachiocephalic artery was microdissected and 
digested at 37°C for 1 h, in an enzymatic cocktail containing 125U/ml collagenase 
type XI, 60 U/ml hyaluronidase type I-s, 60 U/ml DNase 1 and 450 U/ml 
collagenase type 1 (all enzymes were from Sigma-Aldrich), in PBS supplemented 
with 20 mM Hepes (Galkina et al., 2006). The artery was then mashed through a 70 
µm strainer to obtain a cell suspension. This latter was resuspended in PBS 
supplemented with 0.2% BSA, and  incubated at 4°C  for 20 min with a combination 
of the following antibodies: Per-CP anti-mouse lymphocyte markers (Lin) including 
B220, CD90, Ly6G, NK1.1; APC anti-mouse F4-80; FITC anti-mouse CD115; PE 
anti-mouse Ly6C or CD11b (all antibodies were from eBiosciences, apart from anti-
mouse B220 which was purchased from Becton & Dickinson). A total of 50 000 
events was acquired and, on post-acquisition analysis performed by using FlowJo 
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software (Tree Star, Ashland, OR), monocytes were identified as CD11bhigh F4-80+ 
CD115+ Lin- [B220, CD90, Ly6G, NK1.1] and distinguished into Ly6Chigh and 
Ly6Clow subsets (Figure 3.4). Monocyte counts were normalised to sample weight. 













Figure 3.4 Monocyte characterization in the brachiocephalic artery. Monocytes were 
defined as CD115+ F4-80+ CD11bhigh Lin- cells. The figure schematises the “gating strategy” 
used  to identify cells.  Step 1:  a first distinction of double positive cells (gate 2)  from those 
negative (gate 1) for the myeloid markers F4-80 and CD115. Step 2: by plotting F4-80 
against Lin markers, exclusion of Lin+ cells from gate 2 was performed and monocytes were 
identified as F4-80+ CD115+ Lin- cells (gate 3 on right hand plot). Analysis of cells in gate 1 
confirmed positivity for Lin markers and negativity for myeloid F4-80 (left hand plot). Step 
3: analysis of CD11b expression in both gate 1 (grey histogram, non monocytic cells) and 
gate 3 (red histogram, monocytes) confirmed the myeloid nature of cells identified as 
monocytes (red). Monocytes were further characterized by differential expression of Ly6C 
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FL4/80+ CD115+ cells (gate 2)
STEP 2: Identification of FL4/80+ CD115+ Lin- cells (gate 3)
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3.3.7  Statistical analysis 
All data are presented as mean ± SD. Statistical analysis was performed using 
GraphPad Prism 4 software. Differences in percentage and total number of  different 
monocytic subsets between ApoE-/- and C57BL/6J mice were evaluated by paired 
Student’s t test. Comparison of monocyte characterization at the different time points 
was conducted by ANOVA, with or without repeated measures as appropriate. In all 
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3.4.1 Ly6Chigh monocytes predominate in the peripheral blood of ApoE-/- mice at 
baseline 
A preliminary analysis was performed to compare monocyte count and phenotype in 
ApoE-/- mice with control C57BL/6J animals at baseline. For this purpose, four mice 
per group (aged 8 weeks, prior to initiation of HFD) were sacrificed and monocyte 
characterization was performed as described above.  
The number of monocytes circulating in the peripheral blood was similar between 
the two strains (1926.5 ± 178.8 and 1862.7 ± 612.8 per 50 000 total events in ApoE-/- 
and C57BL/6J respectively; p=ns).  However, ApoE-/- mice showed a predominance 
of Ly6Chigh over Ly6Clow cells (93.0 ± 4.7% and 7.0 ± 4.7% respectively of total 
monocytes; p<0.001), whereas C57BL/6J mice demonstrated similar proportions of 
Ly6Chigh and Ly6Clow monocytes (45.9 ± 10.6% and 54.0 ± 10.6% respectively; 
p=ns). Consequently, the absolute number of circulating Ly6Chigh cells was higher in 
ApoE-/- than control mice, and conversely absolute Ly6Clow monocyte numbers were 
lower in ApoE-/- than C57BL/6J mice (Figure 3.5). 
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Figure 3.5 Monocyte characterization in ApoE-/- and C57BL/6J mice at baseline (before 
commencing HFD) (A) Absolute number of Ly6Chigh (black bars) and Ly6Clow (white bars) 
in ApoE-/- and C57BL/6J (ApoE+/+) mice; *p=0.02 vs ApoE+/+ mice; † p=0.03 vs ApoE+/+ 
mice; (B) Representative flow cytometry dot plots showing SSClowB220-CD115+F4/80low 
cells in ApoE-/- (left) and ApoE+/+ (right) mice; (C) Representative flow cytometry dot plots 
showing distribution pattern of Ly6Chigh and Ly6Clow cells in ApoE-/- (left) and ApoE+/+ 
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(right) mice; (D) Monocyte characterization in ApoE-/- (left) and ApoE+/+ (right) mice aged 8 
weeks; the pie charts show accumulated data from 8 animals. Black= Ly6Chigh; white= 
Ly6Clow. 
 
3.4.2 Monocyte count increases with age in ApoE-/- mice  
ApoE-/- mice studied at 4 and 8 weeks post-commencement of HFD exhibited a time-
dependent increase in the total number of circulating monocytes. As a consequence, 
the absolute number of both Ly6Chigh and Ly6Clow cells circulating in the peripheral 
blood increased over the 8-week period of HFD, with the increase being especially 
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Figure 3.6 Monocyte characterization in ApoE-/- mice after different times on HFD 
Monocyte count (A) and distribution pattern of Ly6Chigh (black) and Ly6Clow (white) (B) in 
the peripheral blood of ApoE-/- mice at baseline and after 4 and 8 weeks of HFD. Absolute 
number of Ly6Chigh (C) and Ly6Clow monocytes (D) at the different time points. Panel E 
compares Ly6Chigh and Ly6Clow numbers directly at the different time points. 
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 3.4.3 Measurement of Ly6Clow is a surrogate marker of extent of 
atherosclerosis 
In order to ascertain the association between circulating monocyte count/phenotype 
and disease progression in ApoE-/- mice, we harvested the brachiochepalic artery to 
analyze plaque burden by Oil Red O staining at the same time points as circulating 
monocytes were characterized: baseline (n=4, Group 1) and after 4 (n=4, Group 2) 
and 8 weeks (n=4, Group 3) of HFD.  
As expected, atherosclerotic lesions were observable in mice fed with HFD for 4 and 
8 weeks, but not at baseline. The extent of disease measured as lesion area was 
highly variable within each group; medians and inter-quartile ranges were 0.05 
(0.02-0.43) mm2 and 0.20 (0.08-0.42) mm2 in Groups 2 and Group 3 respectively (p= 
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Figure 3.7 Atherosclerosis development in ApoE-/- mice. Pictures are representative of Oil 
Red O staining of the brachiocephalic artery of ApoE-/- mice at baseline (A), and after 4 (B) 
and 8 weeks (C) from commencing HFD (3.5x magnification). The arrows indicate plaques.  
Corresponding flow cytometry dot plots illustrating monocyte characterization in these 3 
animals are also shown, along with data showing total monocyte count (grey bars), Ly6Chigh 
(black bars) and Ly6Clow (white bars) in these same animals. 
 
In accordance with the results described above, the monocyte analyses performed in 
the three animals shown in Figure 3.7 demonstrated progressive monocytosis and 
increase in the absolute number of both Ly6Chigh and Ly6Clow cells after 4 and 8 
weeks of HFD compared to baseline (Figure 3.8). A shift was also observed in the 
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percentage of Ly6Clow and simultaneous decrease in the percentage of Ly6Chigh cells 
compared to the predominance of Ly6Chigh monocytes at baseline. However, as 
described above for extent of plaque development, great variability was seen within 
each group of animals on HFD, and comparison between Group 2 and Group 3 
therefore showed no significant difference in terms of percentage of Ly6Chigh (65.07 
± 12.8% vs 59.95 ± 11.3% respectively; p=ns) or of Ly6Clow (34.87 ±12.81% vs 
40.05 ± 11.3% respectively; p=ns) cells. Absolute numbers were also not different 
between Groups 2 and 3 (Ly6Chigh: 2317 ± 723.2 vs 3844 ± 990.3 per 50 000 total 
events respectively, p=ns; Ly6Clow: 1216 ± 461.9 vs 2528 ± 620.6 per 50 000 total 
events respectively, p=ns).  
On the other hand, in examining the relationship between lesion area and circulating 
monocyte characteristics, a direct correlation was found between the lesion area and 
both percentage and absolute number of Ly6Clow cells. By contrast, no relationship 
was observed between lesion area and either total monocyte count or Ly6Chigh 
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Figure 3.8 Monocyte characterization and relationship to plaque burden in ApoE-/- mice. 
Monocyte count (A) in the peripheral blood of ApoE-/- mice on HFD (n=12 in total) in which 
atherosclerosis was evaluated by means of Oil Red O staining of the brachiocephalic artery at different 
time points as shown. Absolute number of circulating Ly6Clow (B) and Ly6Chigh (C) at the same time 
points. Panel D shows % of monocytes which are Ly6Clow at these same time points. Panel E illustrates 
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We performed similar experiments in parallel in C57BL/6J mice, as controls for the 
ApoE-/- mice that do not develop atherosclerosis on HFD. 
As described above, C57BL/6J displayed similar numbers of circulating monocytes 
to ApoE-/- mice at baseline (i.e before commencing HFD). The two subsets of 
monocytes were equally represented in the blood, with Ly6Chigh and Ly6Clow 
accounting for 45.90 ± 10.56%  and 54.00 ± 10.57 % respectively of total 
monocytes, whereas Ly6Chigh cells were predominant in ApoE-/- mice at baseline 
(Figure 3.9).  
In order to ascertain the effect of Western diet on monocyte count/phenotype 
independently of the presence of atherosclerosis, we studied wild-type mice after 4 
and 8 weeks of the HFD regime. As expected, C57BL/6J did not develop 
atherosclerosis over the 8 week period of the study. However, the phenotype of 
circulating monocytes progressively changed to acquire, after 8 weeks of HFD, a 
pattern similar to that observed in ApoE-/- mice at baseline (Figure 3.6). Indeed, HFD 
induced a progressive increase in both the percentage and absolute number of 
Ly6Chigh cells, with concomitant decreases in both the percentage and count of 
Ly6Clow monocytes. A simultaneous expansion of the total monocytic population 
was observed, with the degree of monocytosis being similar to that seen in  ApoE-/- 
mice by the end of the study, whilst – unlike in ApoE-/- mice – the vast majority of 
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Figure 3.9 Effect of HFD on total monocyte count and Ly6Chigh vs Ly6Clow distribution 
pattern in wild-type (ApoE+/+) compared with ApoE-/- mice. (A), The pie charts show the 
distribution pattern of Ly6Chigh (black) and Ly6Clow (white) over the 8 week-period of HFD 
in both strains. (B), Total monocyte count (black bars), Ly6Chigh (grey bars) and Ly6Clow 
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3.4.4 Anti-platelet therapy abolishes atherosclerosis-related blood monocytosis 
Atherosclerosis-related monocytosis observed in ApoE-/- mice at the end of the 8-
week HFD regime was significantly reduced by the concomitant treatment with 
either clopidogrel or aspirin; in the case of aspirin, efficacy was similar when 
administered at high- (300 mg/kg/day) or low-dose (5 mg/kg/day) (Figure 3.10). All 
these anti-platelet regimes reduced the absolute number of both Ly6Chigh and 
Ly6Clow cells in the peripheral blood to a level that was comparable to that seen in 
ApoE-/- mice before commencing HFD. Moreover, the distribution pattern of the 
different monocytic subsets also was modulated by the anti-platelet drugs, inasmuch 
as the progressive increase in percentage of  Ly6Clow over Ly6Chigh cells was 
attenuated, although not to baseline levels (Figure 3.10). Measurement of P-selectin-
expressing platelets, as a marker of in vivo platelet activation, demonstrated that both 
aspirin and clopidogrel inhibit platelet P-selectin expression in ApoE-/- mice on 
HFD, and the efficacy of clopidogrel in reducing P-selectin positive platelets was 
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Figure 3.10 Effect of aspirin and clopidogrel on circulating monocytes. Total monocyte 
count (A); percentage of P-selectin expressing platelets  (B); absolute number of Ly6Chigh 
(C) and Ly6Clow cells (D) in the peripheral blood of ApoE-/- mice at the end of the 8 week 
HFD-period, either in the absence (8 WKS) or in the presence of concomitant anti-platelet 
treatment with aspirin or clopidogrel as specified in the graphs. Aspirin was administrated at 
high (300 mg / kg /d) and low (5 mg / kg /d) doses. Clopidogrel was given at a dose of 25 
mg /kg /d. Level of monocytes in the peripheral blood of ApoE-/- mice before commencing 
HFD (baseline) is also shown. The pie charts (E) show the distribution pattern of Ly6Chigh 
(black) and Ly6Clow (white) in the different experimental conditions/time points. *, p<0.001 
vs 8 WKS; †, p<0.01 vs 8 WKS. 
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3.4.5 Aspirin and clopidogrel do not inhibit plaque development but 
differentially regulate monocyte and lipid composition of plaques 
Neither clopidogrel nor aspirin inhibited atherosclerotic plaque development in the 
brachiocephalic artery of ApoE-/- mice on HFD. Lesions were observable in both 
treated and untreated animals at the end of the 8 week HFD-period, and the total 
plaque area was similar between all groups (Figure 3.11). However, the 
atherosclerotic brachiocephalic artery of mice on aspirin- but not clopidogrel - 
therapy displayed a reduction in the macrophage-dependent lipid content of plaque, 
as evaluated by ORO-positive plaque area (Figure 3.11). On  further characterization 
of plaque composition performed by tissue flow cytometry analysis to specifically 
assess monocyte content, the brachiocephalic arteries obtained from ApoE-/- mice 
treated with aspirin- but not clopidogrel - exibited less total monocyte infiltration 
compared to untreated animals. Moreover, the phenotype of monocytes within 
plaques was different between the groups. ApoE-/- mice on HFD only had the highest 
degree of monocyte plaque infiltration, to which the two subpopulations almost 
equally contributed, with a slight predominance of Ly6Clow over Ly6Chigh cells. 
Aspirin-treated animals developed plaques with a reduced content of total monocytes 
compared to untreated animals, this being mainly attributable to a suppressed 
recruitment of Ly6Chigh cells into the lesions. By contrast, clopidogrel did not alter 
total monocytic infiltration into the plaques, but did significantly reduce the 
percentage of Ly6Clow monocytes (46.94±6.72% in clopidogrel-treated animals vs 
55.21±4.4% in untreated animals; p<0.05) (Figure 3.11). 
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Figure 3.11 Effect of aspirin and clopidogrel on plaque development and composition. 
(A), Pictures are representative of Oil Red O staining of the brachiocephalic artery of ApoE-
/-
 mice at the end of 8-week HFD-period in untreated animals (8 WKS) and those treated 
with either clopidogrel (25 mg/kg/d) or aspirin (low dose, 5 mg/kg/d) as indicated (3.5x 
magnification, pictures on the left hand side). For better visualization, images were zoomed 
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and cropped at the level of plaques (pictures on right hand side). The flow cytometry dot 
plots are representative of monocyte characterization in the brachiocephalic artery of each 
group of animals (upper right quadrant and lower right quadrant show Ly6Chigh and Ly6Clow 
respectively within plaques). Accumulated data (8 WKS n=4; clopidogrel n=4; and aspirin 
n=5) are shown in the pie charts, which show percentage of Ly6Chigh (black) and Ly6Clow 
cells measured in the brachiocephalic artery of each group of animals. (B), Total (black bars) 
and Oil Red O (ORO) positive area (white bars) of plaques in the different experimental 
conditions. (C), ORO positive area expressed as percentage of total plaque area in the 
different groups of animals. (D), (E), and (F) report the absolute numbers of total, Ly6Chigh 
and Ly6Clow monocytes respectively  in untreated animals (8 WKS) and those treated with 
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3.5.1 Monocyte characterization as a biomarker of atherosclerotic disease 
Our results show that expansion of circulating monocyte numbers occurs in the 
peripheral blood of both wild-type and ApoE-/- mice on HFD with age. In accordance 
with previous reports (Swirski et al., 2007) predominance of Ly6Chigh over Ly6Clow 
cells was observed at baseline in ApoE-/- but not in wild-type mice. However, the 
major expansion with time was in Ly6Clow cells in ApoE-/- mice; and Ly6Clow 
numbers, but neither Ly6Chigh numbers nor total monocyte count, were predictive of 
extent of atherosclerotic disease in the brachiocephalic artery. 
Unlike wild-type mice, ApoE-/- animals are predisposed to develop atherosclerosis. 
In our study, we observed divergence in the phenotype of circulating monocytes 
between the two strains when both were fed with rodent chow diet. The 
compromised cholesterol metabolism in ApoE-/- mice is likely to account for the 
distinct monocytic pattern seen at baseline compared to C57BL/6J mice. Indeed, it 
has been demonstrated that elevated levels of cholesterol induce an increase in 
Ly6Chigh cells, by inhibiting their differentiation into Ly6Clow and enhancing their 
survival (Swirski et al., 2007). Our results demonstrate that HFD in wild-type mice 
leads to a shift in the distribution of the two monocytic subpopulations in the blood, 
from an equal amount of Ly6Chigh and Ly6Clow cells towards a dominance of  
Ly6Chigh over Ly6Clow cells. In ApoE-/- mice this pattern was observable at baseline, 
before commencing HFD, while in C57BL/6J this only developed after an 8 week-
period of HFD. In both cases, the  change in monocytic phenotype preceded plaque 
development, since neither ApoE-/- mice at baseline nor C57BL/6J at the end of the 
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8-week period of HFD had atherosclerotic lesions detectable in the brachiocephalic 
artery. Therefore, predominance of Ly6Chigh over Ly6Clow cells is likely to be a 
predisposing factor for plaque development.  
Previous studies have evaluated the pro-atherogenic effect of the distinct monocytic 
subpopulations in mice, by analysing the phenotype of monocytes infiltrating the 
vascular wall. Swirski found that Ly6Chigh cells enter plaques preferentially over 
Ly6Clow cells (Swirski et al., 2007), whereas Potteaux observed a preferential influx 
of Ly6Clow cells into the lesions (Potteaux et al., 2011). The distinct anatomic site 
evaluated by the two groups might have determined the differences seen in their 
results (aortic root vs brachiocephalic artery), since the two cell subsets appear to 
have different abilities to colonize atherosclerotic lesions in different regions of the 
arterial wall (Teupser et al., 2004), with  Ly6Clow cells mainly implicated in 
monocytic infiltration in the brachiocephalic artery whilst Ly6Chigh cells being 
predominant in the colonization of the vascular wall at the aortic root. These findings 
are in accordance with our results, that show a strong direct relationship between 
expansion of Ly6Clow cells in the blood and progression of atherosclerotic disease as 
evaluated at the brachiocephalic artery. Indeed, over the course of 8-week HFD 
period, ApoE-/- mice but not C57BL/6J developed plaques, and this was paralleled 
by a concomitant increase in the Ly6Clow subtype, such that from representing less 
than 10% of total monocytes in ApoE-/- mice at baseline they progressively expanded 
to constitute almost half of the total circulating monocytic population at 8 weeks. In 
particular, the increase in absolute number of  Ly6Clow cells over time, rather than 
the simple percentage of this subpopulation over the total monocytes, was found to 
be the main determinant of disease progression.  
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The increase in Ly6Clow cell number in ApoE-/- mice seemed to be an effect 
unconnected to the HFD regime, even though this accelerates atherogenesis in this 
animal model (Reddick et al., 1994).  Wild-type mice on HFD displayed an increase 
of Ly6Chigh cells and  a concomitant  reduction of Ly6Clow cells, an effect opposite to 
that observed in ApoE-/- mice fed on HFD. HFD induced marked monocytosis in 
both strains to similar levels, although the effects on Ly6Chigh vs Ly6Clow were 
divergent. 
 
3.5.2 Anti-inflammatory effect of anti-platelet therapies 
In accordance with the in vitro data described in Chapter 2, we have found that in 
vivo platelet activation has an important effect on circulating monocytes. Indeed, 
treatment with either aspirin or clopidogrel resulted in suppression of 
atherosclerosis-related expansion of all monocytes in the circulation, both Ly6Clow 
and Ly6Chigh, in our model. The current study did not address the mechanistic basis 
underlying the suppressive effect of anti-platelet drugs on blood monocytosis. This 
mechanistic basis may be attributable to inhibition of monocyte precursor 
proliferation within the bone marrow, or of cell mobilisation from the bone marrow 
to the peripheral circulation, or to a modulation of the survival of these cells in the 
peripheral blood. Indeed, all of these may occur together. Figure 3.12 shows in 
schematic form the potential mechanisms of action of anti-platelet treatment on 
monocyte count and phenotype. Whatever the mechanism, the effects demonstrated 
here of pharmacological platelet inhibition on circulating monocytes are novel and 
the first time in vivo demonstration that modulating platelet activity has important 
effects on circulating monocyte in the context of atherosclerosis. Clopidogrel is 
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likely to act through inhibition of P-selectin expression on the platelet plasmalemma 
and consequent formation of MPA, although our study only examined the former 
because of the methodological limitations abovementioned that precluded the direct 
estimation of MPA level in the peripheral blood. The well described ability of 
clopidogrel to decrease MPA formation in vivo (Storey et al., 2002; Klinkhardt et al., 
2003; Braun et al., 2008), along with our previous demonstration that interference in 
the physical interaction between monocytes and platelets inhibits platelet-dependent 
change in the phenotype and function of human monocytes (Passacquale et al., 
2011c; Chapter 2), support this hypothesis. A similar action may be ascribed to 
aspirin, which also decreased P-selectin expression on circulating platelets, although 
to a lesser degree than clopidogrel. However, our in vitro experiments previously 
conducted in human samples (Passacquale et al., 2011c; Chapter 2), suggest an 
additional mechanism by which aspirin may affect monocyte phenotype, that relates 
to ability to inhibit COX activity. Even the lower dose used in our animals (5 mg Kg-
1
 day-1, which would correspond to a daily dose of 180-240 mg in humans) may act 
on both COX-1 and COX-2 isoforms (Patrono et al., 2005), thus producing a 
simultaneous inhibition of platelet COX-1 activity with consequent defective TxA2-
mediated platelet-activation, and of monocytic COX-2 activity which we have 
previously found to be strongly involved in platelet-mediated alteration in monocyte 
phenotype (Passacquale et al., 2011c; Chapter 2).  Therefore, it is reasonable to 
hypothesise that aspirin may be acting through complementary effects on both 
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3.5.3 Pro-atherogenicity of Ly6Chigh and Ly6Clow monocytes 
As previously mentioned, several authors have investigated the pro-atherogenic 
activity of phenotypically distinct monocyte subsets by monitoring the trafficking of 
these cells into atherosclerotic lesions, in order to identify whether a particular cell 
population displays a preferential influx into plaques. The conflicting data obtained 
in different laboratories has made it difficult to establish whether and how Ly6Chigh 
and Ly6Clow cells differentially contribute to lesion development (Teupser et al., 
2004; Swirski et al., 2007; Potteaux et al., 2011). The evidence provided by 
Combadiere and colleagues (Combadiere et al., 2008), who showed that only 
concomitant inhibition of  chemokine receptors involved in both Ly6Clow and 
Ly6Chigh endothelial trans-migration can completely abolish vascular lesion onset 
and progression, suggests an equal contribution of these monocyte subsets in 
atherosclerosis development. In this context, the strong correlation found in the first 
part of our study between expansion of Ly6Clow cells and plaque size is suggestive of 
a greater pro-atherogenic activity exerted by this monocyte subpopulation over the 
Ly6Chigh subtype. However, the tissue phenotype characterization we carried out 
appears to contradict this hypothesis. Indeed, although showing perhaps a slight 
predominance of Ly6Clow over Ly6Chigh cells, no significant differences were 
detectable by vessel flow cytometry analysis between the content of the two cell type 
within plaques.  Therefore, the increase of Ly6Clow cells in the peripheral blood 
seems to provide a good biomarker of disease in this atherosclerotic animal model, 
whereas both Ly6Chigh and Ly6Clow cells appear to be involved in atherosclerosis at 
the level of the plaque itself. 
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3.5.4. Effect of anti-platelet drugs on plaque composition  
In our anti-platelet-treated ApoE-/- mice the marked reduction in blood monocytosis, 
with simultaneous  decrease of both monocytic subpopulations to a level similar to 
that observed in disease-free animals, did not result in a reduction in plaque size. The 
multi-factorial and multi-cellular nature of atherosclerosis (Ross 1999; Libby 2002) 
suggests that monocytes, although being fundamental players in vascular lesion 
development, are not the sole mediators of disease. Similarly, the activity of 
platelets, that is strongly related to atherosclerosis onset and progression by virtue of 
their pro-thrombotic and pro-inflammatory actions, is contributory but again only 
part of the larger picture. As a consequence, the therapeutic modulation of these two 
cell types, as occurs with an anti-platelet treatment, is not enough to abolish 
development of disease in this animal model. Endothelial damage sustained by 
chronic lipid dysmetabolism (Gaudreault et al., 2012) is likely to exert a fundamental 
role in plaque formation, independent of the phenotype of circulating monocytes and 
platelets, through the release of chemotactic stimuli and expression of adhesion 
molecules that promote inflammatory cell recruitment and colonization of the 
vascular wall.  
However, we found that a reduction in monocyte count in the peripheral blood as a 
consequence of anti-platelet therapy, especially with aspirin, dramatically decreased 
the monocyte-macrophage content of plaques, most likely through decreasing the 
number of monocytes in the blood available for vascular infiltration. Therefore, even 
if not sufficient in reducing plaque size, as also previously reported by other 
investigators in different animal models (Tous et al., 2004; Schulz et al., 2008), our 
data demonstrate that anti-platelet therapy can have an important effect on plaque 
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composition. These findings are in agreement with those of previous researchers 
(Cyrus et al., 2002; Afek et al., 2009), and our data add important information as 
regards the mechanism underlying this pharmacological effect, namely that it is 
mediated by a systemic action of these agents on circulating monocytes, either 
through an indirect mechanism sustained by platelet inhibition, or a direct action on 
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Figure 3.12 Anti-inflammatory activity of aspirin and clopidogrel. The diagram shows 
the multiple levels at which action of aspirin and clopidogrel may exert their effects on 
monocytes, which after originating from the bone marrow are released into the peripheral 
blood and reach atherosclerotic lesions through the systemic circulation. Release of pro-
inflammatory mediators from the vascular lesions may feed back on bone marrow monocyte 
proliferation, stimulate mobilisation of monocytes from the bone marrow to the peripheral 
blood, and locally recruit these and other inflammatory cells (Shi & Pamer, 2011). Aspirin 
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and clopidogrel may modulate any or all of these steps, through either  direct or indirect 
pharmacological actions, the latter being mediated by platelet inhibition.  
1) A direct effect of both drugs could be exerted at the site of origin of monocytes, in the 
bone marrow, where aspirin-dependent COX-inhibition or clopidogrel-dependent P2Y12-
receptor blockade could potentially inhibit stem cell proliferation (mRNA for P2Y12 receptor 
has been detected in stem cells and leukocytes by Wang et al., 2004).  
2) Aspirin and clopidogrel could regulate monocyte mobilization from the bone marrow by 
acting on their phenotype, particularly on the expression of chemokines involved in their 
trans-endothelial migration at the level of the bone marrow and their consequent release into 
the systemic circulation. 
3) Aspirin and clopidogrel could directly act on circulating monocytes by modifying 
proliferation, survival, and differentiation via COX-inhibition or P2Y12-receptor blockade 
respectively. Moreover, aspirin, but not clopidogrel, could exert an additional effect on the 
capability of circulating  monocytes to take up lipids in the peripheral blood (asterisked).  
4) At the site of a vascular lesion, aspirin, but not clopidogrel, could reduce endothelial 
inflammation and the consequent recruitment of Ly6Chigh monocytes (asterisked). 
5) Both drugs could exert indirect effects on bone marrow, peripheral circulation and 
vascular wall mediated by platelet inhibition, with consequent suppression of release of 
platelet-derived factors, MPA formation and platelet adherence to the endothelial monolayer 
that in turn affect monocyte phenotype and endothelial trans-migration.  
 
The reduced plaque content of monocyte-macrophage cells, which are the main 
determinants of plaque vulnerability (Shashkin et al., 2005), strongly suggests that 
aspirin and clopidogrel may exert beneficial effects by reducing the susceptibility of 
atherosclerotic lesions to rupture, and hence to develop superadded thrombosis. 
However, the detailed mechanisms by which the two drugs may do this is likely to 
be different. Although both exert a systemic effect on circulating monocytes, aspirin 
and clopidogrel seem to exert an additional action at the site of plaques, where the 
two drugs differentially regulate the influx of the two distinct monocyte 
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subpopulations. Based on the fact that the drugs have a similar effect on the count 
and phenotype of circulating monocytes, it is reasonable to hypothesise that they 
have a distinct effect on the interaction of monocytes with the vascular wall, 
favouring the influx of one cell type over another depending on differential 
modulation of endothelial adhesive phenotype. However, how the different 
monocytic subsets may relate to plaque vulnerability is unclear. The ORO staining 
data show that aspirin, but not clopidogrel, can suppress foam cell content compared 
to untreated animals. Given the reduced level of Ly6Chigh cells in plaques from 
aspirin-treated animals, it is conceivable that lipid-laden macrophages mainly derive 
from this subset of monocytes rather than Ly6Clow cells. In accordance with this, 
Swirski has shown that Ly6Chigh monocytes give rise to macrophages within plaques 
(Swirki et al., 2007; Weber & Noels, 2011). On the other hand,  Ly6Clow monocytes, 
that were suppressed by clopidogrel, have been demonstrated to have a greater 
tendency than Ly6Chigh cells to terminally differentiate into resident dendritic cells 
(Peng et al., 2009; Giessman et al., 2010; Weber & Noels, 2011). The precise role of 
these cell types in vascular wall remodelling is uncertain. Given the patrolling 
behaviour of Ly6Clow cells in non-inflamed tissues compared to the predominant 
infiltration of Ly6Chigh cells within inflamed areas reported by Geissmann in the 
microcirculation (Geissmann et al., 2003), one could hypothesise that aspirin  may 
exert a greater vascular anti-inflammatory activity than clopidogrel in the large 
arteries, leading to reduced Ly6Chigh numbers which in turn may decrease the 
macrophage-dependent lipid  content of plaques . On the other hand, lipid uptake by 
monocytes also occurs in the peripheral circulation, before such cells enter into 
plaques (Gaudreault et al., 2011). Therefore, the possibility cannot be excluded that 
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aspirin may act at a systemic level to modify the capability of circulating monocytes 
to phagocytose lipids in the blood (Figure 3.12). 
 
3.5.5 Conclusion 
This study demonstrates that expansion of the murine counterpart of human CD16+ 
monocytes in the peripheral circulation occurs during the pro-inflammatory process 
that sustains and accompanies atherosclerosis, and the level of this monocyte 
subpopulation in the blood reflects the extent of vascular disease in the ApoE-/- 
model of atherosclerosis. The anti-platelet drugs aspirin and clopidogrel reduce 
atherosclerosis related-monocytosis with similar efficacy, and this associates with 
reduced monocyte-macrophage content in atherosclerotic plaques. However, the two 
anti-platelet agents, despite having a similar systemic effect on circulating monocyte 
phenotype and count, differentially regulate the influx of Ly6Chigh and Ly6Clow cells 
into lesions, thus altering plaque composition in a divergent manner. In particular, 
the reduced trafficking of Ly6Chigh cells into the atheroma observable with aspirin 
but not clopidogrel is associated with a decrease in lipid / foam cell content. This 
may have important consequences on plaque vulnerability and hence predisposing to 
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Atherosclerosis is a chronic and diffuse inflammatory process within the arterial 
wall that promotes the formation of atheromatous plaques composed of a lipid core 
with an overlying fibrous cap (Ross, 1999). The atherosclerotic process is 
accompanied by increased thrombogenicity of the blood, which (as reviewed in 
Chapter 1) not only gives rise to the thrombotic complications (which occur when a 
vulnerable plaque fissures or ruptures) but also contributes to lesion initiation by 
favouring monocyte recruitment into the sub-endothelial space and, in turn, the 
development of a pro-inflammatory milieu within the vascular wall (Davi’ & 
Patrono, 2007). Atherosclerosis progression is by and large a slow and long-term 
process, which generally takes many years before it becomes clinically manifest, 
when occlusive vascular symptoms occur; although thrombotic complications can 
occur at any stage of the disease, largely dependent on plaque composition, degree 
of inflammation and haemodynamic factors. 
The need to develop more effective strategies for both prevention and early 
diagnosis of atherosclerosis has gained increasing attention in recent years, due to 
the recognition that atherosclerotic sequelae, including ischaemic heart disease and 
cerebrovascular events, remain major causes of mortality and morbidity, accounting 
for 30% of all deaths worldwide (World Health Organization, 2007). Moreover, 
health projection studies on the global burden of disease for the next ten years, 
predict a dramatic increase in the prevalence of atherosclerosis-related 
cardiovascular disease (Murray & Lopez, 1997; World Health Organization, 2007).  
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In patients with established atherosclerotic disease that is clinically evident, 
addressing cardiovascular risk factors vigorously (smoking cessation, blood pressure 
and glycaemic control to target, cholesterol lowering with statins) and reducing 
blood thrombogenicity with anti-platelet therapy give rise to important reductions in 
myocardial infarction and stroke, and retard the progression of atherosclerotic 
disease (Joint British Societies – JBS-2 Guidelines 2005). However, a major 
challenge is the difficulty in early diagnosis in asymptomatic patients, in whom 
recognition of early disease and consequent vigorous risk factor reduction will help 
to retard progression of atherosclerosis as well as consequent occlusive/thrombotic 
arterial events. 
At present, management of asymptomatic patients is based on clinical assessment, 
aiming to evaluate classical cardiovascular risk factors (age, sex, smoking, presence 
of diabetes, lipid profile) and the presence/absence of target-organ damage such as 
left ventricular hypertrophy and proteinuria (JBS-2 Guidelines 2005).  A number of 
cardiovascular risk calculators, such as the risk charts provided by the JBS (JBS-2 
Guidelines, 2005) or by the WHO/ISH (World Health Organization, 2007), or the 
Framingham equation (Anderson et al., 1991), combine these clinical parameters to 
estimate the probability for a given individual to experience a future cardiovascular 
event (including ischaemic heart disease/myocardial infarction and stroke) over a 
period of time. Asymptomatic patients can therefore be distinguished into different 
categories of cardiovascular risk profile ranging from low (<10%) to high (>20%) 
risk over the next 10 years, and such stratification guides decision-making on the 
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intensity as well as the nature of preventative strategies to be adopted in individual 
patients.   
However, since these tools are based on statistical risk in populations, they are of 
limited usefulness in individual patients. In order to determine extent/severity of 
atherosclerosis in a given individual, it is necessary to image the vasculature using 
either invasive (including angiography) or non-invasive methods (such as CT 
coronary calcium score or CT angiography). These are expensive and laborious 
investigations, and therefore can only realistically be used in specific groups of 
patients with strong clinical indications, who often turn out to be at an advanced 
stage of disease. There is therefore an urgent need to develop simple, non-invasive, 
relatively inexpensive tests that are widely applicable in the population for early 




The current study aimed to investigate whether analysis of platelet activation by 
MPA measurement and/or characterization of the phenotype of circulating 
monocytes can provide a useful, non-invasive, inexpensive and generally applicable 
measure of silent atherosclerotic disease, and whether such a measure can give 
information regarding presence of atherosclerotic disease over and above  standard 
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4.3.1 Subject recruitment and characteristics 
The study was approved by the St Thomas’ Research Ethics Committee, London, 
UK. All participants gave written informed consent. Forty-five patients were 
recruited sequentially from the Hypertension (n=23) and Diabetic (n=22) Clinics at 
Guy’s & St Thomas’ Hospitals, London, UK.  
Inclusion criteria: 
• 18 years of age or older  
• able and willing to comply with study procedures 
•  no previous history of cardiovascular events and/or symptomatic 
atherosclerotic disease.  
Exclusion criteria: 
• patients with diagnosed secondary hypertension 
• clinical evidence of atherosclerotic disease or other significant co-morbidity 
•  previous cardiovascular events  
• cardiac dysrythmia 
•  significant renal impairment (eGFR < 30 mL/min/1.73 m2) 
•  pregnancy or breastfeeding 
•  mental disorders or inability to give informed consent. 
Patients were studied at the Clinical Research Facility of St Thomas’ Hospital. Each 
participant underwent a full history and clinical examination including measurement 
of blood pressure by Omron 705CP, body weight and height for calculation of body 
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mass index (BMI). 12-lead electrocardiogram was performed, and blood (32 ml) 
collected by venepuncture for measurement of full blood count, full blood 
biochemistry, including renal and liver profiles, lipids, glycated hemoglobin (HbA1c) 
and high-sensitivity C-reactive protein (hs-CRP). 100 µl of this blood was also taken 
for analysis of circulating monocyte phenotype and MPA according to the methods 
described in the following section. The Framingham equation and JBS-2 risk charts 
were used for cardiovascular risk stratification. Patient characteristics are 
summarized in Table 4.1.  
 
4.3.2 Measurement of circulating MPA and monocyte characterization 
Monocyte characterization and MPA measurement were performed by flow 
cytometry analysis on whole blood collected in sodium citrate (0.3% final 
concentration). Immediately after venepuncture, 100 µl blood was incubated in the 
dark and at 4°C with a combination of the following antibodies: phycoerythrin (PE)-
conjugated anti-human CD14, fluorescein isothiocyanate (FITC)-conjugated anti-
human CD16 and allophycocyanin (APC)-conjugated anti-human CD42b (all 
antibodies were purchased from BD Bioscience). Isotype control antibodies were 
used as negative control. After red cell lysis using FACS lysing solution (BD 
Bioscience), samples were washed twice in PBS containing 0.2% BSA and 0.1 
sodium azide, and then fixed in 1% paraformaldehyde and kept at 4°C until analyzed 
within a maximum of 48h from sample preparation. 
Using flow cytometry (FACSCalibur, Becton Dickinson (BD), Oxford, UK), 
forward and side light scatter parameters were used to access the monocyte 
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population, and a total of 20,000 events were acquired within the monocyte gate. 
The negative and positive delineators were determined from the isotype control 
fluorescence.  
Monocyte subsets were identified by double immunostaining for CD14 and CD16 
which allowed the identification of three cell subpopulations: CD14+CD16-, 
CD14highCD16+ and CD14lowCD16+ monocytes. The percentage of CD14+ cells 
expressing CD42b (a constitutive platelet marker) was taken as representative of 
circulating MPA. Post-acquisition analysis was performed using FlowJo software 
(Tree Star, Ashland, OR). 
 
4.3.3 Carotid ultrasonography.  
Carotid ultrasonography was performed by Dr Ben Yu Jiang at the Clinical Research 
Facility of St Thomas’ Hospital. Carotid intima-media-tickness (IMT) was measured 
by ultrasonography (Accuson Sequoia 512 machine with an 8-MHz transducer). 
IMT was taken as the distance between the blood/intima borderline and the 
media/adventitia borderline, and evaluated on the far wall of the left and right 
common carotid artery (CCA), specifically in the distal 1 cm of the artery just 
proximal to the bulb. Mean carotid IMT was measured using a semi-automated 
computer analysis system over this 1 cm segment, and confirmed by the mean of 
five manual readings at 20mm intervals along the CCA. Mean values of IMT in the 
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4.3.4 Statistical analysis 
All data were expressed as median ± inter-quartile range. Statistical analyses were 
performed in GraphPad Prism. Between-group comparisons were made using one-
way ANOVA with Dunn’s correction. Multivariate linear regression analysis was 
conducted to examine the correlation between IMT and all the variables measured in 
the study: age, systolic and diastolic blood pressure (SBP and DBP respectively), 
total cholesterol and low-density and high-density lipoprotein fractions (LDL and 
HDL), triglycerides, HbA1c, hs-CRP, BMI, estimated glomerular filtration rate 
(eGFR), MPA levels and percentage of different monocyte subsets. Associations 
were analysed by least squares and multiple regression analyses. In all cases, p < 
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4.4 Results  
4.4.1 MPA level and monocyte CD16 positivity do not relate to cardiovascular 
risk stratification as assessed  by standard risk calculators  
Using the Framingham equation, patients were divided into three categories of 
global cardiovascular risk: Group 1, low (n=22); Group 2, moderate (n=15);  and 
Group 3 high (n=8) representing 10-year calculated cardiovascular risk <10%, 10% - 
20%, and >20% respectively. These three sub-populations differed in age, 
prevalence of diabetes, SBP and renal function (Table 4.1). The low risk group had 
the lowest median age and SBP; 87.5% of patients in the high-risk group were 
diabetic compared to 31.25% and 59% in the moderate- and low-risk groups 
respectively; and median eGFR in the high-risk group was lower than that in the 
other two groups.  
No differences were seen between groups in total monocyte numbers, MPA levels 
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Table 4.1 Characteristics of study patients. Participants were distinguished into different 
categories of cardiovascular risk profile based on the Framingham equation (LR, low-risk; 
MR, moderate-risk; HR, high-risk, corresponding to <10%, 10-20% and >20% 10-year 
calculated cardiovascular risk respectively).  
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density 
lipoproteins; BMI: body mass index; hs-CRP: high-sensitivity C reactive protein; eGFR: 
estimated glomerular filtration rate; ns: non significant. 








Age (years) 38 (25-57) 52 (47-68) 62 (51-73) <0.001
(HR vs LR
MR vs LR)
Women (%) 7 (31.81%) 7 (43.75%) 3(37.5%)
Smokers (n) 0 1 0
Diabetes mellitus (%) 13 (59%) 5 (31.25%) 7 (87.5%)
HbA1c (%) 7.6 (5.2-11.10) 5.9 (4.9-9.5) 8.05 (5.6-10.5) ns
SBP (mmHg) 135(110-165) 147 (126-190) 145.5(115-175) 0.03
(MR vs LR)
DBP (mmHg) 76(56-108) 90 (65-130) 78.5 (64-103) ns
Total  cholesterol (mmol/L) 4.6 (3.2-6.88) 4.23 (2.75-6.27) 4.2 (3.41-5.9) ns
HDL-cholesterol (mmol/L) 1.29 (1.05-1.7) 1.4 (1.2-1.63) 1.14 (1.14-1.3) ns
BMI (kg/m2) 28.40 (20.2-40) 31.85 (21.7-37.5) 32.95 (26.1-37.2) ns
hs-CRP (mg/dl) 2.72 (0.23-12.5) 1.66 (0.4-6.55) 3.13 (2.5-4.08) ns




Triglycerides (mmol/L) 1.4(0.53-2.07) 1.15 (0.57-2.67) 1.58 (1.2-2) ns
Monocytes (109/L) 0.63 (0.45-0.65) 0.45 (0.27-0.78) 0.69 (0.34-0.78) ns
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Figure 4.1 Level of MPA (measured as CD14+CD42b+ events) (A) and the distinct 
monocyte subpopulations comprising “classical” CD14+CD16- (B), CD14highCD16+ (C) and 
CD14lowCD16+ (D) in the study population, stratified according to risk as calculated using 
the Framingham equation. HR: high-risk; MD: moderate risk; LR: low risk corresponding to 
<10%, 10-20% and >20% 10-year calculated cardiovascular risk. Graphs show medians and 
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When the population study was stratified according to the JBS-2 risk charts, all 
diabetic patients were classified as being at high cardiovascular risk. In this case, no 
differences were observed in age and eGFR between groups. However, the low-risk 
group had the highest median DBP and total cholesterol (Table 4.2), most likely 
because of a less aggressive preventative strategy adopted in these patients by their 
treating clinicians compared to the other groups.  
A similar level of MPA was measured in the high-, moderate- and low-risk 
categories. On the other hand, monocyte characterization showed an increase in the 
level of CD14highCD16+ cells in the peripheral blood of patients at high- compared to 
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Table 4.2 Characteristics of study patients. Participants were distinguished into different 
categories of cardiovascular risk profile based on the JBS-2 risk charts (LR, low-risk; MR, 
moderate-risk; HR, high-risk, corresponding to <10%, 10-20% and >20% 10-year calculated 
cardiovascular risk respectively).  
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density 
lipoproteins; BMI: body mass index; hs-CRP: high-sensitivity C reactive protein; eGFR: 
estimated glomerular filtration rate; ns: non significant. 








Age (years) 38 (27-57) 54.5 (45-67) 50 (25-73) ns
Women (%) 4 (57.14%) 4 (50%) 12 (40%)
Smokers (n) 0 1 0
Diabetes mellitus (%) 0 0 25 (83.3%)
HbA1c (%) 5.4 (5.2-5.9) 5.6 (4.9-6.1) 8.2 (5.6-11.10) <0.0001
(HR vs MR;
HR vs LR)
SBP (mmHg) 137(110-190) 145.5 (134-167) 137.5(110-190) ns
DBP (mmHg) 98 (85-130) 87 (76-98) 75.5 (56-115) 0.001 
(HR vs LR)
Total  cholesterol (mmol/L) 3.48 (3.12-5.46) 3.12 (1.97-4.58) 2.11 (1.7-3.47) 0.05
(HR vs LR)
HDL-cholesterol (mmol/L) 1.25 (1.05-1.7) 1.39 (1.2-1.63) 1.31 (1.14-1.68) ns
BMI (kg/m2) 30.48 (23.7-34.4) 30 (21.7-37.24) 29.85 (20.2-50) ns
hs-CRP (mg/dl) 2.72 (0.23-12.5) 1.66 (0.4-6.55) 3.13 (2.5-4.08) ns
eGFR (ml/min/1.73 m2) 94(85-105) 91.5 (75-107) 100 (37-170) ns
Triglycerides (mmol/L) 1.37(0.53-2.07) 1.27 (0.57-1.53) 1.3 (0.73-2.67) ns
Monocytes (109/L) 0.55 (0.45-0.65) 0.52 (0.27-0.69) 0.59 (0.46-0.78) ns
Anti-platelet therapy (%) 0 0 6 (28.57%)
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Figure 4.2 Level of MPA (measured as CD14+CD42b+ events) (A) and the distinct 
monocyte subpopulations comprising “classical” CD14+CD16- (B), CD14highCD16+ (C) and 
CD14lowCD16+ (D) in the study population, stratified according to risk as calculated using 
the JBS-2 risk charts. HR: high-risk; MD: moderate risk; LR: low risk corresponding to 
<10%, 10-20% and >20% 10-year calculated cardiovascular risk. Graphs show medians and 
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Due to the high prevalence of diabetes in our study population, a further sub-group 
analysis was conducted by dividing the high-risk group into three categories of 
patients: type 2 diabetic patients (T2; n=15), type 1 diabetic patients (T1; n=10) and 
non-diabetic high-risk patients (n=5). Their clinical characteristics, as well as MPA 
levels and monocyte phenotype were compared using one-way ANOVA multiple 
comparison test with Dunn’s correction also including data from moderate (n=8) and 
low-risk non-diabetic patients (n=7).  
Groups differed in age, renal function and blood pressure. T1 diabetic and low-risk 
patients had similar age (medians were 30 (25-52) and 35 (27-57) years respectively) 
and were younger than the other categories. No differences were detected in eGFR 
between diabetic and non-diabetic patients, although renal function was better in T1 
than in T2 (eGFR 108 (37-123) ml/min/1.73m2 vs 92 (37-123) ml/min/1.73m2 
respectively; p=0.01). Levels of SBP and DBP were higher in non-diabetic 
compared with diabetic groups (Figure 4.3). All other clinical parameters, including 
lipid profile, hsCRP, BMI and total monocyte count, were similar between groups.  
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Figure 4.3 Characteristics of patient sub-groups.  Graphs display differences in clinical 
parameters when the study population was divided into diabetic (type 1 (T1) and type 2 
(T2)) and non-diabetic subjects, this latter  stratified further into high- (HR), moderate- 
(MR) and low- risk (LR) in accordance with the JBS-2 risk charts. HR, MR and LR 
correspond to <10%, 10-20% and >20% 10-year calculated cardiovascular risk. 
Graphs show medians and inter-quartile ranges of each parameter. *, p<0.05 vs HR; †, 
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Although MPA levels were similar between groups, a significantly higher level of 
CD14highCD16+ monocytes was found in the peripheral blood of type 2 diabetic 
compared with that measured in low-risk subjects. Comparison between type 2 and 
type 1 diabetic patients, as well as between the other groups, revelead no other 
detectable inter-group differences in the level of pro-inflammatory monocytes 





Figure 4.4. MPA and monocyte characterization in patient sub-groups. Level of MPA 
(measured as CD14+CD42b+ events) (A) and CD14highCD16+ monocytes (B) in patients with 
type 1 (T1) and type 2 (T2) diabetes, and in non-diabetic subjects stratified into high- (HR), 
moderate- (MR) and low-risk (LR) according to the JBS-2 risk charts. HR, MR and LR 
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4.4.2 Carotid atherosclerotic disease correlates with levels of 
CD14highCD16+monocytes but not with cardiovascular risk as assessed by 
standard risk calculators 
Twenty-two of these forty-five patients underwent carotid ultrasonography for 
evaluation of IMT. These included three patients of the eight classified into the high 
risk group, nine of the fifteen in the moderate risk group, and ten of the twenty-two 
in the low-risk group (as assessed using the Framingham equation). Atherosclerotic 
plaque, as defined by a focal lesion with IMT > 1.5 mm, was found in ten patients: 
two low-risk subject, six moderate risk subjects, and two high-risk subjects. These 
findings suggest that the presence of carotid plaque disease has no – or very little – 
relation to calculated cardiovascular risk. 
We then compared level of MPA and monocyte distribution pattern between patients 
with carotid plaque disease (n=10) and those without (n=12). MPA levels were 
similar between the two groups: 22.09% (10.89% - 31.32%) vs 18.22% (12% - 
29.23%) in patients with and without plaques respectively, p=ns. By contrast, the 
percentage of circulating CD14highCD16+ monocytes was higher in patients with 
carotid plaque disease compared to those without plaques: 7.53% (3.55%-20.12%) 
vs 3.95% (2.29%-7.5%) respectively; p=0.008 (Figure 4.5).  
In a multivariate linear regression analysis incorporating age, SBP, DBP, lipid 
profile, HbA1c, hs-CRP, eGFR, BMI, MPA level, cardiovascular risk as calculated 
with the Framingham equation, and IMT, percentage of circulating CD14highCD16+ 
monocytes was found to strongly correlate with age and IMT and, to a minor extent, 
with eGFR (Figure 4.5). 
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Figure 4.5 Level of MPA (measured as CD14+CD42b+ events) (A) and CD14highCD16+ 
monocytes (B) in patients with (n=10) and without (n=12) carotid atherosclerotic plaques. 
Also shown are the relationships of CD14highCD16+ monocytes with age (C), eGFR (D) and 
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Patients with and without plaque disease differed  in age, DBP and eGFR as shown 
in table Table 4.3. 
 
Table 4.3 Characteristics of patients with and without carotid atherosclerotic plaques. 
Variables are presented as percentage or medians with inter-quartile ranges, as appropriate. 
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density 
lipoproteins; BMI: body mass index; hs-CRP: high-sensitivity C reactive protein; eGFR: 























Age (years) 61.5 (51-73) 44.5(33-56) 0.002
Women (n) 5 6 
Smokers (n) 0 1
Diabetes mellitus (n) 2 1
HbA1c (%) 6.15 (4.9-8.2) 5.7 (5.2-7) ns
SBP (mmHg) 143.5 (125-167) 154.5 (135-190) ns
DBP (mmHg) 85.2 (77-98) 100.5 (76-130) 0.02
Total  cholesterol (mmol/L) 4.31 (2.5-5.57) 5.23 (3.57-6.88) ns
HDL-cholesterol (mmol/L) 1.49 (1.05-1.63) 1.34 (1.14-1.7) ns
BMI (kg/m2) 34 (21.7-37.5) 29.38  (23.7-50) ns
hs-CRP (mg/dl) 3.45 (0.4-12.5) 2.32 (0.237-3.34) ns
eGFR (ml/min/1.73 m2) 85.5 (37-92) 96 (86-107) 0.002
Triglycerides (mmol/L) 0.84 (0.53-2.67) 1.3 (0.63-2.07) ns
Monocytes (109/L cells) 0.45 (0.27-0.6) 0.63 (0.41-0.78) ns
Anti-platelet therapy (n) 4 0
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We next performed multivariate regression analysis using a model incorporating 
age, SBP, DBP, lipid profile, HbA1c, hs-CRP, eGFR, BMI, MPA level, monocyte 
subsets and cardiovascular risk as calculated with the Framingham equation. IMT 
was found to correlate strongly with age (r2=0.4426; p=0.001), and, to a minor 
extent, with eGFR (r2=0.2973; p=0.01). However, no correlation was found between 
IMT and other classical cardiovascular risk factors or cardiovascular risk assigned as 
calculated using the Framingham equation. On the contrary, IMT was found to be 
linearly related to percentage of total CD14+CD16+ monocytes (r2=0.5247; 
p=0.0002), particularly the level of the CD14highCD16+ subset (r2=0.5505; 
p=0.0001), whilst no relationship was found with the subpopulation of 
CD14lowCD16+ cells. Similarly, no relationship was observed between IMT and 
classical CD14+CD16- monocytes or MPA levels (Figure 4.6). 
Using the JBS-2 charts to calculate cardiovascular risk in those patients who were 
found to have carotid plaques, two were stratified at low cardiovascular risk, five at 
moderate cardiovascular risk and three at high cardiovascular risk. Again, therefore, 
there appeared to be no– or very little -  relationship between the presence of carotid 
plaque disease and calculated cardiovascular risk. 
Concerning the level of hs-CRP, only five of the ten patients with plaques and two 
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Figure 4.6 The relationship of IMT to age (A), eGFR (B), hs-CRP (C), cardiovascular risk 
score according to the Framigham equation (D),  total pro-inflammatory CD14+CD16+ 
monocytes (E), CD14highCD16+ monocytes (F), CD14lowCD16+ cells (G) and MPA 
(measured as percentage of CD14+CD42b+ cells) (H) IMT: intima-media thickness, eGFR: 
estimated glomerular filtration rate; hsCRP: high-sensitivity C reactive protein; CV: 
cardiovascular. 
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4.4.3 CD14highCD16+monocytes and MPA levels: relationship to classical 
cardiovascular risk factors 
In all forty-five patients enrolled in this study, the relationship was studied between 
levels of CD14highCD16+ monocytes and other parameters: age, blood pressure, lipid 
profile, hs-CRP, HbA1c, BMI and cardiovascular risk as calculated using the 
Framingham risk equation. We found that CD14highCD16+ levels correlated 
positively with age (r2=0.1132; p=0.03) and negatively with DBP (r2=0.1627; 
p=0.01), but not with the other parameters examined (Figure 4.5). No correlation 









Figure 4.7 Correlation between CD14highCD16+ monocytes and age (A) and DBP (B) in the 
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This study demonstrates that the standard cardiovascular risk calculators examined 
here (the Framingham equation and JBS-2 risk charts) have limited ability to predict 
the presence of atherosclerotic disease at an individual level, when applied to a 
cohort of patients with one or more cardiovascular risk factors who are 
asymptomatic for atherosclerotic disease. Classical biomarkers currently used in 
clinical practice to predict future cardiovascular events, in particular hs-CRP, also 
did not reliably identify those subjects with silent disease. This highlights the need to 
develop novel biomarkers able to refine the stratification of cardiovascular risk in a 
population of clinically healthy patients with cardiovascular risk factors, in order 
that the clinical management of such subjects can be improved and preventative 
strategies be targeted in a more effective manner. 
Our study suggests that evaluation of the phenotype of circulating monocytes, and 
particularly the measurement of levels of pro-inflammatory CD14highCD16+cells, 
provides a useful adjunct for cardiovascular risk stratification, over and above the 
standard approach based on the clinical assessment of traditional cardiovascular risk 
factors.  
 
4.5.1 Monocyte characterization as a surrogate marker of silent atherosclerosis 
In agreement with Rogacev (Rogacev et al., 2010) who has previously demonstrated 
a strong correlation between levels of CD14highCD16+ monocytes and IMT in a 
population of healthy subjects, a similar relationship between percentage of pro-
inflammatory monocytes and asymptomatic atherosclerosis was found in our study 
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population, comprising patients with different cardiovascular risk profiles. Of note, a 
major expansion of CD14highCD16+ cells was found in the peripheral blood of those 
patients with carotid plaque disease, who were by and large older and had a lower 
eGFR than disease-free subjects. Accordingly, levels of CD14highCD16+ cells were 
strongly related to age and renal function, and this is likely to reflect the well-
established effect of chronic exposure to cardiovascular risk factors, as well as 
impaired kidney function, on development of a pro-inflammatory phenotype that, in 
turn, favours development and progression of atherosclerosis.     
In keeping with this, among all the parameters evaluated in our study, age and renal 
function were also related to IMT. The detrimental effect of ageing on function and 
anatomical integrity of the vasculature, and the consequent age-related increase in 
cardiovascular disease, is well recognized (Remsberg & Siervogel, 2003). Elderly 
people have increased probability of developing cardiovascular disease, 
independently of the presence of other cardiovascular risk factors. However, 
stratifying patients based only on their age carries no cardiovascular predictive value 
without concomitant clinical assessment of other cardiovascular risk factors, 
including hypertension, dyslipidaemia, smoking and presence of diabetes. The 
correlation between IMT and age found in our study is likely purely to reflect the 
chronic nature of atherosclerotic disease and its progressive development over the 
years.  
Similarly, the relationship between IMT and eGFR observed in our study cohort is 
likely to reflect the well established increased susceptibility of patients with 
impaired kidney function to accelerated atherosclerosis (Hemmelgarn et al., 2010). 
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However, eGFR measurement does not provide a good marker of atherosclerosis due 
to the lack of a recognized threshold above which further clinical investigations, 
including cardiovascular imaging, are required in an individual. Levels of eGFR, 
especially where they show normal or mild impairment of kidney function as 
observed in our patients, are not reliable indicators of the presence of atherosclerotic 
disease. In keeping with this, two of the patients with evidence of carotid plaques on 
ultrasonography had eGFR>90 mL/min/1.73 m2, and the remainder had levels of 
eGFR ranging between 73 and 86 mL/min/1.73m2.  
In this context, monocyte characterization has the potential to offer a reliable 
diagnostic tool widely applicable to a population at risk of future cardiovascular 
events, enabling the early detection of silent atherosclerosis with a superior 
predictive value compared to the classical inflammation biomarker hs-CRP and to 
traditional cardiovascular risk scoring based on either the Framigham equation or 
JBS-2 risk charts. Coupled to the fact that silent carotid disease was prevalent in 
subjects classified at low and moderate cardiovascular risk, this is a strong case that 
introduction of monocyte characterization in clinical practice might be of particular 
benefit for these two categories of patients. Indeed, although preliminary, our 
clinical data have shown under-estimation of probability of disease by the 
Framingham and JBS-2 risk charts in half of the patients with silent disease.   
Conversely, the high risk group was mainly composed of diabetic patients, and only 
a few of them (three out of twenty-five patients in total) underwent carotid 
ultrasonography. Therefore, it is difficult to establish if any clinically relevant 
advantage may derive from the introduction of monocyte phenotypic 
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characterization into cardiovascular screening of such patients. Our data showed that 
type 2, but not type 1 diabetes, associates with expansion of pro-inflammatory 
CD14highCD16+ monocytes Furthermore, a negative linear relationship was found 
between pro-inflammatory monocytes and DBP, so that increased numbers of 
CD14highCD16+ cells were seen in those patients with the lowest levels of DBP, and 
these patients were in fact diabetic. However, the increase in CD14highCD16+ cells 
observed in type 2 diabetic patients reached statistical significance only when 
compared to levels measured in the low-risk group. This finding could be ascribed to 
the well established higher predisposition of type 2 diabetics to develop 
atherosclerosis compared with non-diabetic patients (Joint British Society 
Guidelines, 2005),  and might therefore reflect the higher prevalence of 
asymptomatic disease in type 2 diabetes. Lack of any difference between type 2 
diabetics and high- or moderate-risk subjects in terms of pro-inflammatory 
phenotype of circulating monocytes might be explained by the heterogeneity of 
patients in these latter categories, which comprised patients both with and without 
silent carotid disease. 
  
 4.5.2 Study limitations 
The number of subjects studied here was relatively small, and in future studies large 
numbers will be requested to confirm the findings postulated here, as well as to 
establish the usefulness of this approach over and above current clinical practice.  
Additionally, although carotid ultrasonography gives useful information about 
atherosclerotic burden, new non-invasive imaging modalities such as cardiovascular 
Chapter Four 
Characterization of circulating monocytes as a novel diagnostic tool for 
improved stratification of CV risk in asymptomatic patients 
187 
 
magnetic resonance imaging (CMRI) will give further useful information and need 
to be incorporated in future studies, to overcome  the multiple technical limitations 
associated with carotid ultrasonography that negatively impact on data 
reproducibility. Indeed, the strong dependency of IMT data on operator experience, 
the nature of scanner and the technique for IMT measurement can give rise to much 
variability of data between different researchers, and thereby affect the predictive 
value of IMT for coronary atherosclerosis and future cardiovascular events 
(reviewed by Komorovsky & Desideri, 2005; Passacquale et al., 2008; Coll & 
Feinstein, 2008). In this context, extension of the present imaging study to other 
vascular territories would shed light on the potential prognostic ability of monocyte 
phenotypic characterization to detect silent atherosclerosis in other vascular beds. 
 
4.5.3 Conclusion 
In conclusion, our data demonstrate that expansion of CD14highCD16+ monocytes 
occurs in the peripheral blood of patients with cardiovascular risk factors and 
asymptomatic carotid atherosclerosis, and the measurement of this subset of 
monocytes in the peripheral blood has strong predictive value for silent 
atherosclerotic disease over and above the standard cardiovascular risk stratification 
methods currently used in clinical practice. The potential clinical applicability of 
















This thesis has explored the clinical usefulness of measuring circulating MPA, and 
the resultant changes in monocyte phenotype, for the early diagnosis of 
asymptomatic atherosclerosis. The methodological approach used was translational, 
in which initial in vitro experiments  (Chapter 2) were followed by a pre-clinical 
investigation in a murine model of atherosclerosis (Chapter 3) and finally by a 
preliminary clinical study in a population of patients at risk of cardiovascular disease 
(Chapter 4). The project was designed to address the dual questions of whether 
abnormal levels of MPA can provide a useful biological indicator of disease and 
whether if they play a pathophysiological role in atherosclerosis development, thus 
representing a potential therapeutic target for cardiovascular prevention. Taken 
together, the evidence provided in this thesis supports two major conclusions. 
Firtsly, MPA measurement per se is of limited usefulness in the early diagnosis of  
atherosclerosis. Hence, this research has refuted our initial hypothesis level of MPA 
in the peripheral blood reflects the stage of vascular disease. However, secondly, 
increased MPA formation, although of limited diagnostic value, leads to a systemic 
pro-inflammatory state mediated by a change in the phenotype and function of 
bound monocytes toward a type more prone to infiltrate the vasculature. This carries 
important pro-atherogenic implications and, importantly, can be easily detected in 
vivo by  flow-cytometry-based monocyte characterization. Unlike MPA assessment, 
this latter  has demonstrated to have high potential as a good biomarker for early 
atherosclerosis. Moreover, the possibility to intervene pharmacologically on the 





inflammatory monocyte phenotype has been described in this thesis.  All these 
aspects will be discussed in detail in the sections below.  
 
 
5.2 Need for novel biomarkers of atherosclerosis 
The development of predictive models of cardiovascular risk incorporating classical 
risk factors (for example the Framingham equation and JBS2 risk charts) provided a 
significant improvement in the clinical management of atherosclerosis-related 
cardiovascular disease, as they offered a standardised method to predict long-term 
cardiovascular risk for a given patient, based on which the nature and intensity of 
preventive measures needed could be assessed (JBS-2 Guidelines, 2005). 
Nevertheless, multiple large population-based studies have shown the limitations of 
this approach in predicting future cardiovascular events in individuals (Brindle et al., 
2003; Coleman et al., 2007; Ramsay et al., 2011), and attempts to discover novel 
biomarkers of atherosclerosis with higher predictive ability for cardiovascular events 
have been the subject of much research over the past twenty years.  
 
In this context, a better understanding of the pathophysiology of atherosclerosis, and 
in particular its pro-inflammatory nature, led to much attention being focussed on 
markers indicative of inflammation. Measurement of C reactive protein (CRP), 
produced by the liver in response to the pro-inflammatory cytokines IL-6, IL-1 and 
TNFα (Hurlimann et al., 1966; Mackiewicz et al., 1991), has been the test most 





inflammation, due to the availability of a standardized methodology and the fact that 
it is relatively inexpensive to measure (Pearson et al., 2003). Levels of CRP have 
been shown to predict future cardiovascular events (Ridker et al., 2007; Sabatine et 
al., 2007; Vidula et al., 2008). However, addition of CRP measurement to the 
standard Framingham risk calculation was not found to improve the estimation of 
future risk consistently (Shah et al., 2009). Moreover, despite a strong correlation 
with future cardiovascular events in patients with known atherosclerosis, level of 
CRP has been reported to be a poor predictor of atherosclerotic burden (Khera et al., 
2006) thus suggesting that CRP assessment is of limited clinical utility in clinically 
healthy patients with underlying cardiovascular risk factors, for whom detection of 
silent atherosclerosis has important implications as regards their clinical 
management. 
 
With this backdrop in mind, the work described here set out to firstly identify a 
novel biological indicator of atherosclerosis that would be easily measurable non-
invasively and inexpensively, and hence potentially applicable to at-risk 
asymptomatic patients as a diagnostic tool; and secondly to verify the ability of this 
biomarker to specifically detect silent atherosclerosis with applicability over and 
above traditional cardiovascular risk stratification based on clinical assessment and 
standard cardiovascular risk prediction tools.  
Our interest in the study of MPA as a potential novel biomarker of silent 
atherosclerosis stemmed from two important considerations: the first relates to the 





pathophysiology of atherosclerosis; the second concerns the fact that MPA 
measurement involves a simple blood test where analysis by flow cytometry is 
relatively cheap and straightforward.   
 
 
5.3 MPA and CD16-positive monocytes: from identification of their role in 
atherogenesis to identification of a novel biomarker of silent atherosclerosis 
We found in vitro that MPA formation is pro-inflammatory, such that it leads to 
changes in the phenotype of circulating monocytes toward CD16+ positivity, which 
exhibit increased capability to interact with the endothelium as well as increased 
expression of Toll-like receptors. Our results also provide mechanistic insight into 
how this occurs, inasmuch as we have found that the observed changes in monocyte 
phenotype and function in response to MPA formation are mediated by platelet-
dependent COX-2 up-regulation and consequent PGE2 synthesis in monocytes. 
These findings provide novel insight into both the molecular and cellular 
mechanisms underlying atherosclerosis, whilst at the same time offering the 
possibility to measure a biomarker which reflects the atherogenic process. 
 
The change observed in the phenotype of circulating monocytes mediated by 
heterotypic aggregation suggested that assessment of the different monocytic 
subpopulations, along with MPA measurement, both of which are easily measurable 
in the peripheral blood by flow cytometry, could provide a novel diagnostic 





found that increased platelet activation and elevated levels of circulating pro-
inflammatory CD14highCD16+ monocytes reflect active inflammation and, whilst not 
necessarily specifically related to atherosclerosis (since we observed the same 
changes in healthy subjects following influenza immunization), are seen in subjects 
with underlying cardiovascular risk factors in the presence of atherosclerotic disease 
as documented by carotid ultrasonography.  Indeed, the data postulated here from 
our clinical study conducted in patients at different levels of cardiovascular risk 
(Chapter 4) strongly support the validity of monocyte phenotype analysis in the 
identification of early atherosclerosis. Unlike MPA measurement, assessment of 
monocyte phenotype offered predictive information in terms of presence of silent 
disease, over and above both classical cardiovascular risk stratification tools and the 
traditional inflammation marker hs-CRP. This is not to imply that traditional 
cardiovascular risk calculators do not have a place, but rather that their value can be 
augmented considerably by also taking into account circulating CD16+ monocyte 
numbers.  
Our preliminary clinical data as presented here has demonstrated good 
correspondence between monocyte phenotype analysis and carotid ultrasonography 
in detecting subclinical atherosclerosis. Considerable evidence supports the add-on 
value of carotid ultrasonongraphy to population-based cardiovascular risk estimation 
in asymptomatic subjects, particularly if non-invasive imaging is applied to 
individuals classified at  moderate risk according to classical algorithms (Peters et 
al., 2011). However, the clinical usefulness of cardiovascular screening based on a 





counterbalanced by the high cost as well as the logistic possibility of such an 
approach. In this context, monocyte characterization offers potential advantages 
inasmuch as it provides a relatively cheap biomarker, easily applied clinically and 
with high predictive ability. Such an approach could be useful to select patients in 
whom further imaging studies (invasive or non-invasive) are indicated. 
As mentioned in Chapter 4, asymptomatic non-diabetic patients at low or moderate 
cardiovascular risk were those in whom carotid ultrasonography along with 
monocyte characterization led to re-classification of many individuals, based on 
detection of asymptomatic carotid plaques, such that adjustment of their therapy 
(addition of statin and/or aspirin) was then indicated.  Our data suggest that such 
patients would benefit considerably by the introduction of a novel biomarker of 
atherosclerosis. Figure 5.1 illustrates the potential applicability of monocyte 
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Figure 5.1 Potential applicability of monocyte characterization into cardiovascular risk 
assessment of asymptomatic patients. Full cardiovascular risk assessment should be 
performed in all people aged between 40 and 74 years who present with cardiovascular risk 
factors (hypertension, dyslipidemia, smoking habit). People aged 75 years and older, and 
those with diabetes, left ventricular hypertrophy, peripheral vascular disease or previous 
cardiovascular events are already considered to be in the high risk category and are not 
included in such risk assessment (NICE guidelines 67, 2010). Population-based tools 
estimate the risk of future cardiovascular events based on clinical assessment, and provide a 
classification of patients into three categories: low, moderate and high cardiovascular risk, 
defined by a probability of <10%, 10-20% and >20% of developing a future event in 10 
years. People classified as being at  low and moderate risk would benefit from additional 





characterization would identify those with increased level of CD16+ monocytes, and such 
patients could then be selected to undergo non-invasive imaging by carotid ultrasonography, 
which would then guide the need for appropriate cardiovascular preventative measures. 
 
 
5.4 Pro-atherogenicity of different monocyte subsets  
Our findings in vitro that human CD16+ monocytes exhibit augmented adhesiveness 
to the vascular endothelium and that their level increases in patients with 
atherosclerosis, together with our data in ApoE-/- mice that the murine homologue of 
CD16+ monocytes, namely Ly6Clow, are elevated in relation to the extent of 
atherosclerotic disease present, are highly suggestive of a pro-atherogenic effect 
resulting from increased levels of pro-inflammatory monocytes. However, a 
definitive answer to the question of whether CD16+ cells are more pro-atherogenic 
than the classical CD14+CD16- subset has not yet been provided. We have partially 
addressed this topic in the pre-clinical study conducted in ApoE-/- mice, by 
comparing the phenotypic pattern of monocytes circulating in the peripheral blood to 
those infiltrating the plaque.  Our data showed that, although it is the increase in 
Ly6Clow cells in the blood that mainly reflects plaque size, both monocytic 
subpopulations are able to infiltrate arterial lesions. This would imply that expansion 
of human CD16+ cells is a biological indicator of atherosclerosis only, without this 
subset of monocytes being preferentially implicated in plaque development despite 
its increased endothelial adhesiveness compared to the classical CD14+CD16- 
subtype.  Moreover, the evidence that aspirin decreases the trafficking of classical 
Ly6Chigh monocytes into lesions, thus reducing the macrophage-dependent lipid 





cells have a minor effect on plaque vulnerability compared to classical monocytes. 
However, a direct translation of such data from murine to human disease would be 
inappropriate, since major differences exist between the two species in their 
inflammatory pathways. For instance, lymphocytes prevail over neutrophils in 
murine blood even under physiological conditions, whilst humans exibit 
predominance of PMN over mononuclear cells (Doeing et al., 2003). Moreover, 
ApoE-/- mice develop monocytosis during atherosclerosis progression, which is 
absent in the human disease. Additionally, although not confirmed by functional 
assays, discrepancies has been identified between murine and human monocytes 
(Ingersoll et al., 2010) in the expression profile of genes involved in phagocytosis of 
apoptotic cells and lipid-dependent activation. Such differences in  white cell count 
and monocyte function can alter the inflammatory milieu and give rise to distinct 
inflammatory responses. As discussed in Chapter 3, ApoE-/- mice provide a good 
animal model of atherosclerosis in which to investigate monocyte vascular 
infiltration, and this has provided a reliable model for  preliminary investigation of 
the in vivo effect of platelet activation on monocyte phenotype and trafficking into 
lesions. However, all the results collected in ApoE-/- mice would require 
confirmation in future clinical studies, as further discussed in the following sections. 
Table 5.1 summarizes and compares important findings in mice and humans, as 
collected  in the current thesis, and the parameters that still need to be investigated in 







Table 5.1 Comparison between murine and human findings in normal physiology and 
atherosclerosis 
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5.5. Pharmacological modulation of monocyte phenotype in cardiovascular 
prophylaxis 
The in vitro study described in Chapter 2 has provided evidence that platelet 
activation and consequent formation of MPA influences the acquisition of a CD16+ 
monocyte phenotype in humans, this effect being sustained by the combined action 
of multiple biomolecular mechanisms involving adhesion molecules and humoral 
factors released by both platelets and monocytes in the microenvironment. Among 
those, we have identified monocytic PSGL-1 ligation by platelet P-selectin and 
enhanced synthesis of the COX-2-derived prostanoid PGE2 as key events. In 
accordance with this, either  interference in MPA formation, such as that induced by 
anti-PSGL-1 blocking antibody, or pharmacological inhibition of COX-2 activity, as 
obtained with NS-398 or aspirin, counteracted platelet-dependent CD16 over-
expression on isolated monocytes with similar efficacy (Passacquale et al., 2011c). 
These findings were confirmed by our in vivo study in ApoE-/- mice, in which 
administration of aspirin and clopidogrel suppressed atherosclerosis-associated 
monocytosis and reduced the expansion of Ly6Clow cells through COX inhibition 
and interference in MPA formation respectively. Aspirin and clopidogrel are widely 
used in cardiovascular prevention (discussed in Chapter 1). Our demonstration that 
they can modulate phenotype/count of murine monocytes during atherosclerosis 
progression suggests that they exert additional anti-inflammatory activity, aside from 
their anti-thrombotic action, which may play a role in counteracting the progression 
of atherosclerosis. Moreover, given the effect of both drugs, particularly of aspirin, 





that a major effect of anti-platelet therapy is on plaque stabilization with consequent 
reduction of acute pro-thrombotic events triggered by plaque rupture. In future work, 
we plan to investigate whether administration of aspirin and clopidogrel to healthy 
subjects undergoing influenza immunization negatively modulate the expansion of 
CD16+ monocytes induced by such immunisation. If this will prove to be the case, 
interventional studies might then be considered to explore the anti-atherosclerotic 
potential of aspirin and clopidogrel in the treatment of those patients with 
asymptomatic disease or those at high risk of such disease (especially if their CD16+ 
monocyte count is high). As discussed in Chapter 1, the dubious role of, and 
conflicting results reported with, anti-platelet interventions in primary 
cardiovascular prevention might be attributable to the large heterogeneity in the 
study populations that have characterized previous trials, and monocyte 
characterization might overcome this problem in a future study.  
Unlike the analysis of circulating monocyte phenotype, it is more difficult to 
evaluate the effect of anti-platelet drugs on plaque composition. Indeed, lack of a 
diagnostic modality enabling the molecular and cellular characterization of 
atherosclerotic lesions limits our ability to understand the impact that change in the 
phenotype of circulating monocytes toward a more pro-inflammatory subset might 
have in terms of disease progression in human disease. We have nw started already 
working in mice on the development of a novel magnetic resonance (MR)-based 
technique that would be applicable eventually to humans and enable the in vivo 
study of the monocyte/macrophage component of atherosclerotic plaques.  However, 





humans. Meanwhile, it will be useful to conduct prospective large population-based 
studies to evaluate the prognostic value of monocyte characterization for future 
cardiovascular events, as well as interventional clinical trials to explore the 
beneficial effects of pharmacological modulation of monocyte phenotype on 
atherosclerosis progression.  
 
 
5.6 Anti-platelet drugs versus selective COX-2 inhibitors 
Our preliminary data suggest that inhibition of platelet heterotypic aggregation or 
COX-blockade, as obtained with clopidogrel or aspirin respectively, might have a 
place in the prevention of atherosclerosis progression over and above their anti-
thrombotic action, by virtue of their ability to counteract the acquisition of a pro-
inflammatory phenotype by circulating monocytes. The anti-inflammatory effect of 
aspirin observed in both the in vitro and pre-clinical studies was most likely 
attributable to inhibition of the COX-2 isoform, which would have occurred with the 
high doses used in our investigations (the smallest dose of aspirin administrered to 
mice would correspond to the equivalent of ~200mg daily in humans). The 
administration of 75mg aspirin daily as recommended for long-term primary and 
secondary prevention would not be enough to modulate the enzymatic activity of 
COX-2 in the systemic circulation (Patrono et al., 2005). Therefore, comparison of  
standard doses of clopidogrel and aspirin (75mg daily of both drugs) would merit 
consideration, since it could highlight differential anti-inflammatory (and hence anti-





ethical to test the efficacy of  selective COX-2 inhibitors due to the well recognized 
detrimental role of these drugs in patients with (or at risk of) cardiovascular disease 
(Konstam et al., 2001; Ray et al., 2002; Warner et al., 2002;  Kearnery et al., 2006). 
Indeed, systemic COX-2 blockade removes protective cardiovascular mechanisms, 
in particular release of endothelium-derived PGI2 (McAdam et al., 1999; Belton et 
al., 2000) that are not affected by low-dose aspirin (Fitzgerald et al., 1983). Our in 
vitro experiments demonstrate solely the pro-inflammatory effect sustained by 
monocytic COX-2, thus suggesting that  monocyte-targeted rather than systemic 
COX-2 inhibition could be of potential benefit in cardiovascular prevention, . 
Similarly, systemic PGE2 receptor antagonism could be harmful due to the variety of 
PGE2 actions in the cardiovascular system depending on the EP receptor isoform 
expressed on cells/tissues and the concentration of the prostanoid in the 
microenvironment (Warner et al., 2011). For instance, low levels of PGE2 inhibit 
whilst high levels stimulate platelet activity, through a differential selectivity for 
distinct EP receptors and activation of distinct signaling pathways (Table 1.2, 
Chapter 1). Similarly, activation of endothelial EP2 and EP4 receptor isoforms, that 
in our co-culture experiments we found to mediate platelet-dependent CD16 over-
expression in monocytes (Passacquale et al., 2011c), induces protective 
vasodilatation (Warner et al., 2011). More detailed characterization of the 
mechanisms underlying platelet-dependent changes in the phenotype of monocytes 
was beyond the scope of this thesis, but should be a focus of future research work in 
this area, since this will help in the identification of novel therapeutic strategies of 





5.7 Future Directions 
Further clinical investigations are required to extend our preliminary findings in a 
larger population-based study. Moreover, it would be useful to ascertain if 
measurement of CD14highCD16+ monocytes leads to improvement of the estimation 
of future cardiovascular events to a clinically important degree, in a longitudinal 
long-term follow-up study. Indeed, although we found that monocyte 
characterization was superior in identifying silent atherosclerosis compared to 
classical tools for cardiovascular risk stratification, this does not necessarily imply 
that early identification of plaque and consequent intensification of preventive 
measures will result in significant benefit in terms of reduction of future 
cardiovascular events in a given individual, compared with the classical approach.  
Finally, we only evaluated carotid atherosclerosis, so further clinical investigations 
are required to define the usefulness of monocyte characterization in detecting early 
asymptomatic disease in other vascular territories, in particular the coronary 
vasculature. We are now planning to examine this question, using cardiac MR to 
image coronary plaque burden as well as composition, and in turn to relate these to 
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